TOWARD AN ENZYME-COUPLED, BIOORTHOGONAL PLATFORM FOR METHYLTRANSFERASES: PROBING THE SPECIFICITY OF METHIONINE ADENOSYLTRANSFERASES by Huber, Tyler D.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Pharmacy College of Pharmacy 
2019 
TOWARD AN ENZYME-COUPLED, BIOORTHOGONAL PLATFORM 
FOR METHYLTRANSFERASES: PROBING THE SPECIFICITY OF 
METHIONINE ADENOSYLTRANSFERASES 
Tyler D. Huber 
University of Kentucky, tyler.huber88@gmail.com 
Digital Object Identifier: https://doi.org/10.13023/etd.2019.398 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Huber, Tyler D., "TOWARD AN ENZYME-COUPLED, BIOORTHOGONAL PLATFORM FOR 
METHYLTRANSFERASES: PROBING THE SPECIFICITY OF METHIONINE ADENOSYLTRANSFERASES" 
(2019). Theses and Dissertations--Pharmacy. 106. 
https://uknowledge.uky.edu/pharmacy_etds/106 
This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It 
has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Tyler D. Huber, Student 
Dr. Jon S. Thorson, Major Professor 
Dr. David J. Feola, Director of Graduate Studies 
 
 
 
 
 
 
 
 
TOWARD AN ENZYME-COUPLED, BIOORTHOGONAL PLATFORM FOR 
METHYLTRANSFERASES: PROBING THE SPECIFICITY OF 
METHIONINE ADENOSYLTRANSFERASES 
 
 
 
 
 
____________________________________ 
 
DISSERTATION 
____________________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the 
College of Pharmacy 
at the University of Kentucky 
 
 
 
By 
Tyler Daniel Huber 
 
Lexington, Kentucky 
 
Director: Dr. Jon S. Thorson, Professor of Pharmaceutical Sciences 
 
Lexington, Kentucky 
 
2019 
 
Copyright © Tyler Daniel Huber 2019 
  
 
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
 
TOWARD AN ENZYME-COUPLED, BIOORTHOGONAL PLATFORM FOR 
METHYLTRANSFERASES: PROBING THE SPECIFICITY OF 
METHIONINE ADENOSYLTRANSFERASES 
 
Methyl group transfer from S-adenosyl-L-methionine (AdoMet) to various 
substrates including DNA, proteins, and natural products (NPs), is accomplished by 
methyltransferases (MTs). Analogs of AdoMet, bearing an alternative S-alkyl group can 
be exploited, in the context of an array of wild-type MT-catalyzed reactions, to 
differentially alkylate DNA, proteins, and NPs. This technology provides a means to 
elucidate MT targets by the MT-mediated installation of chemoselective handles from 
AdoMet analogs to biologically relevant molecules and affords researchers a fresh route to 
diversify NP scaffolds by permitting the differential alkylation of chemical sites vulnerable 
to NP MTs that are unreactive to traditional, synthetic organic chemistry alkylation 
protocols. 
 
The full potential of this technology is stifled by several impediments largely 
deriving from the AdoMet-based reagents, including the instability, membrane 
impermeability, poor synthetic yield and resulting diastereomeric mixtures. To circumvent 
these main liabilities, novel chemoenzymatic strategies that employ methionine 
adenosyltransferases (MATs) and methionine (Met) analogs to synthesize AdoMet analogs 
in vitro were advanced. Unstable AdoMet analogs are simultaneously utilized in a one-pot 
reaction by MTs for the alkylrandomization of NP scaffolds. As cell membranes are 
permeable to Met analogs, this also sets the stage for cell-based and, potentially, in vivo 
applications. 
 
In order to further address the instability of AdoMet and analogs thereof, MAT-
catalyzed reactions utilizing Met and ATP isosteres generated highly stable AdoMet 
isosteres that were capable of downstream utilization by MTs. Finally, the development, 
use, and results of a high-throughput screen identified mutant-MAT/Met-analog pairs 
suitable for postliminary bioorthogonal applications. 
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Chapter One: AdoMet analog synthesis and utilization: Current state of the art 
 
1.1 Introduction 
 
Methyltransferase (MT)-catalyzed S-adenosyl-L-methionine (AdoMet, SAM, or 
SAMe)-dependent methylation is a key enzymatic reaction that enables the functional 
modulation of a vast array of biomolecules ranging from small metabolites to 
macromolecules (Figure 1.1a; Figure 1.2a).1–5 Consistent with this, alterations in 
methylation are associated with a wide range of human pathologies and variability in drug 
response.2–4 Despite great advances in methylation-dependent bioinformatics and disease-
associated biomarkers, the study of intracellular MT spatial/temporal resolution, specificity 
and/or function remains a challenge.3,4 Within this context, the early proof of concept 
studies revealing synthetic non-native AdoMet analogs to function as efficient cosubstrates 
for DNA6 or natural product (NP)7 MTs inspired a range of subsequent conceptually similar 
strategies to study NP,8–11 protein,12–18 and nucleic acid19–23 methylation. Subsequent 
development of permissive enzyme-based strategies for the synthesis of differentially S-
alkylated AdoMet analogs has further simplified access to these unique cosubstrates 
11,14,19,24 and also facilitated emerging cell-based applications.14 Within this context, this 
brief review attempts to highlight recent advances in the generation and application of 
differentially S/Se-alkylated AdoMet analogs and what are perceived to be key remaining 
challenges in further advancing the impact of these unique reagents. While a wide array of 
AdoMet adenosyl and/or L-methionine (L-Met) chain modified analogs have been pursued 
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within the context of inhibitor design, it is important to note that these fall outside the scope 
of this review.25–27 
 
1.2 Chemical synthesis of AdoMet analogs 
 
 Differentially S/Se-alkylated AdoMet surrogates have been constructed via both 
chemical and enzyme-catalyzed synthesis, the former of which is briefly summarized 
within this section with an emphasis on analogs demonstrated as functional cosubstrates 
for downstream AdoMet-utilizing enzymes. Alkylation of S-adenosyl-L-homocysteine 
(AdoHcy) with alkyl halides in HCOOH/AcOH in the presence or absence of Lewis acid 
(AgClO4 or AgOTf) as the predominate synthetic strategy of choice, has enabled the 
synthesis of >20 chemically diverse S/Se-alkylated AdoMets (Figure 1.2b). Table 1 
highlights functionally active analogs synthesized to date, where subtle variations from the 
conventional synthetic strategy are noted. While synthetic strategies opened the door to the 
interrogation of methyltransferases,6,7,21,28,29 typical synthetic yields range from 3% to 90% 
of (S/R)-sulfonium diastereomeric mixtures where residual starting materials (AdoHcy, a 
potent product inhibitor of AdoMet-utilizing enzymes) are commonly detrimental to the 
target enzymes to be studied.30,31 Thus, purification via reverse-phase chromatography32–
34 or cation-exchange HPLC35 is typically required, the nature of which often restricts 
practical scale. AdoMet chemical lability can also be disadvantageous to lengthy synthetic 
manipulations and/or purification schemes where intramolecular cyclization, depurination 
and sulfonium epimerization contribute to AdoMet t1/2 (Figure 1.1b).
19,20,35,36 
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1.3 Chemoenzymatic synthesis of AdoMet analogs 
 
The complement to conventional AdoMet cosubstrate synthesis is enzyme-
catalyzed production. Two distinct enzymes have been employed (methionine 
adenosyltransferases and halogenases, Table 1), a main advantage of which is the potential 
to directly couple AdoMet analog production to downstream utilization reactions and 
thereby circumvent the fundamental AdoMet stability issues and/or the need for tedious 
purification procedures noted in previous section.  
 
1.3.1 Methionine adenosyltransferases (MATs, EC 2.5.1.6) 
MATs (also known as S-adenosylmethionine synthetase/synthase, SAMS) catalyze 
the formation of AdoMet from adenosine triphosphate (ATP) and (L-Met) as a predominate 
strategy for AdoMet production in nature (Figure 1.2c). Within this context, Singh et al. 
surveyed the capabilities of a representative set of wild-type bacterial, archaeal and 
mammalian MATs with 44 structurally diverse differentially S/Se-alkylated L-Met analogs. 
This cumulative effort highlighted human MAT II catalytic alpha subunit (hMAT2A) and 
the archael thermophilic Methanocaldococcus jannaschii MAT (mMAT) as notably 
permissive.11 Using the same suite of putative substrates, Wang and Singh et al. reported 
similar promiscuity for the archael Sulfolobus solfataricus MAT (sMAT)  and, notably, the 
corresponding first structural elucidation for a thermostable MAT (sMAT, PDB ID 4HPV) 
and corresponding non-native ligand-bound complex (S-adenosylethionine, AdoEth; PDB 
ID 4L2Z).24 The Luo group also reported the successful hMAT2A-catalyzed synthesis of 
two differentially S-alkylated AdoMet analogs carrying bulky chemoselective handles and 
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the design of key hMAT2A mutants to improve activity toward targeted non-native L-Met 
analogs.14 In a similar fashion, a wild-type MAT from Bacillus subtilis was recently 
reported to accept four of 11 differentially S-alkylated methionine analogs tested along 
with key mutants that displayed improved proficiency, permissivity and an apparent 
reduction in product (AdoMet) inhibition.37 In addition to L-Met analogs bearing 
alternative S-alkyl groups, six different carboxyl- and/or amino-modified L-Met analogs 
were also recently assessed for their viability as alternative cosubstrates of pathogenic 
bacterial MATs.38 Cumulatively, well over 50 L-Met analogs have been assessed as 
putative substrates for a wide array of wild-type and mutant MATs within the last 5 years 
toward enabling non-native AdoMet production and, in many cases, subsequent utilization 
in coupled systems.8,11,14,24,37–39 In addition, tetrazole-based surrogates AdotMet and 
7dzAdotMet (Figure 1.2d) recently generated via hMAT2A-catalyzed synthesis were 
demonstrated to serve as functional cosubstrates for the prototypical class I MT DnrK 
involved in daunorubicin biosynthesis.40 This latter study notably highlighted a dramatic 
improvement in the corresponding 7dzAdotMet isostere stability where structure elucidation 
of DnrK ligand-bound structures also revealed AdotMet to occupy the AdoMet site with a 
slight shift toward the DnrK-bound acceptor coinciding with a slight improvement in kcat. 
 
1.3.2 Halogenases (SalL, EC 2.5.1.94; FDAS, EC 2.5.1.63) 
The innovative application of two wild-type microbial halogenases (5′-chloro-5′-
deoxyadenosine synthase or adenosyl-chloride synthase, SalL; 5′-fluoro-5′-
deoxyadenosine synthase or adenosyl-fluoride synthase, FDAS) have recently been 
reported for differentially S-alkylated AdoMet production. SalL and FDAS catalyze the 
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reversible formation of L-Met and 5′-chloro or 5ʹ-fluoro-5′-deoxyadenosine (ClDA or 
FDA, respectively) from AdoMet and chloride or fluoride, respectively, where the 
equilibrium typically favors the reactants (Figure 1.2e).41–45 In this pioneering work,19 
SalL and FDAS were found to catalyze the production of six differentially S-alkylated 
AdoMet analogs from their respective L-Met analogs and commercially available ClDA or 
FDA. Structure-based rational design of SalL (PDB ID 2Q6I and 2Q6L) and FDAS (PDB 
ID 1RQR) mutants also led to catalytic improvements with targeted non-native 
substrates.19 In addition, SalL-catalyzed AdoMet analog production has been successfully 
coupled to the model MTs arginine methyltransferase 1 (PRMT1), DNA MT HhaI and the 
natural product MT MtfA.19,46 Reminiscent of the 7dzAdotMet isosteres described in the 
prior section, SalL-catalyzed synthesis of the thieno[3,4-d]pyrimidine-based thAdoMet was 
also recently reported.47 While thAdoMet stability was not assessed, thAdoMet served as a 
functional cosubstrate for the model DNA MT M.TaqI. Like MATs, halogenases 
importantly enable coupling to downstream AdoMet-utilizing processes in vitro. Whether 
ClDA/FDA uptake (compared to readily available cellular ATP for MAT) impacts cell-
based applications remains to be determined. 
 
1.4 AdoMet analog applications 
 
The pioneering applications of non-native AdoMet cosubstrates in MT-catalyzed 
reactions to afford non-native alkylation of DNA6 and the indolocarbazole rebeccamycin7 
reported in 2006 by Weinhold group and the Rajski/Thorson collaborative team, 
respectively, served as the key proof of concept for an array of subsequent innovative 
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advances and applications (Table 1). This section briefly summarizes recent representative 
examples in the context of modifying nucleic acids, proteins and complex natural products. 
 
1.4.1 Nucleic acids 
DNA/RNA methylation plays a key role in epigenetic regulation of gene expression 
where the vast temporal and spatial complexity presents a notable technological challenge 
to molecular and mechanistic study, further complicated by the high structural conservation 
among nucleic acid MTs (NAMTs).48,49 While cytosine methylation is a highly conserved 
modification across many species and among the best understood nucleic acid 
modifications, many other nucleic acid methylation events also contribute to epigenetic 
regulation.49 AdoMet analogs present a valuable new tool to study these essential processes 
via MT-catalyzed installation of isotopic or chemoselective handles as a framework for 
epigenetic mapping.6,20–23,50–52 This concept has been further extended to track RNA 
modification.53–55 
 
1.4.2 Proteins 
Protein methylation is a key post-translational protein function modulator as 
exemplified by the role of histone and transcription factor methylation in cellular 
differentiation and proliferation.56–58 Here again, the structural conservation among protein 
MTs (PMTs), vast array of protein targets, and corresponding temporal and spatial 
occurrence present significant experimental barriers.3 As with the nucleic acid strategies 
highlighted in the previous section, AdoMet analogs also enable selective installation of 
novel chemoselective handles to track and identify methylation events catalyzed by 
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PMTs,12–18,57–66 the proof of concept of which was first demonstrated by Weinhold and 
coworkers using the wild-type PMT Dim-5 and AdoMet analog 18 (Table 1).59 
Interestingly, while 18 is also a validated substrate of other wild-type PMTs and 
NAMTs,50,53 Luo and collaborators more recently reported the need for engineered PMTs 
to accommodate this AdoMet analog in the pursuit of putative bioorthogonal reagents to 
study PMT-catalyzed methylation events in vitro and in living cells.14,17,18,62,64,66,67 Isotopic 
tags have also been installed using corresponding PMTs and suitably-labeled AdoMet 
analogs (Table 1, entries 1 – 3).68–73 
 
1.4.3 Natural products 
Natural product (NP) methylation is a highly prevalent biosynthetic reaction where 
natural product methyltransferase (NPMT)-catalyzed regio/stereospecific O-, N-, S- and/or 
C-methylation of the fundamental NP core can contribute to bioactivity modulation.5,74 
Within this context, AdoMet analogs in conjunction with both NPMT domains of large 
multi-functional modular enzyme complexes and standalone late-stage tailoring NPMTs 
have enabled NP ‘alkylrandomization’ (i.e., differential alkylation, the terminology 
reminiscent of NP ‘glycorandomization’75,76) to afford novel coumarins,9 fungal 
polyketides,10 indolocarbazoles,7,11 macrolides,8 nonribosomal peptides,46 and related 
small molecules.9,40,77 Importantly, these technologies present a clear complement to 
conventional synthesis to extend NP structure-activity relationships (SAR) via selective 
NPMT-catalyzed installation of non-native alkyl groups, protecting groups and/or uniquely 
functionalized handles for subsequent downstream chemoselective diversification where 
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C-MTs also offer new avenues to potentially access synthetically difficult C-C bond-
forming operations.9 
 
1.5 Conclusions 
 
As exemplified by the platform development and innovative applications 
summarized within this brief review, S-alkylated AdoMet analogs serve as useful chemical 
biology tools, where practical access has paved the way for a rapidly expanding array of 
opportunities in fundamental discovery and targeted synthesis. A perceived area for 
considerable growth in this regard are cell-based applications, the key for which will be the 
development of universal bioorthogonal AdoMet surrogate/catalyst pairings with high 
catalytic turnover and exquisite selectivity. ‘Bump-and-hole’ technologies,78 such as those 
pioneered by Shokat and colleagues,79 serve as the basis for similar AdoMet adenine-
modified strategies to achieve MT bioorthogonality as exemplified by the early work of 
Schultz and Gray80 and a more recent example by the Zhou group.81 Alternatively, Luo and 
collaborators have pursued putative bioorthogonality via targeting specific AdoMet S-alkyl 
modifications.17,67 This growing precedent suggests a vibrant future for cell-based, and 
possibly even whole animal, applications where the fundamental key to achieving true 
bioorthogonality will depend on the development of AdoMet surrogate/catalyst pairings 
that display suitable selectivity for the targeted process/reaction over native biochemical 
processes/enzymes.82 
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Table 1.1 Summary of AdoMet analog syntheses and applications. 
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Table 1.1 (continued). 
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Figure 1.1. Representative AdoMet utilization and degradation pathways. (a) AdoMet 
serves as a critical alkyl donor in most MT-catalyzed reactions within the context of 
modifying nucleic acids, proteins and small molecule-based metabolites (blue sphere 
signifies methyl in native systems). (b) AdoMet chemically degrades via intramolecular 
cyclization (pathway i) and depurination (pathway ii). 
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Figure 1.2. Key reactions and reagents. (a) General MT-catalyzed reaction scheme 
(AdoHcy, S-adenosyl-L-homocysteine; also known as SAH). MTs can catalyze C-, O-, N- 
or S-methylation. (b) Typical synthetic strategy for AdoMet analog chemical synthesis 
where common leaving groups include halides, triflates, mesylates and tosylates. (c) 
General methionine adenosyl transferase (MAT; also known as S-adenosylmethionine 
synthetase/synthase, SAMS)-catalyzed reaction scheme. (d) Stabilized functional AdoMet 
surrogates afforded via MAT-catalyzed turnover of (S)-3-(methylthio)-1-(1H-tetrazol-5-
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yl)propan-1-amine (tetrazole-L-methionine, L-tMet) and ATP or L-tMet and 7-deaza-ATP 
(7dzATP) to give AdotMet and 7dzAdotMet, respectively.  (e) General halogenase-catalyzed 
reaction scheme (HAL: adenosyl-chloride synthase, SalL, or adenosyl-fluoride synthase, 
FDAS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Portions of Chapter 1 were previously published.83 Reproduced with permission from 
Elsevier: Current Opinion in Biotechnology, Volume 42, Pages 189 – 197, Table 1, Figures 
1 – 2, and Text. Copyright 2016 is given to the publication in which the material was 
originally published. 
Copyright (C) Tyler D. Huber 2019  
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Chapter Two: Facile strategies for the synthesis and utilization of S-adenosyl-L-methionine 
analogs. 
 
2.1 Introduction 
 
 Enzyme-catalyzed late stage group transfer-based tailoring reactions contribute to 
the structural and functional diversity of many complex natural products (NPs).84,85 
Representative examples of include amination, acylation, alkylation, glycosylation, 
halogenation, phosphorylation and sulfation and, in some cases, enzymes responsible for 
such transformations display notable flexibility with respect to their substrate scope.86–88 
Such promiscuity is an enabling feature of chemoenzymatic NP diversification platforms 
as exemplified by NP glycorandomization (a platform for differential glycosylation of 
natural products/drugs).75,89–92 Among the examples above, enzyme-catalyzed alkylation is 
a highly prevalent occurrence that leads to NP N-, O-, S- and/or C-alkylation (Figure 2.1).5 
Thus, a platform to co-opt natural product methyltransferases (MTs) for broad natural 
product differential alkylation (alkylrandomization) is anticipated to dramatically expand 
the potential scope of NP chemical diversity. 
 The typical alkyl donor for MT-catalyzed alkylation is S-adenosyl-L-methionine 
(SAM) and importantly, we and others have demonstrated NP,7,9,10  protein,13,14,19,33,61,62 
and nucleic acid6,22,32,93 MTs to transfer alternative alkyl groups in the presence of suitably 
modified SAM analogs. However, reminiscent of the restriction imposed upon 
glycorandomization by sugar nucleotide availability, access to stable SAM analog arrays 
similarly restricts NP alkylrandomization development. Current state-of-art for SAM 
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analog chemical synthesis relies upon multi-step syntheses of diastereomeric SAM analog 
mixtures and requires HPLC purification to remove starting material, S-adenosyl-
homocysteine (SAH, a strong inhibitor of MTs).94 The desired purified SAM analogs from 
this process are also markedly unstable, therby limiting their practical development as 
standalone synthetic reagents and/or biological probes. Within this context, a general 
platform to enable the generation and direct utilization of SAM analogs, beginning from 
stable precursors, would be considered advantageous. 
 To address this need, herein we describe the broad substrate specificity assessment 
of a representative set of five distinct methionine adenosyltransferases (MATs) from 
various sources. MAT (EC 2.5.1.6; also sometimes referred to as AdoMet synthetase or 
SAM synthetase) is the primary catalyst used for the biosynthesis of SAM from adenine 
triphosphate (ATP) and L-methionine (Met) (Scheme 2.1a) and there is preliminary 
evidence to suggest certain MATs to be capable of Met analog utilization.14,95,96 Consistent 
with this notion, the studies highlighted herein reveal human MAT II (hMAT2) to enable 
the cumulative synthesis of a broad panel of unnatural SAM analogs (29 analogs detected) 
starting from synthetic S/Se-alkylated Met analogs (44 analogs) or commercial sources (3 
analogs). To demonstrate the feasibility of NP alkylrandomization, this study also 
highlights the subsequent generation of a small set of indolocarbazole analogs using a 
coupled hMAT2-RebM system, where RebM is the sugar C4’-O-MT involved in 
rebeccamycin biosynthesis.7,97–100 This study offers both a strategic advance in terms of NP 
diversification and reveals hMAT2 to display surprising permissivity. 
 Given the conflicting reports regarding the relative stability of S- versus Se-
SAM13,33,36,101 and the fact that Se-SAM is considered a better alkyl donor than S-SAM in 
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MT-catalyzed reactions due to the inherently longer and weaker Se-C bond,101 both S- and 
Se-Met analogs were synthesized for this study. The general strategy for the synthesis of 
the S- and Se-Met analog panel employed direct or reductive alkylation of the 
corresponding L-homocysteine dimer (1 or 1-Se, Scheme 2.1b i and iii, respectively), L-
Hcy (Scheme 2.1b, ii) or 2-Se (Scheme 2.1b, iv) following simple modifications of 
previously reported strategies.102,103 The desired S- and Se-Met analogs were purified from 
crude reaction mixtures by reverse phase high pressure liquid chromatography (RP-
HPLC), C18 RP flash chromatography or Dowex 50W8X-200 resin to afford isolated yields 
ranging from 20–90% (Table 2.1).  
 A representative set of MATs from variant sources, including bacterial, archaeal 
and mammalian orthologs, were selected for the initial assessment. Specifically, the 
exploratory set included human  MAT II catalytic alpha and regulatory beta subunit 
(hMAT2),104 human MAT II catalytic alpha subunit alone (hMAT2A),104 human MAT I 
catalytic subunit alpha (hMAT1A),104 Escherichia coli MAT (eMAT),105 and the 
thermophilic Methanocaldococcus jannaschii MAT (mMAT).106 The basis for inclusion of 
the human homologs derives from an interest to interrogate the substrate specificities of 
disease-relevant hMATs,4 while the additional bacterial and archaeal homologs were 
selected to compare and contrast the current study with prior work relating to their substrate 
specificities.95,107  
 Standard uniform assay conditions (2 mM Met analog, 1 mM ATP, 5 µM MAT, 25 
mM Tris, 5 mM MgCl2, 50 mM KCl, pH 8, 4 h) were adopted to facilitate this broad 
assessment. For the thermophilic counterpart (mMAT), reactions were conducted at 65 °C, 
while all other reactions were incubated at 37 °C. Production of SAM analogs was 
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determined by a simple RP-HPLC end point assay to afford complete analysis of the 
desired SAM analog and/or any corresponding degradation products known to directly 
derive from the desired SAM analog intermediate. Putative SAM analog and SAM-derived 
degradative product formation was subsequently confirmed via HRMS analysis for all 
positive reactions (see Table 2.2). 
 
2.2 Results and discussion 
 
 A cumulative comparison of the substrate specificity for all five MAT model 
systems based upon RP-HPLC is illustrated in Figure 2.2 wherein observed 5ʹ-methyl-
thio(seleno)-5ʹ-deoxyadenosine (MTA) production (via RP-HPLC)  was interpreted as 
product based upon the well-established SAM decay pathways indicating MTA to directly 
derive from SAM (not ATP).13,35,36 This cumulative analysis revealed hMAT2 to be the 
most permissive of the MATs tested at 37 °C, while the thermophilic mMAT also displayed 
notable permissivity at 65 °C. Of the 47 putative substrates tested with hMAT2, 10 led to 
appreciable (>50%) SAM analog production, an additional 8 led to moderate (25-50%) 
conversion, while 11 offered detectable product (<25%) under the conditions described. In 
general, smaller alkyl substitutions were better tolerated, suggesting steric infringement to 
possibly prohibit larger substitutions. Interestingly, in the case where direct comparisons 
could be made, the degree of unsaturation correlated with a reduction in turnover (e.g., 
propyl > allyl > propargyl). Also, in most cases, Se- analogs were preferred over their S- 
comparators, most notably for hMAT2. Consistent with previous studies,108 the regulatory 
beta subunit of MAT2A improved the overall proficiency of hMAT2 and, in some cases, 
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this increase in proficiency translated to a slight increase in permissivity in the current 
study. Finally, the addition of inorganic pyrophosphatase in an attempt to drive the reaction 
via degradation of the pyrophosphate co-product did not appreciably increase turnover. 
 Based on these results, the corresponding MATs can be generally classified as 
having broad (hMAT2/hMAT2A), medium (mMAT) or stringent (eMAT and hMAT1A) 
substrate specificities. Superimposition of available X-ray structures (hMAT1A, hMAT2A 
and eMAT) reveal a root mean square deviation (rmsd) of 0.268 Å between hMAT2A and 
hMAT1A (sequence identity of ~85%) and ~0.56 Å between eMAT and hMAT1A or 
hMAT2A (sequence identity of ~58%) (Figure 2.6). Structural comparison of the 
permissive (hMAT2A) and stringent (hMAT1A and eMAT) MATs highlights key 
distinctions among residues (Figure 2.3). Interestingly, while hMAT2A active site 
mutagenesis has led to a slight improvement in turnover with an unnatural analog,14 the 
current structural comparison suggests the broad substrate specificity of hMAT2A to be 
predominately mediated by residues within the secondary shell and/or on the solvent-
exposed surface distal to active-site loops that likely contribute to interdomain 
movement/dynamics. Whether or not these residues contribute to the hMAT2 alpha/beta 
interface is currently unknown. 
 To subsequently assess the feasibility of ‘alkylrandomization’ via a single vessel 
coupled MAT/MT reaction, the rebeccamycin MT RebM was selected as the 
representative MT. RebM is the sugar C4’-O-MT involved in rebeccamycin biosynthesis 
and has previously been demonstrated to tolerate both alternative acceptors and alkyl 
donors.7,97–100 The coupled system also employed standard assay conditions (2 mM Met 
analog, 1 mM ATP, 50 μM rebeccamycin congener 31, 5 µM hMAT2, 10 µM RebM, 5 
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µM SAH-hydrolase, 25 mM Tris, 5 mM MgCl2, 50 mM KCl, pH 8, 24 h at 37 °C) and 
included only S/Se-Met analogs that afforded ≥20% turnover with hMAT2 under 
standard conditions (Figure 2.2). From this pilot study, 8 out of 18 of the selected S/Se-
Met series led to the production of the corresponding differentially alkylated 
indolocarbazoles in appreciable yields (≥40%, Scheme 2.2 and Figure 2.7b). 
Importantly, inclusion of SAH-hydrolase (SAHH) in the coupled reaction, to prevent 
product inhibition associated with most if not all MTs,109 improved overall product yields 
by 15-40%.  Notably, this is the first report of MT-catalyzed acetonitrilylation (35 
deriving from L-Met analog 6 or 6-Se). 
 
2.3 Conclusions 
 
 In conclusion, the broad substrate specificity analysis presented revealed 
hMAT2/2A and mMAT to display notably broad substrate tolerance. Of these, hMAT2A 
is over-expressed in a number of tumor types,110–112 where inhibition of hMAT2A by small 
molecule inhibitors or siRNA affords dramatic tumor reduction.113,114 The discovered 
substrate malleability of hMAT2A in conjunction with aberrant cancer-specific hMAT2A 
overexpression therefore may offer the potential to employ suitable S/Se-Met analogs as 
cell-based metabolic probes of the role of methylation in cancer. In addition, the work 
highlighted herein enables the facile syntheses of SAM analogs directly compatible with 
downstream SAM-utilizing enzymes, including MTs, and is advantageous over other 
recently reported chemoenzymatic strategies that depend upon synthetic non-native 
alkylated amino acid alkyl donors and nucleoside acceptors.19 As such, this platform 
20 
 
circumvents a major liability of prior SAM analog/MT strategies, namely SAM analog 
decomposition, and thereby opens the door to the further interrogation of a host of MTs 
which operate upon macromolecular (protein/nucleic acid) and small molecule (natural 
products) substrates. Finally, the strategy presented unveils a single vessel proof of concept 
for natural product ‘alkylrandomization’ which, while currently somewhat limited via 
enzyme specificity, is expected to be further advanced via MT/MAT directed evolution 
and/or structure-based engineering in a manner reminiscent to that used for advancing 
glycorandomization.75,89–92,115–122 
 
2.4 Materials and methods 
 
2.4.1 General materials 
 Unless otherwise stated, all general chemicals and reagents were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) or Acros (New Jersey, USA) and were reagent grade 
or better. L-homocysteine was purchased from Bachem (Torrance, CA, USA). L-
homocystine123 and L-selenohomocystine124 were synthesized following previously 
published protocols. E. coli BL21(DE3) competent cells were purchased from Invitrogen 
(Carlsbad, CA). The pET28a E. coli expression vector was purchased from Novagen 
(Madison, WI). Primers were purchased from Integrated DNA Technology (Coralville, 
IA). Pfu DNA polymerase was purchased from Stratagene (La Jolla, CA). Restriction 
enzymes and T4 DNA ligase were purchased from New England Biolabs (Ipswich, MA). 
PD-10 column and Ni-NTA superflow columns were purchased from GE Healthcare 
(Piscataway, NJ). 
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2.4.2 General methods 
 High-resolution mass spectrometric data were obtained using a Waters (Milford, 
MA) LCT time-of-flight spectrometer for electrospray ionization (ESI) or AB SCIEX 
TripleTOF® 5600 System. NMR spectra were obtained on Varian Unity Inova 400 or 500 
MHz instruments (Palo Alto, CA) at the NMR facility of College of Pharmacy at University 
of Kentucky using 99.8% CDCl3 with 0.05% v/v TMS, 99.8% CD3OD or 99.8% D2O from 
Cambridge Isotopes (Cambridge Isotope Laboratories, MA, USA). 1H and 13C chemical 
shifts were referenced to internal solvent resonances. Multiplicities are indicated by s 
(singlet), d (doublet), t (triplet), q (quartet), quin (quintet), m (multiplet), and br (broad). 
Chemical shifts are reported in parts per million (ppm) and coupling constants J are given 
in Hz. Routine 13C NMR spectra were fully decoupled by broad-broad WALTZ 
decoupling. All NMR spectra were recorded at ambient temperature. Normal-phase flash 
chromatography was performed on 40 – 63 µm, 60 Å silica gel (from Silicycle, Quebec, 
Canada). Analytical TLC was performed on silica gel glass TLC plates (from EMD 
chemical Inc). Visualization was accomplished with UV light (254 nm) followed by 
staining with dilute sulfuric acid (5% in ethanol) solution or 10% ninhydrin in ethanol and 
heating. HPLC was accomplished using an Agilent 1260 system equipped with a DAD 
detector.  Method A (HPLC): Analytical reverse-phase (RP) HPLC was conducted with 
a Luna C-18 (5 μm, 4.6 mm × 250 mm) column (Phenomenex, Torrance, California, USA) 
[gradient of 1% B to 40% B over 22 min, 55% B to 100% B over 3 min, 100% B for 6 min, 
100% B to 5% B over 1 min, 5% B for 3 min (A = ddH2O with 0.1% TFA; B = acetonitrile) 
flow rate = 1 mL min-1; A218]. The reaction was monitored by the retention time difference 
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between starting material and product. Method B (HPLC): Semi-preparative RP HPLC 
was conducted on a Gemini C18 (5 μm, 10 × 250 mm; Phenomenex, Torrance, California, 
USA) column to purify the methionine analogs [gradient of 5% B to 55% B over 25 min, 
55% B to 100% B over 2 min, 100% B for 6 min, 100% B to 5% B over 1 min, 5% B for 
4 min (A = ddH2O with 0.1% TFA; B = acetonitrile) flow rate = 4.5 mL min
-1; A218]. 
Method C (flash chromatography): Pilot reversed-phase purification was conducted by 
flash column chromatography using an Alltech C18 Extract-Clean column (10,000 mg, 75 
mL, Alltech Associates, Deerfield, IL, USA) for the scale-up purification of methionine 
analogs. The column was pre-equilibrated with ddH2O/0.1% TFA and after loading the 
solid crude material, a gradient of 100/0 to 60/40 water:acetonitrile containing 0.1% TFA 
was used as the mobile phase. Eluted fractions were checked by TLC (15:1:84 
MeOH/NH4OH/CHCl3, ninhydrin stain) and confirmed via analytical HPLC (method A) 
to identify product fractions. Method D (HPLC): To monitor MAT reactions, analytical 
RP HPLC employed a Luna C18 column (5 μm, 4.6 mm × 250 mm; Phenomenex, Torrance, 
California, USA) [gradient of 10% B to 40% B over 15 min, 40% B to 75% B over 5 min 
(A = 10 mM NaH2PO4, 5 mM octane sulfonic acid, pH was adjusted to 3.5 using 
phosphoric acid; B = acetonitrile) flow rate = 1 mL min-1; A254]. Method E (HPLC): To 
monitor the coupled hMAT2/RebM reactions, analytical RP HPLC was conducted with a 
Luna C18 column (5 μm, 4.6 mm × 250 mm; Phenomenex, Torrance, California, USA) 
[gradient of 10% B to 100% B over 20 min (A = ddH2O with 0.1% TFA; B = acetonitrile) 
flow rate = 1 mL min-1; A315].  
 The sequence of MATs involved in this study can be found within the National 
Center for Biotechnology Information (NCBI) Protein database and include: Homo sapiens 
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MAT2A (hMAT2A; genebank accession number AAH01686.1); Homo sapiens MAT1A 
(hMAT1A, genebank accession number AAQ89058.1);  Homo sapiens MAT II (co-
expression of MAT2A with MAT2B; genebank accession number AAH01686.1); 
Escherichia coli MAT (eMAT; genebank accession number AAG58073.1); and 
Methanocaldococcus jannaschii (mMAT; genebank accession number Q58605.1). All 
DNA sequencing was conducted by the University of Wisconsin Biotechnology Center 
with the primers T7 promoter (5’-TAATACGACTCACTATAGGG) or T7 terminator (5’-
GCTAGTTATTGCTCAGCGG). All Luria-Bertani (LB) media and agar were 
supplemented with 35 μg mL-1 kanamycin. High-throughput assay absorbance readings 
were conducted using a FLUOstar Omega plate reader (BMG Labtechnologies, Cary, NC, 
USA). HPLC peak areas were integrated with Star Chromatography Workstation Software 
(Varian, Palo Alto, CA, USA) and the percent conversion calculated as a percent of the 
total peak area. High resolution electrospray ionization (ESI) mass spectra were recorded 
on a AB Sciex Triple TOF 5600 instrument coupled with an Eksigent Ekspert micro LC 
200 system with source temperature of 150 °C, ion spray voltage floating (ISVF) of 5000 
V in positive mode. Samples were infused at 20 µL min-1 and spectra collected for 3 min 
at a resolution greater than 31000. In negative mode ISVF of -4000 V was used. C17 
lysophosphatidyl choline with a mass of 510.3554 and C17 lysophosphatidic acid with a 
mass of 423.2517 were used as internal references to calibrate the spectra in positive and 
negative modes respectively. 
 
2.4.3 General procedure for azido installation 
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 See Figure 2.4a. This method was used for the syntheses of compounds 17, 21, 23, 
23-Se, 28, 29, and 30. Dibromo-alkane (1.0 g, 1.0 eq) was dissolved in 20 mL CH2Cl2 and 
to this was added nBu4NHSO4 (0.5 eq) and NaN3 (0.8 eq) under stirring. A 20 mL sat. 
NaHCO3 solution was subsequently added and the reaction was stirred vigorously for 2 h. 
The organic layer was washed with water and brine (20 mL each) and then dried over 
Na2SO4. After the CH2Cl2 solvent was concentrated in vacuo carefully, the product was 
used directly as a monobromo or dibromo mixture without further purification for the 
alkylation reaction. 
 
2.4.4 General procedure for the Na/NH3 reduction & S-alkylation of L-homocystine 
 See Figure 2.4b. This method was used for the syntheses of compounds 3, 4, 5, 8-
19, 21-23, 25, 26, and 28-30. L,L-homocystine (100 mg, 0.37 mmol) (from Bachem, 
Torrance, CA, USA) was added to 20 mL liquid ammonia at -78 ºC and stirred until fully 
dissolved. Small fragments of sodium metal (34 mg, 1.5 mmol) were added until a deep 
blue color persisted for at least 1 min. The corresponding alkyl bromide (2.0 eq) was then 
introduced, which caused the blue solution to quickly proceed to a mixture with a white 
precipitate. Ammonium chloride (20 mg, 0.37 mmol) was then added to the reaction and 
the reaction was immediately removed from the cooling bath. The reaction flask was left 
open to the atmosphere at ambient temperature to allow ammonia to evaporate. The 
resulting residue was dissolved in 5 mL deionized water and the pH was adjusted to pH 5 
- 7 by the addition of 1 M HCl. The solvent was removed under reduced pressure and the 
residue was dried. A fraction (10 mg) of the dried residue was dissolved with 400 µL dH2O 
with 0.1% TFA, adjusted to pH 3 by the addition of 1 M HCl, centrifuged and subsequently 
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purified by semi-preparative HPLC (method B) to ultimately afford the desired S-alkylated 
L-methionine analogs in 22% - 99% yield. 
 
2.4.5 General procedure for the S-alkylation of L-homocysteine 
 See Figure 2.4c. This method was used for the syntheses of compounds 6, 7, 20, 
and 27. L-homocysteine (10 mg, 0.07 mmol) was dissolved in 1 mL acetone and to this was 
added the corresponding alkyl bromide (2.0 eq) and K2CO3 (20 mg, 0.14 mmol). The 
reaction was stirred under room temperature until HPLC indicated the completion of the 
reaction (method A, see general methods). The solvent was removed in vacuo, the resulting 
residue was dissolved in 400 µL dH2O with 0.1% TFA, adjusted to pH 3 by the addition 
of 1 M HCl, centrifuged and subsequently purified by semi-preparative HPLC (method B) 
to ultimately afford the desired S-alkylated L-methionine analogs in 20% - 60% yield. 
 
2.4.6 General procedure for the Na/NH3 reduction & Se-alkylation of L-selenohomocystine 
 See Figure 2.4d. This method was used for the syntheses of compounds 3-Se, 4-
Se, 7-Se, 12-Se, and 23-Se. L-Selenohomocystine (100 mg, 0.27 mmol) was treated in 
manner identical to that described in section 3.1. to provide the desired Se-alkylated L-
selenomethionine analogs in yields ranging from 16% - 85% yield. 
 
2.4.7 General procedure for the NaBH4 reduction & Se-alkylation of L-selenohomocystine 
 See Figure 2.4e. This method was used for the syntheses of compounds 6-Se, 8-
Se, 10-Se, 13-Se, 15-Se, 19-Se, 20-Se, 24-Se, and 27-Se. According to a procedure from 
Zhang et al.,103 to the THF solution of L-selenohomocystine (100 mg, 0.276 mmol) in a 
26 
 
small flask was added alkyl bromide (4.0 eq) under N2 with stirring at room temperature. 
NaBH4 (83.5 mg, 2.21 mmol, 8 eq) was dissolved in 0.12 M NaOH/water and this solution 
was introduced to the reaction flask drop-wise via syringe. The reaction was subsequently 
stirred under N2 at room temperature for 5 h and then adjusted to pH 5 – 7 by addition of 
1 M HCl. The solvent was removed completely under reduced pressure and the residue was 
dried. A portion (10 mg) of the dried residue was dissolved with 400 µL H2O with 0.1% 
TFA, adjusted to pH 3 by addition of 1 M HCl, centrifuged and the supernatant was purified 
by preparative HPLC (method B) to provide the desired Se-alkylated L-selenomethionine 
analogs in yields ranging from 18% - 99% yield. 
 
2.4.8 General procedure for the demethylation & Se-alkylation of L-selenomethionine 
 See Figure 2.4f. This method was used for the syntheses of compounds 9-Se and 
22-Se. According to a procedure from Dekker, et al,125 L-selenomethionine (100 mg, 0.51 
mmol) was dissolved in 5 mL of concentrated HCl and to this was added the corresponding 
alkyl bromide (5.0 eq). The reaction was refluxed at 100 oC for 12 h. The reaction was then 
allowed to cool down to room temperature, diluted with water (10 mL), and adjusted with 
30% NH4OH to pH = 7. The solvent was concentrated under reduced pressure to less than 
1 mL, frozen at -80 oC, and lyophilized to form a dry powder. The powder was purified by 
reversed-phase flash chromatography (method C), to give 9-Se (9% yield) and 22-Se (7% 
yield). 
 
2.4.9 Specific procedures for the syntheses of L-(seleno)methionine analogs 
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(2S)-2-amino-4-(ethylsulfanyl)butanoic acid (3). Slight modications of the strategy 
illustrated in Fig. 2.4b were employed for the synthesis of 3. Specifically, the dried 
residue after completion of the L-Homocystine (250 mg, 0.932 mmol)/iodoethane (165 
µL, 2.04 mmol) and subsequent evaporation of NH3 was dissolved in ddH2O (30 mL) 
and solid NaOH (1.20 g, 0.03 mol) was added, creating a 1 M sodium hydroxide solution. 
After stirring for 1 h, the basic solution was slowly loaded onto a Dowex 50W8X-200 
2.5 cm x 3 cm column  column prequilibrated with ddH2O. The column was washed with 
several column volumes of ddH2O and the product subseqeuntly eluted with 2.5% 
aqueous NH4OH. The fractions, identified by TLC (15:1:84 MeOH/NH4OH/CHCl3, 
ninhydrin stain), were combined and lyophilized to a white amorphous solid (184 mg, 
61% yield). 1H NMR (DMSO-d6/TFA-d1 = 20/1, 500 MHz) δ  4.01 (t, J = 6.2 Hz, 1 H), 
2.48 - 2.64 (m, 2 H), 2.49 (q, J = 7.3 Hz, 2 H), 2.00 (m, 2 H), 1.17 (t, J = 7.3 Hz, 3 H); 
13C NMR (DMSO-d6/TFA-d1 = 20/1, 125 MHz) δ 175.9, 56.3, 35.4, 31.4, 30.0, 20.1; 
HRESI Calcd for C6H14NO2S ([M+H]
+) m/z 164.0740; measured m/z 164.0744. 
 
(2S)-2-amino-4-(ethylselanyl)butanoic acid (3-Se). Fig. 2.4d with bromoethane yielded 
3-Se (4.1 mg, 85% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 3.85 (t, J = 6.2 
Hz, 1 H), 2.43 - 2.50 (m, 4 H), 2.01 - 2.11 (m, 2 H), 1.19 (t, J = 7.6 Hz, 3 H); 13C NMR 
(D2O, 100 MHz) δ 172.6, 53.5, 30.8, 17.0, 16.8, 14.7; HRESI Calcd for C6H14NO2Se 
([M+H]+) m/z 212.0184; measured m/z 212.0187. 
 
(2S)-2-amino-4-(prop-2-yn-1-ylsulfanyl)butanoic acid (4). Fig. 2.4b with propargyl 
bromide yielded 4 (4.5 mg, 75% yield) as a white solid together with 5 (0.3 mg) as a 
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white oil. 1H NMR (D2O/TFA = 20/1, 400 MHz) δ 4.09 (t, J = 6.4 Hz, 1 H), 3.24 (d, J = 
2.8 Hz, 2 H), 2.74 (t, J = 6.8 Hz, 2 H), 2.53 (t, J = 2.4 Hz, 1 H), 2.07 – 2.26 (m, 2 H); 13C 
NMR (D2O/TFA = 20/1, 100 MHz) δ 171.3, 80.0, 72.0, 51.4, 28.8, 26.0, 17.8; HRESI 
Calcd for C7H12NO2S([M+H]
+) m/z 174.0583; measured m/z 174.0582.  
 
(2S)-2-amino-4-(prop-2-yn-1-ylselanyl)butanoic acid (4-Se). Fig. 2.4d with propargyl 
bromide yielded 4-Se (0.8 mg, 16% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 
3.97 (t, J = 6.3 Hz, 1 H), 3.15 (t, J = 1.6 Hz, 2 H), 2.74 (t, J = 7.6 Hz, 2 H), 2.49 (t, J = 
2.6 Hz, 1 H), 2.08 - 2.27 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 172.0, 81.3, 72.0, 53.0, 
30.3, 18.4, 6.3; HRESI Calcd for C7H12NO2Se([M+H]
+) m/z 222.0028;  measured m/z 
222.0035.    
 
(2S)-2-amino-4-(propa-1,2-dien-1-ylsulfanyl)butanoic acid (5). Fig. 2.4b with 
propargyl bromide yielded 5 (0.3 mg, 6% yield) as a white oil together with 4 (4.5 mg, 
75% yield) as a white solid. 5.69 (t, J = 6.4 Hz, 1 H), 4.94 (d, J = 10.4 Hz, 2 H), 4.06 (t, 
J = 6.4 Hz, 1 H), 2.70 (t, J = 7.6 Hz, 2 H), 2.07 – 2.19 (m, 2 H); HRESI Calcd for 
C7H12NO2S([M+H]
+) m/z 174.0583; measured m/z 174.0582. 
 
(2S)-2-amino-4-[(cyanomethyl)sulfanyl]butanoic acid (6). Fig. 2.4c with L-
homocysteine (10 mg, 74 µmol) and bromoacetonitrile yielded 6 (7.6 mg, 59% yield) as 
a white solid. 1H NMR (D2O, 500 MHz) δ 4.10 (t, J = 6.5 H, 1 H), 3.46 (s, 2 H), 2.80 (t, 
J = 11.5 Hz, 2 H), 1.98 – 2.27 (m, 2 H); 13C NMR (D2O, 125 MHz) δ 171.4, 118.5, 51.4, 
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29.0, 27.3, 16.1; HRESI Calcd for C6H11N2O2S([M+H]
+) m/z 175.0536; measured m/z 
175.0534.  
 
(2S)-2-amino-4-[(cyanomethyl)selanyl]butanoic acid (6-Se). Fig. 2.4e with 
bromoacetonitrile yielded 6-Se (1.2 mg, 20% yield) as a white solid. 1H NMR (D2O,  400 
MHz) δ 3.91 (t, J = 6.5 Hz, 1 H), 3.29 (s, 2 H), 2.81 (dd, J = 15.6, 6.8 Hz, 1 H), 2.77 (dd, 
J = 13.2, 6.8 Hz, 1 H), 2.11 - 2.29 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 172.3, 119.6, 
53.2, 30.4, 19.9, 1.9; HRESI Calcd for C6H11N2O2Se([M+H]
+) 222.9980; measured m/z 
222.9973.  
 
(2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic acid (7). Fig. 2.4c with allyl bromide 
yielded 7 (5.3 mg, 41% yield) as a white solid. 1H NMR (D2O/TFA = 20/1,  400 MHz) δ 
5.61 - 5.72 (m, 1 H), 5.04 (d, J = 10.8 Hz, 1 H), 4.98 (d, J = 2.0 Hz, 1 H), 3.85 (t, J = 6.8 
Hz, 1 H), 3.05 (dd, J = 7.2, 0.8 Hz, 2 H), 2.48 (t, J = 7.6 Hz, 2 H), 1.92 - 2.10 (m, 2 H); 
13C NMR (DMSO-d6/TFA-d1 = 8/1, 125 MHz) δ 171.2, 134.9, 117.9, 51.5, 34.0, 30.4, 
25.9; HRESI Calcd for C7H14NO2S([M+H]
+) m/z 176.0740; measured m/z 176.0728. 
  
(2S)-2-amino-4-(prop-2-en-1-ylselanyl)butanoic acid (7-Se). Fig. 2.4d with allyl 
bromide yielded 7-Se (3.0 mg, 59% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 
5.70 - 5.77 (m, 1 H), 4.9 (m, 2 H), 3.90 (t, J = 6.3 Hz, 1 H), 3.08 (d, J = 7.8 Hz, 2 H), 
2.45 (t, J = 8.2 Hz, 2 H), 2.03 - 2.10 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 172.1, 134.6, 
116.6, 53.2, 30.5, 25.2, 16.7; HRESI Calcd for C7H14NO2Se([M+H]
+) m/z 224.0184;  
measured m/z 224.0179. 
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(2S)-2-amino-4-(propylsulfanyl)butanoic acid (8). A protocol identical to that described 
for 3 using L-Homocystine (150 mg, 0.559 mmol) and 1-bromopropane (112 µL, 1.23 
mmol) gave compound 8 (181 mg, 91% yield) as a white amorphous solid. 1H NMR 
(DMSO-d6/TFA-d1 = 20/1, 400 MHz) δ 4.05 (t, J = 6.8 Hz, 1 H), 2.61 (m, 2 H), 2.50 (t, 
J = 7.3 Hz, 2 H), 2.03 - 2.09 (m, 2 H), 1.56 (quin, J = 7.3 Hz, 2 H), 0.96 (t, J = 7.2 Hz, 3 
H); 13C NMR (DMSO-d6/TFA-d1 = 20/1, 125 MHz) δ 171.2, 51.5, 33.3, 30.6, 26.9, 22.9, 
13.6; HRESI Calcd for C7H16NO2S ([M+H]
+) m/z 178.0896;  measured m/z 178.0900. 
 
(2S)-2-amino-4-(propylselanyl)butanoic acid (8-Se). Fig. 2.4e with 1-bromopropane 
yielded 8-Se (3.1 mg, 50% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 3.97 (t, J 
= 6.8 Hz, 1 H), 2.34 (t, J = 7.6 Hz, 2 H), 2.27 (t, J = 7.0 Hz, 2 H), 1.95 - 2.13 (m, 2 H), 
1.30 (dt, J = 7.2, 7.0 Hz, 2 H), 0.59 (t, J = 7.2 Hz, 3 H); 13C NMR (D2O, 100 MHz) δ 
171.3, 52.6, 30.4, 25.9, 22.9, 17.1, 13.5; HRESI Calcd for C7H16NO2Se([M+H]
+) m/z 
226.0341;  measured m/z 226.0353. 
 
(2S)-2-amino-4-(propan-2-ylsulfanyl)butanoic acid (9). Fig. 2.4b with 2-bromopropane 
yielded 9 (1.2 mg, 22% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 4.01 (t, J = 
6.5 Hz, 1 H), 2.89 (quin, J = 6.8 Hz, 1 H), 2.59 (t, J = 7.4 Hz, 2 H), 1.96 - 2.12 (m, 2 H), 
1.09 (d, J = 6.7 Hz, 6 H); 13C NMR (D2O, 100 MHz) δ 171.8, 52.0, 34.2, 29.8, 24.8, 22.2 
(2 carbons); HRESI Calcd for C7H16NO2S([M+H]
+) m/z 178.0896;  measured m/z 
178.0887.  
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(2S)-2-amino-4-(propan-2-ylselanyl)butanoic acid (9-Se). Fig. 2.4f with 2-
bromopropane (0.24 mL, 2.54 mmol) yielded 9-Se (10 mg, 9% yield) as a white solid. L-
selenomethionine (94.9 mg) was recovered after flash reversed-phase chromatography 
via method C (see general methods). 1H NMR (D2O,  400 MHz) δ 3.83 (t, J = 6.3 Hz, 1 
H), 3.09 (quin, J = 6.85 Hz, 1 H), 2.55 (t, J = 7.8 Hz, 2 H), 2.04 - 2.17 (m, 2 H), 1.24 (d, 
J = 7.0 Hz, 6 H); 13C NMR (D2O, 100 MHz) δ 110.0, 53.9, 31.3, 29.4, 23.5, 23.4, 16.7; 
HRESI Calcd for C7H16NO2Se([M+H]
+) m/z 226.0341; measured m/z 226.0333. 
 
(2S)-2-amino-4-(but-3-yn-1-ylsulfanyl)butanoic acid (10). Fig. 2.4b with 4-bromo-1-
butyne yielded 10 (1.9 mg, 33% yield) as a white oil. 1H NMR (D2O,  400 MHz) δ 3.88 
(t, J = 6.4 Hz, 1 H), 2.62 (t, J = 5.2 Hz, 2 H), 2.58 (t, J = 7.2 Hz, 2 H), 2.40 (td, J = 6.8 
Hz, 2.4 Hz, 1 H), 2.27 (t, J = 2.54 Hz, 1 H), 1.98 - 2.14 (m, 2 H); 13C NMR (D2O, 100 
MHz) δ 172.8, 83.6, 70.3, 52.7, 29.8, 29.5, 26.4, 18.6; HRESI Calcd for 
C8H14NO2S([M+H]
+) m/z 188.0740;  measured m/z 188.0759. 
 
(2S)-2-amino-4-(but-3-yn-1-ylselanyl)butanoic acid (10-Se). Fig. 2.4e with 4-bromo-1-
butyne yielded 10-Se (2.1 mg, 33% yield) as a light yellow solid. 1H NMR (D2O,  400 
MHz) δ 3.92 (t, J = 6.3 Hz, 1 H), 2.61 (t, J = 6.8 Hz, 2 H), 2.57 (t, J = 8.0 Hz, 2 H), 2.44 
(td, J = 7.2 Hz, 2.8 Hz, 2 H), 2.20 (t, J = 2.4 Hz, 1 H), 2.02 - 2.20 (m, 2 H); 13C NMR 
(D2O, 100 MHz) δ 172.1, 84.3, 70.1, 53.1, 30.7, 21.4, 19.5, 17.7; HRESI Calcd for 
C8H14NO2Se([M+H]
+) m/z 236.0184; measured m/z 236.0200.   
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(2S)-2-amino-4-[(2E)-but-2-en-1-ylsulfanyl]butanoic acid (11). A protocol identical to 
that described for 3 using L-Homocystine (150 mg, 0.559 mmol) and (2E)-1-bromo-2-
butene (125 μL, 1.23 mmol) gave compound 11 (169 mg, 80% yield) as a white 
amorphous solid. 1H NMR (D2O,  400 MHz) δ 5.40 (m, 1 H), 5.24 (m, 1 H), 3.97 (t, J = 
6.0 Hz, 1 H), 2.92 (d, J = 7.2 Hz, 2 H), 2.42 (t, J = 7.6 Hz, 2 H), 1.91 – 2.03 (m, 2 H), 
1.44 (d, J = 5.6 Hz, 3 H); 13C NMR (D2O, 100 MHz) δ 171.4, 129.8, 125.9, 51.7, 32.4, 
29.11, 24.6, 16.7. HRESI Calcd for C8H16NO2S([M+H]
+) m/z 190.0896; measured m/z 
190.0904.    
 
(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)sulfanyl]butanoic acid (12). A protocol 
identical to that described for 3 using L-Homocystine (150 mg, 0.559 mmol) and 3-
bromo-2-methylpropene (223 μL, 2.20 mmol) gave compound 12 (169 mg, 80% yield) 
was obtained as a white amorphous solid. 1H NMR (DMSO-d6/TFA-d1 = 20/1, 400 MHz) 
δ 4.88 (dd, J = 4.6, 3.2 Hz, 2 H), 4.04 (t, J = 6.4 Hz, 1 H), 3.15 (s, 2 H), 2.53 (m, 2 H), 
2.05  -2.09 (m, 2 H), 1.78 (s, 3 H); 13C NMR (DMSO-d6/TFA-d1 = 20/1, 125 MHz) δ 
171.1, 141.4, 136.5, 51.5, 38.4, 30.1, 26.1, 20.8; HRESI Calcd for C8H16NO2S ([M+H]
+) 
m/z 190.0896;  measured m/z 190.0904. 
 
(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)selanyl]butanoic acid (12-Se). Fig. 2.4d with 
3-bromo-2-methylpropene yielded 12-Se (5.0 mg, 85% yield) as a white solid. 1H NMR 
(D2O,  400 MHz) δ 4.6 (m, 2 H), 3.99 (t, J = 6.5 Hz, 1 H), 3.11 (s, 2 H), 2.43 - 2.50 (m, 2 
H), 1.98 - 2.11 (m, 2 H), 1.54 (s, 3 H); 13C NMR (D2O, 100 MHz) δ 171.4, 142.4, 113.0, 
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52.7, 30.5, 30.3, 20.0, 17.2; HRESI Calcd for C8H15NO2SeNa([M+Na]
+) m/z 260.0160; 
measured m/z 260.0157.  
  
(2S)-2-amino-4-(butylsulfanyl)butanoic acid (13). Fig. 2.4b with 1-bromobutane 
yielded 13 (6.4 mg, 99% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 4.00 (t, J = 
6.3 Hz, 1 H), 2.56 (t, J = 7.4 Hz, 2 H), 2.45 (t, J = 7.2 Hz, 2 H), 1.96 – 2.11 (m, 2 H), 
1.41 (quin, J = 7.4 Hz, 2 H), 1.23 (dt, J = 7.4, 6.8 Hz, 2 H), 0.73 (t, J = 7.2 Hz, 3 H); 13C 
NMR (D2O, 100 MHz) δ 172.0, 52.1, 30.6, 30.4, 29.5, 26.2, 21.2, 12.7; HRESI Calcd for 
C8H18NO2S([M+H]
+) m/z 192.1053;  measured m/z 192.1074.  
 
(2S)-2-amino-4-(butylselanyl)butanoic acid (13-Se). Fig. 2.4e with 1-bromobutane 
yielded 13-Se (9.3 mg, 100% yield) as a white solid. 1H NMR (D2O,  400 MHz) δ 4.01 
(t, J = 6.5 Hz, 1 H), 2.53 (m, 4 H), 2.05 - 2.15 (m, 2 H), 1.49 (quin, J = 7.4 Hz, 2 H), 1.23 
(dt, J = 7.6, 7.4 Hz, 2 H), 0.74 (t, J = 7.4 Hz, 3 H); 13C NMR (D2O, 100 MHz) δ 171.8, 
52.8, 31.6, 30.6, 23.4, 22.2, 17.1, 12.6; HRESI Calcd for C8H18NO2Se([M+H]
+) m/z 
240.0497; measured m/z 240.0510. 
 
(2S)-2-amino-4-[(2-methylpropyl)sulfanyl]butanoic acid (14). Fig. 2.4b with 2-bromo-
propane yielded 14 (6.4 mg, 99% yield) as a white solid. 1H NMR (D2O/TFA = 20/1,  400 
MHz) δ 4.04 (t, J = 6.3 Hz, 1 H), 2.54 (t, J = 7.4 Hz, 2 H), 2.32 (d, J = 7.0 Hz, 2 H), 2.00 
- 2.12 (m, 2 H), 1.6 (m, 1 H), 0.78 (d, J = 6.7 Hz, 6 H); 13C NMR (D2O/TFA = 20/1, 100 
MHz) δ 171.5, 51.6, 39.9, 29.4, 27.7, 26.8, 21.0 (2 carbons); HRESI Calcd for 
C8H18NO2S([M+H]
+) m/z 192.1053;  measured m/z 192.1043. 
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(2S)-2-amino-4-[(3-aminopropyl)sulfanyl]butanoic acid (15). Fig. 2.4b with 3-
bromopropylamine hydrobromide yielded 15 (1.4 mg, 24% yield) as a white solid. 1H 
NMR (D2O,  400 MHz) δ 3.89 (t, J = 6.3 Hz, 1 H), 2.96 (t, J = 7.6 Hz, 2 H), 2.51 - 2.58 
(m, 4 H), 1.99 - 2.10 (m, 2 H), 1.82 (quin, J = 7.3 Hz, 2 H); 13C NMR (D2O, 100 MHz) 
δ 172.8, 52.6, 38.3, 29.7, 27.3, 26.2 (2 carbons); HRESI Calcd for C7H17N2O2S([M+H]
+) 
m/z 193.1005;  measured m/z 193.1019.  
 
(2S)-2-amino-4-[(3-aminopropyl)selanyl]butanoic acid (15-Se). Fig. 2.4e with 3-
bromopropylamine hydrobromide yielded 15-Se (5.7 mg, 86% yield) as a white solid. 1H 
NMR (D2O,  400 MHz) δ 3.97 (t, J = 6.3 Hz, 1 H), 2.94 (t, J = 7.4 Hz, 2 H), 2.56 (m, 4 
H), 2.08 - 2.13 (m, 2 H), 1.87 (quin, J = 7.4 Hz, 2 H); 13C NMR (D2O, 100 MHz) δ 172.0, 
52.9, 39.1, 30.6, 27.2, 19.1, 17.5. HRESI Calcd for C7H17N2O2Se([M+H]
+) m/z 
241.0450;  measured m/z 241.0465. 
 
(2S)-2-amino-4-[(2E)-penta-2,4-dien-1-ylsulfanyl]butanoic acid (16). According to the 
protocol reported by Sato et al.,126 to a 50 mL solution of 1,4-pentadien-3-ol (0.5 g, 5.94 
mmol) in water was added 48% HBr in water (1.2 g, 7.13 mmol) drop wise. The reaction 
was stirred at 0 oC until TLC indicated the reaction was complete (~2 h). The reaction 
was then diluted with ether and washed with NaHCO3 (sat, 3 x 30 mL), water, and brine. 
The organic layer was dried with Na2SO4 and concentrated in vacuo to afford 4-bromo-
1,3-pentadiene (0.46 g, 3.2 mmol) as a yellow liquid with a yield of 53%. Fig. 2.4b with 
this 4-bromo-1,3-pentadiene yielded 16 (1.4 mg, 22%) as a white solid. 1H NMR (D2O,  
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400 MHz) δ 6.10 (dt, J = 17.1, 10.2 Hz, 1 H), 5.92 (dd, J = 15.3, 10.6 Hz, 1 H), 5.42 (dt, 
J = 15.1, 7.7 Hz, 1 H), 4.94 (dd, J = 16.8, 1.6 Hz, 1 H), 4.80 (dd, J = 10.8, 1.4 Hz, 1 H), 
3.91 (t, J = 6.5 Hz, 1 H), 2.95 (d, J = 7.4 Hz, 2 H), 2.35 (t, J = 7.2 Hz, 2H),  1.80 – 1.99 
(m, 2 H); 13C NMR (D2O, 100 MHz) δ 171.2, 136.1, 133.5, 129.2, 117.2, 51.3, 32.1, 29.0, 
24.8. HRESI Calcd for C9H16NO2S([M+H]
+) m/z 202.0896; measured m/z 202.0905.  
     
(2S)-2-amino-4-[(2-azidoethyl)sulfanyl]butanoic acid (17). Fig. 2.4a with 
dibromomoethane (0.46 mL, 5.32 mmol) yielded a mixture of dibromoethane:1-azido-2-
bromoethane (1:2, 1.0 g). Fig. 2.4b with this mixture yielded 17 (2.1 mg, 33% yield) as 
a white solid together with dimer 28 (4.2 mg, 46% yield) as a white solid. 17: 1H NMR 
(D2O,  400 MHz) δ 3.88 (t, J = 6.5 Hz, 1 H), 3.39 (t, J = 6.5 Hz, 2 H), 2.65 (t, J = 6.5 Hz, 
2 H), 2.58 (t, J = 7.4 Hz, 2 H), 1.96 - 2.11 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 172.6, 
52.5, 50.2, 30.2, 29.8, 26.5; HRESI Calcd for C6H13N4O2S([M+H]
+) m/z 205.0754;  
measured m/z 205.0767. 
 
(2S)-2-amino-4-[(3-methylbutyl)sulfanyl]butanoic acid (18). Fig. 2.4b with 1-bromo-3-
methylbutane yielded 18 (6.5 mg, 99% yield) as a white solid. 1H NMR (D2O/TFA = 
20/1,  400 MHz) δ 4.03 (t, J = 6.5 Hz, 1 H), 2.52 (t, J = 7.4 Hz, 2 H), 2.41 (t, J = 7.8 Hz, 
2 H), 1.94 - 2.05 (m, 2 H), 1.38 - 1.47 (m, 1 H), 1.23 - 1.31 (q, J = 7.6 Hz, 2H), 0.68 (d, 
J = 6.7 Hz, 6 H); 13C NMR (D2O/TFA=20/1, 100 MHz) δ 171.5, 51.6, 37.5, 29.3, 28.7, 
26.6, 26.1, 21.3 (2 carbons). HRESI Calcd for C9H20NO2S([M+H]
+) m/z 206.1209;  
measured m/z 206.1223. 
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(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)sulfanyl]butanoic acid (19). A protocol 
identical to that described for 3 using L-Homocystine (150 mg, 0.559 mmol) and 3,3-
dimethylallyl bromide (250 μL, 2.15 mmol) gave compound 19  (304 mg, 76% yield) as 
a white amorphous solid. 1H NMR (DMSO-d6/TFA-d1 = 20/1, 500 MHz) δ 5.16 (t, J = 
7.8 Hz, 1 H), 4.00 (t, J = 6.2 Hz, 1 H), 3.12 (d, J = 7.7 Hz, 2 H), 2.49 - 2.56 (m, 2 H), 
1.94 – 2.04 (m, 2 H), 1.68 (s, 3 H), 1.61 (s, 3 H); 13C NMR (DMSO-d6/TFA-d1 = 20/1, 
125 MHz) δ 175.8, 140.1, 125.7, 56.3, 35.5, 33.8, 31.3, 30.7, 22.9; HRESI Calcd for 
C9H18NO2S ([M+H]
+) m/z 204.1053;  measured m/z 204.1053. 
 
(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)selanyl]butanoic acid (19-Se). Fig. 2.4e with 
3,3-dimethylallyl bromide yielded 19-Se (2.8 mg, 41% yield) as a white solid. 1H NMR 
(D2O/TFA = 20/1,  400 MHz) δ 5.19 - 5.26 (m, 1 H), 3.92 (t, J = 6.3 Hz, 1 H), 3.17 (d, J 
= 8.6 Hz, 2 H),2.49 (t, J = 8.0 Hz, 2 H), 2.04 - 2.18 (m, 2 H), 1.59 (s, 3 H), 1.52 (s, 3 H); 
13C NMR (D2O/TFA = 20/1, 100 MHz) δ 175.8, 140.1, 125.7, 56.4, 35.5, 33.8, 31.3, 
30.7, 22.9. HRESI Calcd for C9H18NO2Se([M+H]
+) m/z 252.0497;  measured m/z  
252.0512.     
 
(2S)-2-amino-4-(cyclohex-2-en-1-ylsulfanyl)butanoic acid (20). Fig. 2.4c with 3-bromo-
cyclohexene yielded 20 (4.6 mg, 30% yield) as a white solid. 1H NMR (D2O,  400 MHz) 
δ 5.70 - 5.77 (m, 1 H), 5.56 (d, J = 8.2 Hz, 1 H), 4.01 (dt, J = 6.4, 0.3 Hz, 1 H), 3.37 (br. 
s, 1 H), 2.54 - 2.69 (m, 2 H), 1.97 - 2.20 (m, 2 H), 1.77 - 1.89 (m, 3 H), 1.39 - 1.66 (m, 3 
H); 13C NMR (D2O, 100 MHz) δ 171.8, 131.1, 126.7, 51.9, 39.94, 39.91, 28.54, 28.51, 
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24.2, 19.0; HRESI Calcd for C10H18NO2S([M+H]
+) m/z 216.1053; measured m/z 
216.1043. 
 
(2S)-2-amino-4-(cyclohex-2-en-1-ylselanyl)butanoic acid (20-Se). Fig. 2.4e with 3-
bromo-cyclohexene yielded 20-Se (1.3 mg, 18% yield) as a white solid. 1H NMR (D2O,  
400 MHz) δ 5.64 - 5.72 (m, 2 H), 3.90 (m, 1 H), 3.58 - 3.66 (m, 1 H), 2.86 (t, J = 1.00 
Hz, 1 H), 2.52 - 2.68 (m, 2 H), 2.05 - 2.20 (m, 2 H), 1.90 (br. s, 2 H), 1.50 – 1.70 (m, 3 
H);13C NMR (D2O, 100 MHz) δ 172.3, 131.4, 127.7, 53.4, 36.2, 31.5, 29.5, 24.2, 19.2, 
17.6; HRESI Calcd for C10H18NO2S([M+H]
+) m/z 264.0497; measured m/z 264.0508.  
   
(2S)-2-amino-4-[(3-azidopropyl)sulfanyl]butanoic acid (21). Fig. 2.4a with 
dibromopropane (0.50 mL, 4.98 mmol) yielded a mixture of dibromopropane:1-azido-3-
bromopropane (2:5, 1.0 g). Fig. 2.4b with this mixture yielded 21 (1.7 mg, 25% yield) as 
a white solid together with dimer 29 (1.0 mg, 10% yield) as a white solid.  21: 1H NMR 
(D2O,  400 MHz) δ 3.93 (t, J = 6.5 Hz, 1 H), 3.26 (t, J = 6.7 Hz, 2 H), 2.54 (t, J = 7.6 Hz, 
2H), 2.49 (t, J = 7.2 Hz, 2H), 1.93 - 2.14 (m, 2 H), 1.70 (quin, J = 6.8 Hz, 2 H); 13C NMR 
(D2O, 100 MHz) δ 172.3, 52.3, 49.7, 29.5, 27.69, 27.65, 26.3. HRESI Calcd for 
C7H15N4O2S([M+H]
+) m/z 219.0910; measured m/z 219.0919.  
 
(2S)-2-amino-4-(benzylsulfanyl)butanoic acid (22). A protocol similar to that described 
for 3 using L-Homocystine (250 mg, 0.93 mmol) and benzyl bromide (0.13 mL, 1.12 
mmol) was employed with slight modifications. Specifically, after the evaporation of 
NH3 the dried residue was dissolved in 15 mL ddH2O and the pH subsequently adjusted 
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to 7 by adding 1 M HCl. A heavy precipitate formed, which was filtered and washed with 
cold ddH2O (3 x 10 mL). The filtrate was purified by recrystallization from ethanol to 
provide compound 22 (0.15 g, 72% yield).  1H NMR (D2O/TFA = 20/1,  400 MHz) δ 7.08 
- 7.19 (m, 5 H), 3.92 (t, J = 6.3 Hz, 1 H), 3.57 (s, 2 H), 2.37 (t, J = 8.2 Hz, 2 H), 1.84 - 
2.04 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 171.3, 138.0, 128.8 (2 carbons), 128.7 (2 
carbons), 127.2, 51.4, 34.6, 29.1, 25.5; HRESI Calcd for C11H15NO2SNa ([M+Na]
+) m/z 
248.0716; measured m/z 248.0716.  
 
(2S)-2-amino-4-(benzylselanyl)butanoic acid (22-Se). Fig. 2.4c with L-selenomethionine 
(100 mg, 0.51 mmol) and benzyl bromide (0.24 mL, 2.03 mmol) yielded 22-Se (10 mg, 
7% yield) as a white solid and L-selenohomocystine (70 mg, 0.19 mmol, 38% yield). 1H 
NMR (D2O,  400 MHz) δ 7.11 (s, 2 H), 7.10 (s, 2 H), 7.00 - 7.06 (m, 1 H), 3.86 (t, J = 6.5 
Hz, 1 H), 3.62 (s, 2 H), 2.33 - 2.39 (m, 2 H), 1.90 – 1.97 (m, 2 H); 13C NMR (D2O, 100 
MHz) δ 171.2, 139.2, 129.0 (2 carbons), 128.6 (2 carbons), 126.8, 46.4, 42.9, 30.3, 26.2; 
HRESI Calcd for C11H16NO2Se([M+H]
+) m/z 274.0341;  measured m/z 274.0339.   
 
(2S)-2-amino-4-{[(2E)-4-azidobut-2-en-1-yl]sulfanyl}butanoic acid (23). Fig. 2.4a with 
(E)-1,4-dibromobut-2-ene (2.0 g, 9.34 mmol) yielded a mixture of (E)-1-azido-4-
bromobut-2-ene:(E)-1,4-dibromobut-2-ene (3:2, 2.31 g). Fig. 2.4b with this (E)-1-azido-
4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene mixture yielded 23 (1.3 mg, 18% yield) as 
a white solid together with dimer 30 (2.3 mg, 23% yield) as a white solid.  23: 1H NMR 
(D2O,  400 MHz) δ 5.52 - 5.69 (m, 2 H), 3.94 (t, J = 6.5 Hz, 1 H), 3.66 (d, J = 6.3 Hz, 2 
H), 3.09 (d, J = 6.7 Hz, 2 H), 2.49 (t, J = 7.4 Hz, 2 H), 1.92 - 2.12 (m, 2 H); 13C NMR 
39 
 
(D2O, 100 MHz) δ 172.2, 130.9, 126.4, 52.1, 51.6, 31.7, 29.3, 24.9; HRESI Calcd for 
C8H15N4O2S([M+H]
+) m/z 231.0910;  measured m/z 231.0922. 
 
(2S)-2-amino-4-{[(2E)-4-azidobut-2-en-1-yl]selanyl}butanoic acid (23-Se). Fig. 2.4d 
with the (E)-1-azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene mixture in the 
synthesis of 23 yielded 23-Se (3.1 mg, 36% yield) as a white solid. 1H NMR (D2O,  400 
MHz) δ 5.77 - 5.88 (m, 1 H), 5.42 - 5.51 (m, 1 H), 3.89 (t, J = 6.1 Hz, 1 H), 3.44 (d, J = 
6.7 Hz, 2 H), 3.12 (d, J = 7.4 Hz, 2 H), 2.41 - 2.50 (m, 2 H), 2.07 - 2.10 (m, 2 H); 13C 
NMR (D2O, 100 MHz) δ 169.8, 134.2, 122.7, 53.2, 40.3, 30.5, 23.3, 16.8; HRESI Calcd 
for C8H15N4O2Se([M+H]
+) m/z 279.0355;  measured m/z 279.0348. 
 
(2S)-2-amino-4-{[(2E)-4-aminobut-2-en-1-yl]selanyl}butanoic acid (24-Se). (E)-1-
azido-4-bromobut-2-ene was synthesized according to the procedure reported by Islam 
et al.15 (E)-1,4-dibromobut-2-ene (2 g, 9.34 mmol) was placed in a round-bottom flask 
and dissolved in THF (10 mL). Sodium azide (800 mg, 12.2 mmol) was dissolved in 1 
mL water and mixed the solution of (E)-1,4-dibromobut-2-ene. T h e  reaction was 
stirred overnight at room temperature, diluted with diethyl ether (100 mL) and 
successively washed with water (15 mL) and saturated NaCl solution (15 mL). The 
organic layer was dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. Crude products were purified by flash silica gel column chromatography 
using EtOAc/Hexanes affording 200 mg of (E)-1-azido-4-bromobut-2-ene (25% yield) 
and 320 mg of (E)-1,4-diazidobut-2-ene (25% yield), both as colorless liquids. Fig. 
2.4e with (E)-1-azido-4-bromobut-2-ene yielded 24-Se (2.6 mg, 45% yield) as a white 
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solid. 1H NMR (D2O,  400 MHz) δ 5.71 - 6.05 (m, 1 H), 5.37 - 5.59 (m, 1 H), 3.75 (t, J = 
6.1 Hz, 1 H), 3.45 (d, J = 6.7 Hz, 2 H), 3.12 (d, J = 7.4 Hz, 2 H), 2.37 - 2.45 (m, 2 H), 
2.01 - 2.07 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 173.2, 134.1, 122.8, 54.0, 40.4, 30.9, 
23.3, 16.7; HRESI Calcd for C8H17N2O2Se([M+H]
+) m/z 253.0450; measured m/z 
253.0464. 
 
(2S)-2-amino-4-{[(4-methylphenyl)methyl]sulfanyl}butanoic acid (25). Fig. 2.4b with 
4-methylbenzyl bromide yielded 25 (2.0 mg, 27% yield) as a white solid. 1H NMR (D2O,  
400 MHz) δ 7.05 (d, J = 8.0 Hz, 2 H), 7.00 (d, J = 8.0 Hz, 2 H), 3.93 (t, J = 6.3 Hz, 1 H), 
3.53 (s, 2 H), 2.36 (t, J = 7.4 Hz, 2 H), 2.07 (s, 3 H), 1.90 - 2.09 (m, 2 H); 13C NMR (D2O, 
100 MHz) δ 171.3, 137.4, 134.9, 129.2 (2 carbons), 128.8 (2 carbons), 51.5, 34.3, 29.1, 
25.6, 19.9; HRESI Calcd for C12H18NO2S([M+H]
+) m/z 240.1053;  measured m/z 
240.1061. 
 
(2S)-2-amino-4-{[(2E)-3-phenylprop-2-en-1-yl]sulfanyl}butanoic acid (26). Fig. 2.4b 
with 3-bromo-1-phenyl-1-propene yielded 26 (4.2 mg, 54% yield) as a white solid. 1H 
NMR (D2O,  400 MHz) δ 7.23 (d, J = 7.0 Hz, 2 H), 7.13 (t, J = 7.4 Hz, 2 H), 7.05 (dd, J 
= 14.5, 7.4 Hz, 1 H), 6.32 (d, J = 16.0 Hz, 1 H), 6.03 (dt, J = 16.0, 7.4 Hz, 1 H), 3.96 (t, 
J = 6.5 Hz, 1 H), 3.14 (d, J = 7.4 Hz, 2 H), 2.44 (t, J = 7.4 Hz, 2 H), 1.93 - 2.05 (m, 2 H); 
13C NMR (D2O, 100 MHz) δ 171.3, 136.4 (2 carbons), 132.1, 128.7 (2 carbons), 126.2, 
125.5, 110.0, 51.6, 32.8, 29.2, 24.9; HRESI Calcd for C13H18NO2S([M+H]
+) m/z 
252.1053;  measured m/z 252.1075.  
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(2S)-2-amino-4-{[(4-nitrophenyl)methyl]sulfanyl}butanoic acid (27). Fig. 2.4c with 4-
nitrobenzyl bromide yielded 27 (3.6 mg, 18% yield) as a white solid. 1H NMR (D2O,  400 
MHz) δ 8.06 (d, J = 9.0 Hz, 2 H), 7.43 (d, J = 9.0 Hz, 2 H), 3.94 (t, J = 6.5 Hz, 1 H), 3.75 
(s, 2 H), 2.45 (t, J = 7.0 Hz, 2 H), 1.90 - 2.09 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 
171.7, 146.6, 129.7 (2 carbons), 123.8 (2 carbons), 117.6, 51.7, 34.2, 29.2, 25.8; HRESI 
Calcd for C11H15N2O4S([M+H]
+) m/z 271.0747;  measured m/z 271.0761. 
 
(2S)-2-amino-4-{[(4-nitrophenyl)methyl]selanyl}butanoic acid (27-Se). Fig. 2.4e with 
4-nitrobenzyl bromide yielded 27-Se (1.6 mg, 18% yield) as a white solid. 1H NMR (D2O,  
400 MHz) δ 8.05 (d, J = 9.0 Hz, 2 H), 7.41 (d, J = 9.0 Hz, 2 H), 3.88 (t, J = 6.4 Hz, 1 H), 
3.83 (s, 2 H), 2.47 (t, J = 6.8 Hz, 2H), 1.96 - 2.03 (m, 2 H); 13C NMR (D2O, 100 MHz) δ 
171.9, 147.9, 146.2, 129.5 (2 carbons), 123.9 (2 carbons), 52.9, 30.5, 25.4, 17.7; HRESI 
Calcd for C11H15N2O4Se([M+H]
+) m/z 319.0192;  measured m/z 319.0201.  
 
(2S)-2-amino-4-[(2-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}ethyl)sulfanyl]butanoic 
acid (28). Fig. 2.4a with dibromoethane (0.46 mL, 5.32 mmol) yielded a mixture of 
dibromoethane:1-azido-2-bromoethane (1:2, 1.0 g). Fig. 2.4b with this dibromoethane:1-
azido-2-bromoethane mixture yielded 17 (2.1 mg, 33%) as a white solid together with 
dimer 28 (4.2 mg, 46%) as a white solid.  28: 1H NMR (D2O,  400 MHz) δ 3.95 (t, J = 6.3 
Hz, 2 H), 2.68 (s, 4 H), 2.58 (t, J = 7.4 Hz, 4 H), 1.94 - 2.15 (m, 4 H); 13C NMR (D2O, 
100 MHz) δ 172.2 (2 carbons), 52.1 (2 carbons), 30.4 (2 carbons), 29.6 (2 carbons), 26.3 
(2 carbons); HRESI Calcd for C10H21N2O4S2([M+H]
+) m/z 297.0937;  measured m/z 
297.0949. 
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(2S)-2-amino-4-[(3-{[(3S)-3-amino-3-
carboxypropyl]sulfanyl}propyl)sulfanyl]butanoic acid (29). Fig. 2.4a with 
dibromopropane (0.50 mL, 4.98 mmol) yielded a mixture of dibromopropane:1-azido-3-
bromopropane (2:5 ,1.0 g). Fig. 2.4b with this dibromopropane:1-azido-3-bromopropane 
mixture yielded 21 (1.7 mg, 25% yield) as a white solid together with dimer 29 (1.0 mg, 
10% yield) as a white solid.  29: 1H NMR (D2O,  400 MHz) δ 3.96 (t, J = 6.3 Hz, 2 H), 
2.56 (d, J = 7.6 Hz, 4H), 2.50 (d, J = 7.2 Hz, 4H), 1.96 - 2.12 (m, 4 H), 1.71 (quin, J = 
7.1 Hz, 2 H); 13C NMR (D2O, 100 MHz) δ 172.1 (2 carbons), 52.0 (2 carbons), 29.5 (2 
carbons), 29.3 (2 carbons), 27.9, 26.2 (2 carbons). HRESI Calcd for 
C11H23N2O4S2([M+H]
+) m/z 311.1094;  measured m/z 311.1101.  
 
(2S)-2-amino-4-{[(2E)-4-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}but-2-en-1-
yl]sulfanyl}butanoic acid (30). Fig. 2.4a with (E)-1,4-dibromobut-2-ene (2.0 g, 9.34 
mmol) yielded a mixture of (E)-1-azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-ene 
(3:2, 2.31 g). Fig. 2.4b with this (E)-1-azido-4-bromobut-2-ene:(E)-1,4-dibromobut-2-
ene mixture yielded 23 (1.3 mg, 18% yield) as a white solid together with dimer 30 (2.3 
mg, 23% yield) as a white solid.  30: 1H NMR (D2O, 400 MHz) δ 5.42 - 5.49 (m, 2 H), 
3.98 (t, J = 6.5 Hz, 2 H), 3.02 - 3.10 (m, 4 H), 2.48 (t, J = 7.4 Hz, 4 H), 1.92 - 2.15 (m, 4 
H); 13C NMR (D2O, 100 MHz) δ 171.9 (2 carbons), 128.9 (2 carbons), 51.9 (2 carbons), 
31.8 (2 carbons), 29.2 (2 carbons), 25.0 (2 carbons); HRESI Calcd for 
C12H23N2O4S2([M+H]
+) m/z 323.1094;  measured m/z 323.1102.  
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2.4.10 Gene cloning and protein expression and purification 
 The Escherichia Coli MAT (eMAT) was amplified using colony PCR from the 
cells of E. Coli BL21(DE3) strain using primers 5’-
ATACTGCATATGGCAAAACACCTTTTTACG (forward, NdeI) and 5’-
CAGTATGGATCCTTACTTCAGACCGGCAGC (reverse, BamHI). The PCR products 
were digested with respective restriction enzymes and ligated into pET28a vector to 
provide expression plasmids for proteins bearing N-terminal-His6 fusions. The expression 
constructs for Homo Sapiens MATs (hMATs) were provided by Prof. Chunming Liu. The 
Methanocaldococcus jannaschii MAT (mMAT) gene was synthesized (sequence provided 
in Fig. 2.5) by GenScript (Piscataway, NJ) with N-terminal NdeI and C-terminal EcoRI 
restriction sites and subsequently also subcloned in the pET28a vector to provide an 
expression construct tor the N-terminal-His6 fusion. Expression and purification of 
rebeccamycin methyltransferase, RebM was carried out as described in Zhang et al.5a The 
E. coli S-adenosylhomocysteine nucleosidase (EC 3.2.2.9) (also known as SAH hydrolase) 
gene was amplified from the genome of E.coli BL21(DE3), using primers 5’-
AGCCATATGAAAATCGGCATCATTGGTG (forward, NdeI) and 5’-
ATAGAATTCTTAGCCATGTGCAAGTTTCTG (reverse, EcoRI). The PCR products 
were digested with respective restriction enzymes and ligated into pET28a vector to 
provide expression plasmids for the corresponding N-terminal-His6 fusion protein.  
 All five MATs with N-terminal-His6 (herein referred to simply as hMAT1A, 
hMAT2A, hMAT2, eMAT, and mMAT), RebM and SAH hydrolase were expressed in a 
corresponding E. coli BL21(DE3) host in the presence of 35 μg mL-1 of kanamycin at 37 °C 
to an OD600 of ~0.6, induced with 0.5 mM IPTG, and continued to grow at 37 °C for another 
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4 h. The cells were harvested by centrifugation (30 min, 5000 rpm), resuspended in buffer 
A (20 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.8). The cells were lysed via 
incubation with 1 mg mL-1 lysozyme (~50,000 U mg-1; Sigma-Aldrich, St. Louis, MO, 
USA) for 30 min on ice followed by sonication (VirSonic 475; Virtis, Gardiner, NY; 100 
W, 4 x 30 s pulses, ~1 min between pulses) on ice.  MATs were purified via affinity 
chromatography (5 mL HiTrap Ni-NTA chelating column, GE Healthcare, Piscataway, NJ) 
following standard linear gradient (50 mM NaH2PO4, 300 mM NaCl, pH 8.0 with a linear 
gradient of imidazole of 10-500 mM) using an AKTA Purifier 10 (GE Healthcare). Buffer 
exchange of pooled fractions containing the purified protein was accomplished using a PD-
10 column (GE Healthcare) eluted with 25 mM Tris-HCl, 80 mM KCl, pH 8. Protein 
concentrations were determined by Bradford assay (Bio-Rad, Hercules, CA, USA) using 
BSA as a standard. For this study, all proteins retained the N-terminal-His6 affinity tag. 
 
2.4.11 In vitro MAT assay 
 In vitro MAT reactions were conducted in a volume of 50 μl with 2 mM S/Se-
alkylated analog (compound 2-30), 1 mM ATP and 5 μM purified MAT in 25 mM Tris 
buffer pH 8.0, 5 mM MgCl2, 50 mM KCl for 4 h. The sMAT and mMAT reactions were 
conducted at 65 °C while hMATs and eMAT were incubated at 37 °C. Reactions were 
quenched by adding an equal volume of methanol followed by centrifugation (10,000 xg 
for 15 min) to remove the precipitated protein and product formation for each reaction was 
subsequently analyzed by RP-HPLC using method D (Figure 2.7a). For each reaction, 
percent yield was based upon the integration of species at 254 nm and calculated by 
dividing the integrated area of product and/or decomposed product by the sum of integrated 
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area of product and/or decomposed product and the remaining substrate. The assays were 
repeated twice under identical conditions and Table 2.2 (and Figure 2.2) represents an 
average value of two assays. The inclusion of adenine and 5’-R-thio-5’-adenosine in these 
calculations is based upon the established SAM and ATP chemical decomposition 
pathways which indicate adenine and 5’-R-thio-5’-adenosine to only derive from SAM (not 
ATP). All putative products were subsequently confirmed by high resolution electrospray 
ionization (ESI) mass spectra with positive (+) and/or negative (-) mode (see general 
methods). 
 
2.4.12 In vitro coupled hMAT2/RebM assay 
 In vitro hMAT2-RebM coupled reactions were carried out in a volume of 25 μl with 
2 mM S/Se-alkylated analogs, 1 mM ATP, 50 μM rebeccamycin ortholog 31 (synthesized 
as previously described),127 5 μM hMAT2, 10 μM RebM, 5 μM SAH hydrolase in 25 mM 
Tris buffer pH 8.0, 5 mM MgCl2, 50 mM KCl for 24 h at 37 °C. Reactions were quenched 
by adding an equal volume of methanol followed by centrifugation (10,000 g for 15 min) 
to remove the precipitated protein and the product formation for each reaction was 
subsequently analyzed by RP-HPLC using method E (Figure 2.7b). The assays were 
repeated twice under identical conditions and Table 2.2 (and Scheme 2) represents an 
average value of two assays. The reactions were scaled (>500 µM 31), purified by semi-
prep HPLC using method E and the putative new products were confirmed by NMR (Table 
2.3) and HRMS. 
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Table 2.1. Summary of synthesized L-methionine and L-selenomethionine analogs. 
  Method 
Code Compound S-alkyl Se-alkyl 
1, 1-Se 
 
c.a.[a] ref124 
2, 2-Se 
 
 
c.a.[a] c.a.[a] 
3, 3-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4d 
 
4, 4-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4d 
 
5 
 
 
Fig. 2.4b 
 
n.a.[b] 
6, 6-Se 
 
 
Fig. 2.4c 
 
Fig. 2.4e 
 
7, 7-Se 
 
 
Fig. 2.4c 
 
Fig. 2.4d 
 
8, 8-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4e 
 
9, 9-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4f 
 
10, 10-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4e 
 
11 
 
 
Fig. 2.4b 
 
n.a.[b] 
12, 12-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4d 
 
13, 13-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4e 
 
14 
 
 
Fig. 2.4b 
 
n.a.[b] 
15, 15-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4e 
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Table 2.1 (continued) 
  Method 
Code Compound S-alkyl Se-alkyl 
16 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
17 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
18 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
19, 19-Se 
 
 
 
Fig. 2.4b 
 
 
Fig. 2.4e 
 
20, 20-Se 
 
 
 
Fig. 2.4c 
 
 
Fig. 2.4e 
 
21 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
22, 22-Se 
 
 
 
Fig. 2.4b 
 
Fig. 2.4f 
23, 23-Se 
 
 
Fig. 2.4b 
 
Fig. 2.4d 
 
24-Se  
 
n.a.[b] 
 
Fig. 2.4e 
 
25 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
26 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
27, 27-Se 
 
 
 
Fig. 2.4c 
 
 
Fig. 2.4e 
 
28 
 
 
 
Fig. 2.4b 
 
n.a.[b] 
29 
 
 
Fig. 2.4b 
 
n.a.[b] 
30 
 
 
Fig. 2.4b 
 
 
n.a.[b] 
 
[a] c.a.: commercially available;  [b] n.a.: not available. 
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Table 2.2. Summary of MAT reactions. 
Analog Percentage Turnover H. R. Mass (m/z) 
eMAT hMAT1A hMAT2A hMAT2 mMAT Theoretical Observed 
2 90 95 100 100 100 399.1445, 297.0896[a] 399.1444, 298.0965[b] 
2-Se 100 100 100 100 100 447.0890, 345.0340[a] 447.0895, 346.0416[b] 
3 8 75 90 88 94 413.1602, 311.1052[a] 413.1599, 312.1121[b] 
3-Se 5 57 53 82 73 461.1046, 359.0497[a] 416.1040, 360.0565[b] 
4 2 2 6 20 6 321.0896[a] 322.1051[b] 
4-Se 0 7 44 58 14 369.0340[a] 370.0411[b] 
6 2 2 13 20 6 322.0848[a] 323.0919[b] 
6-Se 2 4 23 33 0 370.0293[a] 371.0371[b] 
7 2 5 50 52 16 425.1602, 323.1052[a] 425.1609, 324.1129[b] 
7-Se 2 10 42 59 15 371.0497[a] 372.0568[b] 
8 2 5 54 55 21 427.1758, 325.1209[a] 427.1759, 326.1281[b] 
8-Se 0 6 24 74 27 475.1203, 373.0653[a] 475.1200, 374.0726[b] 
9 0 2 2 2 8 427.1758, 325.1209[a] 427.1762, 326.1282[b] 
9-Se 5 5 11 10 10 373.0653[a] 374.0743[b] 
10 0 0 12 40 16 437.1602, 335.1052[a] 437.1599, 336.1124[b] 
10-Se 2 6 22 55 17 383.0497[a] 384.0566[b] 
11 2 2 5 25 30 439.1758, 337.1209[a] 439.1754, 338.1275[b] 
12 0 0 2 2 6 439.1758, 337.1209[a] 439.1754, 338.1282[b] 
12-Se 3 5 11 12 14 385.0653[a] 386.0730[b] 
13 0 0 12 13 12 441.1915, 339.1365[a] 441.1966, 340.1477[b] 
13-Se 0 6 26 49 32 489.1359, 387.0810[a] 489.1358, 388.0882[b] 
14 0 0 0 0 1 441.1915, 339.1365[a] 441.1918, 340.1439[b] 
16 4 2 4 44 8 451.1758 451.1756 
17 0 4 18 49 29 454.1616, 352.1066[a] 454.1615, 353.1140[b] 
18 0 0 0 0 1 455.2071, 353.1522[a] 455.2123, 354.1634[b] 
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[a] theoretical mass of degraded 5’-alkyl-thio(seleno)-5’-deoxyadenosine (MTA);  observed mass of degraded 5’-alkyl-
thio(seleno)-5’-deoxyadenosine (MTA): [b][M+H];  
  
Table 2.2 (continued) 
Analog Percentage Turnover H. R. Mass (m/z) 
eMAT hMAT1A hMAT2A hMAT2 mMAT Theoretical Observed 
19 3 0 4 6 13 453.1915 453.2044 
19-Se 5 3 9 15 16 399.0810[a] 400.0878[b] 
21 0 0 19 46 31 468.1772, 366.1223[a] 468.1772, 367.1296[b] 
23 0 2 5 12 32 480.1772, 378.1223[a] 480.1768, 379.1292[b] 
23-Se 5 4 9 15 18 426.0667[a] 427.0687[b] 
24-Se 8 7 16 25 30 400.0762[a] 401.0830[b] 
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Table 2.3. NMR Chemical Shift (in PPM) of 4′-O-R-Rebeccamycin in CD3OD; where 
R= 
Atom -H   -CH3 -CH2CH3 - CH2CHCH2 - CH2CCH - CH2CCN 
C1’/H1' 86.2/6.20 
 
86.2/6.20 86.2/6.20 86.2/6.20 86.2/6.20 86.2/6.20 
C2’/H2’ 74.5/3.83 
 
74.6/3.83 74.4/3.82 74.8/3.81 74.9/3.82 74.8/3.82 
C3’/H3’ 78.3/3.74 
 
78.2/3.83 78.2/3.82 78.3/3.87 78.6/3.89 78.3/3.95 
C4’/H4’ 69.0/4.26 
 
78.8.0/3.98 77.0/4.07 77.0/4.14 76.8/4.21 78.0/4.26 
C5’/H5’ 80.3/3.99 
 
79.2/3.99 79.2/3.99 79.2/4.05 79.2/4.05 78.73/4.12 
C6’/H6’, 
H6” 
59.8/4.25,4.03 
 59.9/4.13,4.0
3 
59.9/4.13,4.03 60.0/4.15, 4.05 60.2/4.24, 4.04 60.1/4.17,4.06 
4-O’-CH3 NA 
 
61.1/3.79[a] NA NA NA NA 
4-O’-
CH2CH3 
NA 
 
NA 
(69.5/4.09,3.96
) 
(15.9/1.33) [a] 
NA NA NA 
4-O’-
CH2CHCH2 
NA 
 
NA NA 
(74.9/4.59,4.44
) (6.10) 
(5.39, 5.22) [a], [b] 
NA NA 
4-O’-
CH2CCH 
NA 
 
NA NA NA 
(61.0/4.70,4.63
) (2.92) [a], [c] 
NA 
4-O’-
CH2CCN 
NA 
 
NA NA NA NA (58.3/4.85) [a] 
[a] resonances listed as C1”/H1”, C2”/H2”, C3”/H3” in sequential order; [b] 13C C2” (CH) and C3” (CH2) were not observed 
in the HSQC; [c] 13C C3” (CH) was not observed in the HSQC.  
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Figure 2.1. Representative methylated natural products where methyl groups deriving from 
SAM via MT-catalyzed methylation are highlighted as spheres. AT3, AT2433; CLC, 
colchicine; ESP, esperamicin; EVM, evernimicin; GLM, geldamycin; MGM, 
megalomicin; NGM, nogalamycin. 
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Scheme 2.1. Chemoenzymatic routes employed for the synthesis of SAM analogs. (a) 
Methionine adenosyltransferase (MAT)-catalyzed reaction, where L-Met (R=CH3, X=S) is 
the native substrate leading to native product S-adenosylmethionine (R=CH3, X=S). The 
variability of both R and X are assessed within the current study. (b) General methodology 
for the synthesis of S- and Se-L-Met analogs (X=S and Se, respectively) (i) Na, NH3, -78 
oC with 1 or 1-Se; (ii) K2CO3, acetone with L-Hcy; (iii) NaBH4/NaOH, H2O, THF, 5 h with 
1-Se; (iv) HCl, Reflux with 2-Se; see Table 2.1 for additional information).  
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Figure 2.2. Turnover of methionine analogs by select MATs. (a) Turnover of S/Se-Met 
analogs to the corresponding S(Se)AM analogs catalyzed by selected MATs based upon 
RP-HPLC (average percent error ≤5%). No product formation was observed in the absence 
of MAT, S/Se-Met analogs or ATP. (b) Structures of the S/Se-Met analogs listed in Figure 
2.2a (X=S, Se). 
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Figure 2.3. Mapping of residue positions that differ among MATs [eMAT (PDB ID:1RG9), 
hMAT2A (PDB ID:2PO2) and hMAT1A (PDB ID:2OBV)] on the hMAT2A homodimeric 
structure. Conserved residues among all three MATs are indicated by grey ribbons; 
residues that differ among all three MATs are highlighted as ball and stick models; and 
conserved residues among ‘stringent‘ MATs (hMAT1A and eMAT) which differ from the 
more permissive hMAT2A are highlighted by yellow ball and stick models. 
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Scheme 2.2. Products of hMAT2A-RebM coupled reaction in the presence of S/Se-Met 
analogs 3/3-Se, 7/7-Se, 4/4-Se, and 6/6-Se (see Figure 2.2). The percent product formation 
is noted in parentheses based upon the S/Se-Met analogs utilized (average percent error 
≤5%). 
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Figure 2.4. Synthesis of S/Se-alkylated L-methionine analogs. a. NaN3, nBu4NHSO4, 
NaHCO3(sat)/CH2Cl2; b. Na, NH3, -78 
oC; c. K2CO3, acetone; d. NaBH4/NaOH, H2O, 
THF, rt, 5 h; e. HCl, Reflux. 
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5’-
CATATGCGTAATATCATTGTGAAAAAACTGGATGTGGAACCGATTGAAGAACGCCCGACGGAAAT
TGTTGAACGTAAAGGTCTGGGTCATCCGGATTCAATTTGCGACGGTATCGCCGAAAGCGTGTCTC
GCGCACTGTGTAAAATGTACATGGAAAAGTTTGGCACGATTCTGCATCACAATACCGATCAGGTC
GAACTGGTGGGCGGTCATGCTTATCCGAAGTTTGGCGGTGGCGTCATGGTGTCACCGATTTACAT
CCTGCTGTCGGGTCGTGCAACCATGGAAATCCTGGATAAGGAAAAGAATGAAGTCATCAAGCTGC
CGGTGGGTACCACGGCAGTTAAAGCAGCCAAGGAATATCTGAAAAAGGTCCTGCGTAACGTTGAT
GTCGACAAAGATGTTATTATCGATTGCCGCATTGGTCAGGGCAGCATGGACCTGGTGGATGTTTT
TGAACGCCAGAAAAACGAAGTGCCGCTGGCTAACGACACGAGTTTCGGTGTTGGCTACGCGCCGC
TGTCCACCACGGAACGTCTGGTGCTGGAAACCGAACGTTTTCTGAACAGCGATGAACTGAAAAAC
GAAATCCCGGCGGTTGGTGAAGACATTAAAGTCATGGGTCTGCGTGAAGGCAAAAAGATTACCCT
GACGATCGCGATGGCCGTGGTTGATCGCTATGTGAAGAACATCGAAGAATACAAAGAAGTGATCG
AAAAGGTTCGTAAAAAGGTCGAAGATCTGGCAAAAAAGATCGCTGACGGCTATGAAGTTGAAATC
CACATTAACACGGCCGATGACTATGAACGCGAATCCGTGTACCTGACCGTTACGGGTACCAGCGC
AGAAATGGGTGATGACGGCTCTGTGGGTCGTGGCAACCGCGTTAATGGCCTGATTACCCCGTTCC
GTCCGATGAGTATGGAAGCAGCTTCCGGTAAAAACCCGGTTAATCACGTCGGCAAGATTTATAAC
ATCCTGGCGAATCTGATTGCCAACGATATCGCAAAACTGGAAGGTGTCAAGGAATGTTACGTGCG
TATTCTGTCACAAATCGGCAAACCGATTAATGAACCGAAGGCCCTGGATATCGAAATTATCACCG
AAGACTCGTACGATATTAAAGACATCGAACCGAAAGCTAAGGAAATTGCGAACAAATGGCTGGAC
AACATTATGGAAGTTCAGAAGATGATCGTCGAAGGCAAGGTCACCACGTTTTGAGAATTC-3’ 
 
Figure 2.5. DNA sequence of synthetic Methanocaldococcus jannaschii MAT (mMAT) 
gene where the bold letters indicate engineered restriction sites for subcloning (5’-NdeI 
and 3’-EcoRI). 
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Figure 2.6. Sequence alignment of hMAT2A, hMAT1A and eMAT as a basis for Figure 
2.3. Grey residues are identical among all three MATs, red are common residues among 
two of the three MATs, blue are the residues that differ among all three sequences and 
green residues are common between hMAT1A and eMAT (both stringent enzymes) but 
differ from hMAT2A (broad substrate specificity). Sequence alignment was performed 
using Multalin; http://multalin.toulouse.inra.fr/multalin/cgi-bin/multalin.pl. 
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Figure 2.7. HPLC traces for representative reactions. (a) Representative reactions (method 
D) catalyzed by hMAT2 illustrating the production of Se-SAM analogs (denoted by a black 
dot) in the presence of a select set of L-SeMet analogs. Starting material (ATP) is 
designated by a star. (b) Representative reactions (method D) catalyzed by hMAT2 
illustrating the production of SAM analogs (denoted by a black dot) and/or 5’-methyl-thio-
5’-deoxyadenosine (MTA, designated by a ‘X’) in the presence of a select set of L-Met 
analogs. Starting material (ATP) is designated by a star and the SAM degradation product, 
adenine, is labeled with an ‘A’. (c) Representative hMAT/RebM coupled reactions (method 
E) where the peaks corresponding to differentially alkylated products are highlighted by 
the black dot and peaks at ‘S’ and ‘M’ correspond to the remaining substrate and 
methylated products, respectively. A small amount of methylated product is formed in the 
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control lacking L-Met/L-Met analog (bottom panel), suggesting purified hMAT2 and/or 
RebM retains a small amount of residual L-Met and/or SAM. For all chromatograms 
illustrated, numbers within each correspond to the Se-Met or S-Met analogs utilized. 
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Figure 2.8. Reaction using 13C-labeled L-Met analogs. Region of 13C-1H gHSQC spectrum 
using selectively 13C labeled [S-13C-CH3]-L-Met (A & C) and [S-
13C-CH2]-L-ethionine (B 
& D). Panels A and B correspond to hMAT–catalyzed reactions and panels C and D 
corresponding to hMAT/RebM-catalyzed coupled reactions, respectively. Reactions were 
conducted under standard reaction conditions in >90% D2O. Products of hMAT/RebM 
reaction were purified by HPLC prior to NMR analysis in CD3OD. 
 
**Portions of Chapter 2 were previously published.11 Reproduced with permission from 
John Wiley & Sons: Angewandte Chemie International Edition, Volume 53, Issue 15, 
Pages 3965 – 3969, Figures 1 – 3, Schemes 1 – 2, and Text. Copyright 2014 is given to the 
publication in which the material was originally published. 
Copyright (C) Tyler D. Huber 2019  
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Chapter Three: Understanding molecular recognition of promiscuity of thermophilic 
methionine adenosyltransferase sMAT from Sulfolobus solfataricus 
 
3.1 Introduction 
 
 S-adenosylmethionine (AdoMet) is the most widely used methyl donor in 
biological systems, and the only known family of enzymes that synthesize AdoMet is 
methionine adenosyltransferase (MAT), which utilizes methionine and ATP as substrates 
(Figure 3.1A).128 The reaction occurs in an unusual two-step mechanism, in which the 
adenosyl group is transferred from ATP to the sulfur atom of methionine cleaving the 
triphosphate and the triphosphate is subsequently hydrolyzed to diphosphate (PPi) and 
phosphate (Pi).129 MAT is present in all living organisms from bacteria to mammals. To 
date, MAT structures from Escherichia coli,130,131 Campylobacter jejuni,132 Burkholderia 
pseudomallei (PDB code 3IML), Entamoeba histolytica (PDB code 3SO4), 
Mycobacterium marinum (PDB code 3RV2), Mycobacterium avium (PDB code 3S82), 
Mycobacterium tuberculosis (PDB code 3TDE), Thermococcus kodakarensis,133 Rattus 
norvegicus134 and Homo sapiens135 have been solved. They are more than 50% identical to 
one other and share several common features: (a) they usually appear as oligomeric 
proteins with a highly conserved three-domain fold;136 (b) divalent cations such as Mg2+ 
are required for activity and monovalent cations such as K+ are able to enhance the reaction 
rate;137 (c) a flexible loop suspended above the active site serves as a ‘gate’ and is involved 
in the catalytic activity of the enzyme.138 In addition, some members of the MAT family 
have recently been demonstrated to produce nonnative AdoMet analogs from non-native 
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methionine analogs.14,95,96 And in the context of coupled reactions containing permissive 
methyltransferases, those MATs enable the generation of natural product 
‘alkylrandomizations’.11 Thus, there is renewed interest in assessing the substrate tolerance 
of additional MATs and extending the molecular level understanding of MAT–substrate 
interactions. 
 In contrast to well-characterized MATs in bacteria and eukaryotes, studies of a 
sequence divergent class of MATs in archaea has been limited. The first archaeal MAT 
was identified from Sulfolobus solfataricus by Porcelli et al. in 1988,139 having only ~20% 
sequence identity with E. coli and human MATs (Figure 3.2). Later, another archaeal MAT 
from Methanococcus jannaschii (mjMAT) was characterized in detail in terms of kinetics 
parameters, substrate specificity and folding.95,140 More recently, an apo crystal structure 
of MAT from Thermococcus kodakarensis has been reported, which provides new 
structural insights on archaeal MAT.133 The improved thermostability but comparable 
kinetics parameters with MATs in bacteria and eukaryotes show archaeal MATs to be of 
great interest for enzyme engineering applications. However, structural information of 
active site contents and broad substrate specificity assessment for archaeal MATs has been 
lacking. Here we report Sulfolobus solfataricus MAT (sMAT) to enable the cumulative 
synthesis of a broad panel of unnatural AdoMet analogs (31 analogs detected) starting from 
synthetic S/Se-alkylated Met analogs (42 analogs) or commercial sources (three analogs). 
In addition, this study highlights the crystal structures of a thermostable MAT (sMAT), in 
three different forms: AdoMet bound, a non-native product S-adenosylethionine (AdoEth) 
bound, and the unbound form. Interestingly, in contrast to its low sequence similarity to 
other MATs, sMAT displays the typical three-domain fold and partly conserved active site 
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architecture. Unlike other known MAT structures, the activity of sMAT cannot be 
stimulated by ionic potassium.139 This can be supported structurally by the presence of a 
lysine side chain (K63) in sMAT, which probably has a similar function to potassium ion 
in other MATs. Further, the capture of the first atypical ligand bound structure of MAT 
provides insights on the nature of sMAT broad substrate specificity and a potential template 
for future engineering toward expanding the substrate scope. Cumulatively, the results in 
this study provide the first atomic view of the poorly explored class of MATs from archaea 
and expose sMAT as an efficient catalyst for AdoMet analog production that is amenable 
to downstream AdoMet utilizing processes. 
 
3.2 Results and discussion 
 
3.2.1 Overall structural organization 
 The crystal structures of sMAT have been determined successfully at 2.19 Å or 
2.39 Å resolution for the Ado-Met-liganded form, 2.49 Å for the AdoEth-liganded form 
and 2.21 Å for the unliganded form (Table 3.1). Similar to E. coli MAT (eMAT),141 rat 
liver MAT (rlMAT)142 and human MATs (hMAT1A and hMAT2A),135 sMAT packs as a 
tetramer (Figure 3.3A). All four sMAT structures contain two subunits, A and B, in the 
asymmetric unit and the tetramer is formed by a two-fold crystallographic symmetry axis. 
The buried surface interfaces between the two subunits A and B and the two dimers AB 
and CD are calculated to be 2570 and 1870 Å2 respectively.143 These areas are similar to 
those from other bacterial MATs,130–132 but larger than rlMAT134 and slightly smaller than 
hMAT.135 In the tetramer, there are four potential ligand binding sites: two sites 
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sandwiched by A and B and the other two sites between C and D. Compared with other 
known MAT structures,136 the sMAT monomer adopts a similar three-domain architecture 
with secondary structure variants (Figure 3.3A). Interestingly, unlike other MATs, 
structural variations were observed between subunits A and B in sMAT with an average 
rmsd of 0.51 Å in both the liganded and unliganded structures. In addition, the maximum 
rmsd between all the A subunits and the maximum rmsd between all the B subunits in all 
sMAT structures are calculated as 0.29 Å and 0.21 Å, respectively. A similar observation 
was also reported in a recently solved archaeal MAT structure.133 As a result, half of the 
active sites within sMAT have a more open conformation than the others. Consistently, in 
all the ligand bound sMAT structures, only half of the active sites within the sMAT 
tetramer are occupied while the other half are unoccupied. In addition, only the gating loops 
outside the occupied active site become ordered (Figure 3.3C,D). 
 The substrate specificity for sMAT based upon RPHPLC is illustrated in Figure 
3.1B wherein observed 5ʹ-methyl-thio(seleno)-5ʹ-deoxyadenosine (MSeA) production (via 
RP-HPLC, Figure 3.4) was interpreted as product based upon the well-established AdoMet 
decay pathways indicating MSeA to directly derive from AdoMet (not ATP).13,35,36 The 
putative substrates tested were those recently reported to profile the substrate specificity of 
a range of MATs and these analogs were specifically designed to interrogate both steric 
and electronic contributions to turnover.11 Of the 45 putative substrates (Table 3.2) tested 
with sMAT, 11 led to appreciable (> 50%) AdoMet analog production, an additional 15 
led to moderate (25%–50%) conversion, while five offered detectable product (< 25%) 
under the conditions described. In general, smaller alkyl substitutions were better tolerated, 
suggesting steric infringement to possibly prohibit larger substitutions. Interestingly, in the 
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case where direct comparisons could be made, the degree of unsaturation correlated with a 
reduction in turnover (e.g. propyl > allyl > propargyl). Importantly, notable turnover was 
observed with branched analogs (Figure 3.1B, highlighted in green) that previously led to 
only trace product with MATs studied to date. 
 Table 3.3 highlights a comparison of the kinetic parameters for L-methionine and 
the non-native substrate for which a ligand bound structure is available (L-ethionine). The 
changes in kinetic parameters of the sMAT for both the substrates are moderate from 37 
°C to 65 °C. Compared with Thermococcus kodakarensis MAT and mjMAT, sMAT 
appears to be a somewhat better enzyme because sMAT has a 100 times smaller Km for 
methionine, a slightly smaller Km for ATP, and a similar kcat. More importantly, the data 
reflect that L-ethionine is kinetically competent and comparable to the native substrate L-
methionine. At either temperature, the kcat values for the sMAT reaction with L-methionine 
or L-ethionine are similar and the reduced proficiency with L-ethionine compared with the 
native substrate L-methionine derives from a combination of higher Km values for both L-
ethionine and ATP. 
 
3.2.2 Active site contents 
 The MAT catalyzed AdoMet formation, as mentioned in the Introduction, occurs 
via a sequential two-step mechanism. In the first step, AdoMet is formed by a direct SN2 
reaction, in which the sulfur atom of methionine attacks the C5ʹ position of ATP and thus 
cleaves the polyphosphate chain from ATP. In the second step, the triphosphate is further 
hydrolyzed to PPi and Pi.136 Komoto et al. identified two critical residues, lysine 165 and 
histidine 14, in eMAT for this proposed SN2 reaction based on their ligand bound 
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structures.130 Interestingly, even with significant sequential variations to eMAT and other 
MATs, several conserved residues were observed in sMAT, mainly located around the 
active site, including the two crucial residues lysine (K201) and histidine (H29) for the 
proposed SN2 reaction (Table 3.4). 
 The interactions between sMAT and products in the active site are multifaceted as 
illustrated in Figure 3.3B. The adenine ring of AdoMet is recognized by a hydrogen bond 
with the side chain of aspartate 144 and a stacking interaction with the aromatic ring of 
tyrosine 270. Several water molecules surrounding the adenine ring also form a hydrogen 
bond network to the enzyme. The 2ʹ-OH and 3ʹ-OH of the adenosine ribose interact with 
the side chains of aspartate 199, aspartate 282 and serine 277. Similar interactions 
involving aspartic acids have been seen in other MAT structures bound with AdoMet, but 
not for serine.130,135 The methionine/ethionine moiety (of AdoMet and AdoEth, 
respectively) forms hydrogen bonds with four residues, in which the amino group interacts 
with the side chain of aspartate 282 and the carboxylate group interacts with the side chain 
of histidine 58, asparagine 60 and asparagine 159. The methyl or ethyl group is buried in a 
slightly hydrophobic pocket surrounded by asparagine 159, aspartate 160, isoleucine 349, 
leucine 145 and the adenine ring. Like similar observations in eMAT,130 the PPi and Pi 
form a U-shaped conformation with two magnesium ions closely stacked on both sides. 
Further, the two magnesium sites are formed with the side chains of aspartate 31, glutamate 
305 and three water molecules. The phosphate groups are surrounded and stabilized by the 
side chains of several basic amino acids: lysine 25, histidine 29, lysine 201, arginine 288 
and lysine 310. 
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 As described, the ligands are solvent inaccessible and thus the entrance of the active 
site requires a dynamic and flexible region. A flexible loop region was previously identified 
as the gate for the active site in MATs.144 This gate loop feature has been confirmed by 
crystal structures of eMAT and hMAT2A, in which the loop becomes ordered when ligands 
are bound and it becomes disordered when the active site is empty.130,135 A similar gating 
loop (residues 141–155) region was identified in sMAT (Figure 3.3), which has a similar 
pose to eMAT and hMAT2A and interacts with the adenine ring and the methionine or 
ethionine moiety. When the active site is empty, residues 141–144 form a β-sheet with 
residues 95–96 while the rest of the loop is poorly seen or unidentifiable in electron density. 
When ligands are bound in the active site, the loop region becomes ordered and is anchored 
above the active site with residues 141–144 shifting from the origin position and with 
residues 145–149 forming a small α-helix. 
 In various structures of eMAT130 and hMAT2A,135 the active site ligand occupation 
is correlated with an ordered active site gating loop. These studies are consistent with our 
observations in sMAT structures. In addition to this, ligand orientations in the eMAT and 
human MAT studies are similar to sMAT’s. Different ligand orientations with an unordered 
gating loop have been reported before in rlMAT structures134 and an earlier set of eMAT 
structures,131 but have some unusual features: (a) in rlMAT the temperature factors of most 
of the ligand coordinates are above 70 Å2, and in earlier eMAT structures the temperature 
factors of ADP (or ADP mimic) are above 114 Å2; (b) the flexible loop above the active 
site was undefined even though the active sites were reported to be occupied;145 (c) even 
though rlMAT and eMAT have a 59% sequence identity and all critical residues are 
conserved, they show completely different ligand orientations in the active site; (d) X-ray 
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data for rlMAT and earlier eMAT structures are not available online, and thus ligand real-
space correlation coefficients cannot be calculated. These unusual features suggest that the 
active site contents of rlMAT and earlier eMAT are questionable. In contrast to rlMAT and 
the earlier eMAT structures, all the hMAT2A, later eMAT and sMAT structures have 
reasonable temperature factors and a good ligand real-space correlation to electron density 
at the active site. 
 
3.2.3 Unusual product formation during crystallization 
 As described in Experimental procedures, two sets of ligand bound crystals were 
obtained in the presence of 5 mM ADP, 10 mM ethionine (or methionine), 10 mM Mg2+ 
ion and 1.4 M NaHPO4/K2HPO4. Thus based on the simulated annealing Fo – Fc omit map 
of the active site, one ADP, one PO4, two Mg
2+ and one ethionine (or methionine) molecule 
were initially built in (Figure 3.5, left). However, this model does not fit the electron 
density perfectly, because the Fo – Fc omit map does not agree with the placement of the 
crucial carbon atom circled in Figure 3.5. Thus, it is very clear that the product has already 
formed and a model including PPi and AdoEth (or AdoMet) is more appropriate. The new 
model (Figure 3.5, right) has a lower temperature factor and a better real-space correlation 
to electron density in the active site. MAT-catalyzed AdoMet/AdoEth formation via ADP 
and Met/Eth has not been previously observed. In addition, incubation of sMAT in the 
presence of ADP and methionine at 65 °C for 90 min under standard assay conditions led 
to < 2% AdoMet formation. Thus, two explanations for this unusual product formation 
have been proposed: (a) the ADP stock solution is contaminated by a sufficient amount of 
ATP; (b) the unusual reaction catalyzed by sMAT can actually occur in vitro, but may take 
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as long as 1 month to complete, which corresponds to the time of crystal growth in this 
experiment. 
 
3.2.4 Structure homology 
 A DALI search146 for structures similar to the sMAT monomer returned several hits, 
all of which are previously solved MAT structures with Z-scores between 23 and 29. These 
MAT structures share a very high level of overall sequence identity (> 50%) and a high 
level of conservation among residues associated with substrate binding. Interestingly, 
sMAT only has a maximum sequence identity of 19% with these known MATs but shares 
a similar three-domain (Figure 3.6A). 
 For the comparison of active site residues, crystal structures of sMAT, eMAT130 
and hMAT2A135 were aligned by ligands as described in Experimental procedures (Table 
3.4). Surprisingly, 16 of 17 active site residues detected in sMAT have an identical or 
similar residue in eMAT and hMAT2A. The only extra residue sMAT has is H315, which 
forms a hydrogen bond with O5 in diphosphate. DALI-based sequence alignment was able 
to identify 11 pairs of residues (Figure 3.2). Eight of them are conserved among sMAT 
and other MATs, including the crucial residues histidine and lysine for the proposed SN2-
like mechanism.130 The other three pairs are very similar residues at the same spot: for 
example, in sMAT tyrosine 270 forms stacking interactions with the adenine ring of 
AdoEth/AdoMet, while in eMAT it is phenylalanine 230. Intriguingly, there are another 
five pairs of residues that are not detectable via DALI search: the side chain of sMAT lysine 
25 (eMAT lysine 245) helps stabilize the triphosphate group; the side chains of sMAT 
histidine 58 and asparagine 60 (eMAT glutamine 98 and lysine 269) form hydrogen bonds 
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with the carboxyl group of methionine or ethionine; the side chain of sMAT glutamate 305 
(eMAT aspartate 271) forms ionic bonds with the magnesium ion; the side chain of sMAT 
lysine 63 occupies the same spot as the eMAT potassium ion and helps stabilize the 
diphosphate ligand (Figure 3.6B). 
 Unlike other known MATs, it has been previously reported that the activity of 
sMAT cannot be enhanced by K+.139 In the present study, all the crystals of sMAT were 
obtained from the crystallization condition containing more than 150 mM potassium, but 
electron density suitable for K+ was not observed in any data sets. In addition, potassium 
dependence has been previously reported in a close MAT homolog from Methanococcus 
jannaschii, which shares the same active site residues with sMAT except for the lysine.140 
Combined with the active sites alignment evidence above (Figure 3.6B), it is very likely 
that the catalytic activity of sMAT is not affected by K+, because the lysine in sMAT serves 
to present the requisite cation properties. 
 Interestingly, eMAT and hMAT2A also have some ability to incorporate ethionine. 
The ethionine turns over with sMAT and hMAT2A is near 100% whereas with eMAT is 
just 10%.11 A ligand-based alignment (Figure 3.6C) shows that sMAT has a larger cavity 
around the ethyl/methyl group than either hMAT2A or eMAT. Placement of the ethyl 
group in eMAT will cause serious clashes with isoleucine 102 and 302, while in hMAT2A 
the ethionine causes moderate clashes with isoleucine 139 and 344. In sMAT a leucine 
(L145) is substituted for one of the conserved isoleucines in other MATs (isoleucine 102 
in eMAT), which provides more active site flexibility for ethyl group binding. The ethyl 
group in sMAT only has minor clashes with leucine 145 and isoleucine 349. Therefore, it 
is very likely that the better proficiency of sMAT is caused by a larger cavity adjacent to 
72 
 
the methyl/ethyl group. Also, branched analogs highlighted in Figure 3.1B turn over 
significantly better with sMAT, comparing with eMAT, hMAT2A and mjMAT.11 
Interestingly, mjMAT is a thermophilic archaeal MAT that has all active site residues 
conserved with sMAT. However, further comparison between their active site cavities 
cannot be conducted because mjMAT structure remains unknown. The current structural 
information suggests that the better turnover rate of branched AdoMet analogs with sMAT 
is possibly mediated by some general orientation/dynamics of the gating loop and/or 
secondary shell variations. The specific residues contributing to this are currently 
unknown. 
 
3.3 Conclusions 
 
 The crystal structures herein provide the atomic view of a clearly divergent class of 
MATs from archaea and add new active site architecture understanding to the MAT family. 
The sMAT has the characteristic fold and the typical tetramer assembly of known MATs, 
but it is the first structure in the Protein Data Bank for a thermostable MAT. In addition, 
the slightly expanded substrate scope of sMAT over other MATs studied to date highlights 
sMAT as a useful tool for the production of AdoMet analogs. In conjunction with the recent 
demonstration of coupled MAT-methyltransferase systems for differential alkylation,11 
this chemoenzymatic strategy circumvents a major liability in the use of synthetic AdoMet 
analogs – namely, the dramatic instability of the AdoMet analogs. Thus, the structural 
insights regarding sMAT provided herein offer another blueprint from which to pursue 
73 
 
future engineering to further broaden the catalyst promiscuity toward AdoMet analog 
production. 
 Further, the elucidation of the active site architecture with the atypical product 
bound, the characterization of the gating loop region, as well as the sMAT turnover 
reactions with different AdoMet analogs provides a blueprint for future AdoMet analog 
production. Since the two-step AdoMet synthesis process catalyzed by sMAT does not 
involve large conformational changes of ATP and methionine/ethionine, the cavity around 
the methyl/ethyl group is most probably the limiting factor for installing more function 
groups on the deoxyribose sugar. Since the cavity is formed by the adenine ring, asparagine 
159, aspartate 160, isoleucine 349 and leucine 145 in the gating loop, mutations of these 
amino acids, especially on isoleucine 349 and leucine 145, or/and mutations on the gating 
loop residues can potentially increase the size of the cavity or change the local electrostatic 
field to accept more functional groups, such as the compounds with low or zero turnover 
rate described in Table 3.2. 
 
3.4 Experimental procedures 
 
3.4.1 Expression and purification of sMAT 
 The MAT gene (UniProt accession: Q980S9) was cloned into NdeI/EcoRI-digested 
pET28a to enable production of recombinant N-His6-sMAT. For protein production, the 
corresponding pET28a-sMAT construct was transformed into the E. coli methionine 
auxotroph strain B834 (DE3) and auto-induction medium147 was used for expression at 37 
°C. The cells were harvested by centrifugation at 4200 g for 30 min and resuspended in 
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buffer 20 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole pH 7.8. The cells were lysed 
via lysozyme incubation followed by sonication on ice. Subsequently, N-His6-sMAT was 
purified via a Ni-nitrilotriacetic acid (Ni-NTA) chelating column (GE Healthcare, 
Piscataway, NJ, USA) following a protocol with a linear imidazole (10–500 mM) elution 
gradient (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) The His6-tag was removed by thrombin 
(Novagen) cleavage and the affinity tag was removed via a second round of Ni-NTA 
affinity chromatography. After the buffer exchange using PD-10 column (25 mM Tris/HCl, 
pH 8), the desired truncated SeMet-labeled sMAT was concentrated to 27 mg·mL-1, flash 
frozen in liquid nitrogen and stored at -80 °C. Protein concentrations were determined by 
Bradford assay (Bio-Rad, Hercules, CA, USA) using BSA as a standard. 
 
3.4.2 Crystallization, diffraction and structure determination 
 General screens were performed with PEGRx HT, Crystal Screen HT, Index HT 
and SaltRx HT (Hampton Research) utilizing a Mosquito® dispenser (TTP labTech) by the 
sitting drop method. Crystal growth was monitored by Bruker Nonius Crystal Farms at 20 
°C. All sMAT crystals with or without substrates were obtained by mixing 2 µL of protein 
solution and 2 µL of reservoir solution, 1.40 M sodium phosphate monobasic 
monohydrate/potassium phosphate dibasic pH 5.6, using the sitting drop method. For 
unbound sMAT crystals, the protein solution contained 0.15–0.2 mM sMAT and 25 mM 
Tris pH 8.0. For sMAT:(AdoMet) condition, the protein solution contains 0.15–0.2 mM 
sMAT, 1 mM AdoMet and 25 mM Tris pH 8.0. For sMAT:(ADP+Met/Eth), the protein 
solution contains 0.2–0.3 mM sMAT, 5 mM ADP, 10 mM Met (or Eth), 10 mM MgCl2, 
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12.5 mM KCl, 7.5 mM dithiothreitol and 25 mM Tris pH 8. All crystals were cryoprotected 
by 25% dimethylsulfoxide or 25% ethylene glycol and flash frozen in liquid nitrogen. 
 X-ray diffraction data were collected at the Life Science Collaborative Access 
Team (LS-CAT) with an X-ray wavelength of 0.98 Å for all sMAT crystals at the 
Advanced Photon Source at Argonne National Laboratory. Data sets were indexed and 
scaled by HKL2000 or XDS.148,149 For structure solution of apo sMAT, PHENIX.HYSS was 
used for determination of selenium atom substructure, AUTOSOL for phasing and 
PHENIX.AUTOBUILD for model building.150 For the other structures of sMAT with ligands, 
molecular replacement was utilized using the apo sMAT structure as a starting model. The 
structures including several double conformations were manually rebuilt in several rounds 
by COOT151 and further refined by PHENIX.REFINE.150 MOLPROBITY was used to validate the 
quality of the coordinates.152 All structural figures in this paper were generated using 
PYMOL.153 
 
3.4.3 Ligand-based structural alignment of MAT homologs 
 In order to best compare the active site contents between structures with low 
sequence identity, four structures were aligned based on ligand positions by PYMOL. They 
are eMAT with AdoMet and PPNP (PDB code 1RG9),130 hMAT2A with AdoMet (PDB 
code 2P02),135 sMAT with AdoMet, PPi and PO4 (PDB code 4K0B) and sMAT with 
AdoEth, PPi and PO4 (4L2Z). 1RG9, 2P02 and 4K0B were first aligned by the AdoMet 
molecule, and thus 4L2Z was aligned to 4K0B via several active-site residues. Atom 
clashes were calculated in the presence of hydrogen atoms using PYMOL and displayed as 
bumps. For clear display, hydrogen atoms are not illustrated in Figure 3.6C. 
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3.4.4 In vitro sMAT assay 
 In vitro sMAT reactions were conducted in a volume of 50 µL with 2 mM S/Se-
alkylated analog, 1 mM ATP and 5 µM purified sMAT in 25 mM Tris buffer pH 8.0, 5 
mM MgCl2, 50mM KCl for 4 h at 65 °C. Reactions were quenched by adding an equal 
volume of methanol followed by centrifugation (10 000 g for 15 min) to remove the 
precipitated protein and product formation for each reaction was subsequently analyzed by 
RP-HPLC using the method described below. For each reaction, percentage yield was 
based upon the integration of species at 254 nm and calculated by dividing the integrated 
area of product and/or decomposed product by the sum of the integrated area of product 
and/or decomposed product and the remaining substrate. The assays were repeated twice 
under identical conditions and Table 3.2 (and Figure 3.4) represents an average value of 
two assays. The inclusion of adenine and 5ʹ-R-thio-5ʹ-adenosine in these calculations is 
based upon the established AdoMet and ATP chemical decomposition pathways which 
indicate adenine and 5ʹ-R-thio-5ʹ-adenosine to only derive from AdoMet (not ATP). All 
putative products were subsequently confirmed by high resolution ESI mass spectra with 
positive (+) and/or negative (-) mode.11 
 
3.4.5 RP-HPLC method 
 Reactions were quenched by the addition of an equal volume of methanol followed 
by centrifugation at 10 000 g for 15 min to remove precipitated protein before applying on 
an analytical Varian ProStar HPLC [Luna C18 column, 5 µm, 4.6 mm × 250 mm; 
Phenomenex, Torrance, CA, USA; gradient of 10% B to 40% B over 15 min, 40% B to 
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75% B over 5 min (A = 10 mM NaH2PO4, 5 mM octane sulfonic acid, pH adjusted to 3.5 
using phosphoric acid; B is acetonitrile); flow rate 1 mL·min-1; A254]. Reaction products 
were confirmed by high-resolution mass spectrometry. 
 
3.4.6 Kinetic measurements of sMAT reactions 
 Pseudo first-order kinetics was assessed in triplicate under saturating ATP (2.5 
mM) and variable L-methionine/L-ethionine (0.007, 0.013, 0.033, 0.066, 0.133, 0.333, 
0.66, 1.33 mM) and saturating L-methionine/L-ethionine (2.5 mM) and variable ATP 
(0.013, 0.033, 0.066, 0.133, 0.333, 0.66, 1.33 mM) concentrations. Reactions were 
performed in buffer containing 25 mM Tris pH 8.0, 40 mM KCl and 5 mM MgCl2, and 0.5 
µg purified sMAT was added and incubated at 37 °C or 65 °C for 30 min in a final volume 
of 20 µL. Reaction products were analyzed using the RP-HPLC method above and product 
quantification was carried out using a standard curve generated by commercial AdoMet. 
The kinetic curves were fitted to the Michaelis–Menten equation using PRISM software. 
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Table 3.1. Data collection and refinement statistics for sMAT in the apo form and ligand 
bound forms. Values in parentheses are for the highest resolution shell. Rfree was calculated 
as Rcryst using 5.0% of randomly selected unique reflections (in thin resolution shells) that 
were omitted from the structure refinement. RSCC is the real-space correlation to electron 
density calculated by PHENIX. 
 sMAT sMAT+SAM sMAT+SAM sMAT+SAE 
Added in 
crystallization  
--- SAM ADP, Met ADP, Eth 
Modeled in structure PPi SAM, PPi SAM, PPi SAE, PPi 
Data collection     
Resolution range (Å) 50-2.21 50-2.19 50-2.39 50-2.49 
Wavelength (Å) 0.98 0.98 0.98 0.98 
Space group P6522 P6522 P6522 P6522 
a, b, c (Å) 151.3, 151.3, 
221.2 
151.6, 151.6, 
226.1 
150.1, 150.1, 
222.6 
151.6, 151.6, 
226.1 
No. of molecules 
per asymmetric unit 
2 2 2 2 
Measured reflections 1,478,624 1,541,606 1,854,076 1,101,136 
Unique reflections 74,368 78,995 59,745 53,034 
Rmerge 0.118 (0.909) 0.142 (0.918) 0.165 (0.606) 0.184 (0.225) 
Completeness 99.61 (96.38) 99.75 (97.50) 100.0 (100.0) 98.31 (82.97) 
Redundancy 19.9 (9.2) 19.5 (14.3) 26.0 (22.2) 20.7 (21.0) 
Mean I/sigma  14.55 (1.41) 14.94 (3.08) 27.01 (5.14) 11.94 (3.85) 
Refinement     
Rcryst/Rfree 0.1990/0.2201 0.1639/0.1888 0.1710/0.1978 0.1595/0.1843 
No. of protein atoms 6301 6,356 6,396 6,410 
No. of ligand atoms --- 48 43 44 
No. of solvent atoms 304 707 596 589 
Average B factor 
(Å2) 
    
        Protein 38.20 31.6 37.5 40.1 
        Ligands --- 28.7 30.3 38.2 
Ligands RSCC --- 0.93 0.98 0.96 
RMSD from ideal     
      Bond length (Å) 0.002 0.007 0.006 0.007 
      Bond angles 
(deg) 
0.69 1.33 0.70 0.97 
Ramachandran plot 
(%) 
    
      Favored regions 99 98 98 99 
      Outliers 0.25 0.12 0.12 0 
PDB ID 4HPV 4L7I 4K0B 4L2Z 
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Table 3.2. Summary of sMAT reactions with methionine analogs. 
Analog                                   Percentage turnover Theoretical mass Observed mass  
 
100 399.1445, 297.0896[a] 399.1444, 298.0965[b] 
 
 
100 447.0890, 345.0340[a] 447.0895, 346.0416[b] 
 
 
84 413.1602, 311.1052[a] 413.1599, 312.1121[b] 
 
 
76 461.1046, 359.0497[a] 416.1040, 360.0565[b] 
 
 
36 321.0896[a] 322.1051[b] 
 
 
28 369.0340[a] 370.0411[b] 
 
 
ND NA NA 
 
68 322.0848[a] 323.0919[b] 
 
 
12 370.0293[a] 371.0371[b] 
 
27 425.1602, 323.1052[a] 425.1609, 324.1129[b] 
 
30 371.0497[a] 372.0568[b] 
 
44 427.1758, 325.1209[a] 427.1759, 326.1281[b] 
 
66 475.1203, 373.0653[a] 475.1200, 374.0726[b] 
 
53 427.1758, 325.1209[a] 427.1762, 326.1282[b] 
 
40 373.0653[a] 374.0743[b] 
 
30 437.1602, 335.1052[a] 437.1599, 336.1124[b] 
 
10 383.0497[a] 384.0566[b] 
 
27 439.1758, 337.1209[a] 439.1754, 338.1275[b] 
 
15 439.1758, 337.1209[a] 439.1754, 338.1282[b] 
 
46 385.0653[a] 386.0730[b] 
 
27 441.1915, 339.1365[a] 441.1966, 340.1477[b] 
 
70 489.1359, 387.0810[a] 489.1358, 388.0882[b] 
 
57 441.1915, 339.1365[a] 441.1918, 340.1439[b] 
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[a] theoretical mass of degraded 5’-alkyl-thio(seleno)-5’-deoxyadenosine (MTA);  observed mass of 
degraded 5’-alkyl thio(seleno)-5’-deoxyadenosine (MTA): [b][M+H]; NDnot detected; NAnot applicable. 
 
Table 3.2 (continued)    
Analog                                   Percentage turnover Theoretical mass Observed mass  
 
ND NA NA 
 
14 451.1758 451.1756 
 
50 454.1616, 352.1066[a] 454.1615, 353.1140[b] 
 
36 455.2071, 353.1522[a] 455.2123, 354.1634[b] 
 
12 453.1915 453.2044 
 
44 399.0810[a] 400.0878[b] 
 
ND NA NA 
 
ND NA NA 
 
60 468.1772, 366.1223[a] 468.1772, 367.1296[b] 
 
ND NA NA 
 
ND NA NA 
 
28 480.1772, 378.1223[a] 480.1768, 379.1292[b] 
 
24 426.0667[a] 427.0687[b] 
 
38 400.0762[a] 401.0830[b] 
 
ND NA NA 
 
ND NA NA 
 
ND NA NA 
 
ND NA NA 
 
ND NA NA 
 
ND NA NA 
 
ND NA NA 
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Table 3.3. Kinetic parameters of sMAT enzyme. 
Temperature 
(°C) 
Constant 
substrate 
Varied 
substrate kcat  (min-1) Km (mM) 
kcat / Km 
(mM-1min-1) 
37 ATP L-methionine 2.06 ± 0.03 0.0023 ± 0.0003 895 ± 100 
ATP L-ethionine 2.34 ± 0.07 0.0056 ± 0.0015 417 ± 47 
L-methionine ATP 1.97 ± 0.08 0.0686 ± 0.0110 29 ± 7 
L-ethionine ATP 2.48 ± 0.09 0.0969 ± 0.0130 26 ± 7 
65 ATP L-methionine 2.92 ± 0.07 0.0028 ± 0.0007 1042 ± 100 
ATP L-ethionine 2.99 ± 0.11 0.0070 ± 0.0016 427 ± 69 
L-methionine ATP 2.806 ± 0.08 0.0145 ± 0.0025 194 ± 32 
L-ethionine ATP 3.10 ± 0.14 0.0592 ± 0.0108 52 ± 13 
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Table 3.4. Ligand-based alignment of active site residues between sMAT and eMAT. 
Residues for proposed SN2 reaction are highlighted in bold. The atom numbers used for 
interaction analysis here are the numbers from the AdoEth bound structure (PDB code 
4L2Z). 
Interaction partner sMAT eMAT DALI alignment Chain 
O1, O2 in PPi, O2 in PO4 K25 K245 Not detected B 
O3 in PPi H29 H14   Detected B 
Mg2+ D31 D16 Detected B 
O7, O8 in SAE H58 Q98 Not detected A 
O7, O8 in SAE N60 K269 Not detected A 
K63 (K+ in eMAT) D62 E42 Detected A 
O5, O7 in PPi K63 K+ - A 
ethyl group in SAE L145 I102 Detected A 
O26 in SAE D199 D163 Detected B 
O3 in PPi K201 K165 Detected B 
stacked with adenine ring Y270 F230 Detected B 
O27 in SAE D282 D238 Detected B 
O1, O3 in PO4 R288 R244 Detected B 
Mg2+ E305 D271 Not detected A 
O6 in PPi, O1 in PO4 K310 K265 Detected A 
O5 in PPi H315 - - A 
ethyl group in SAE I349 I302 Detected A 
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Figure 3.1. Turnover of S/Se-Met analogs by sMAT. (A) The reaction catalyzed by 
methionine adenosyltransferase. (B) Turnover of S/Se-Met analogs to the corresponding 
AdoMet analogs catalyzed by sMAT based upon RP-HPLC (average percentage error ≤ 
4%; see Table 3.2 and Figure 3.4). Bars colored green (referring to branched L-alkyl-
substituted analogs) denote analogs for which only trace turnover was observed with MATs 
studied to date.11 As controls, no product formation was observed in the absence of sMAT, 
S/Se-Met analogs or ATP. 
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Figure 3.2. The structure-based sequence alignment of MATs from Sulfolobus solfataricus 
(sMAT), E. coli (eMAT) and human (hMAT2A). Secondary structural features of sMAT 
are shown at the bottom. The numbering of the amino acids in the figure corresponds to 
sMAT. Identical residues between all three sequences are shown in green; identical 
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residues between two sequences are shown in yellow. The critical residues involved in 
substrate binding are highlighted in red letters. 
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Figure 3.3. The overall molecular structure and active site contents of sMAT. (A) Tetramer 
assembly of sMAT in the crystal structure as calculated by PISA. The surface of the protein 
is displayed: four protein monomers are shown in light blue or yellow and the gating loops 
are shown in red. One protein monomer is displayed on the right showing the three 
intertwined domains as cartoon and the ligands as sticks. (B) Stereoview of sMAT–ligand 
interactions. The stick model of AdoEth, PPi, PO4
3- and Mg2+ is depicted in spheres and 
the interacting sMAT residues are labeled and illustrated in green. (C) Side view of sMAT 
dimer with AdoEth bound. The gating loop region is highlighted in red. (D) Side view of 
apo sMAT dimer. The gating loop region is highlighted in red. 
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Figure 3.4. HPLC traces for representative sMAT reactions illustrating the production of 
AdoMet analogs and/or 5ʹ-methyl-thio(seleno)-5ʹ-deoxyadenosine (MSeA) in the presence 
of a select set of L-Met analogs. Starting material (ATP) is designated by a dot. 
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Figure 3.5. The active site of sMAT with the simulated annealing Fo – Fc omit map 
(contoured at 3.0σ). Substrates including ADP, ethionine, PO4
3- and Mg2+ are modeled on 
the left. Products including AdoEth, PPi, PO4
3- and Mg2+ are modeled on the right. 
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Figure 3.6. Folding and active site comparisons between sMAT, hMAT2A and eMAT. (A) 
Monomers of sMAT, hMAT2A and eMAT show a similar threedomain fold. (B) Substrate-
based alignment of sMAT and eMAT shows a space overlap between lysine in sMAT and 
K+ in eMAT. (C) Substrate-based alignment of sMAT, hMAT2A and eMAT displays the 
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clashes around the sMAT ethyl group. The clashes are calculated by ‘show bumps’ in 
PYMOL and the serious/medium/minor clashes are shown in red/brown/green. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Portions of Chapter 3 were previously published.24 Reproduced with permission from 
John Wiley & Sons: Federation of European Biochemical Societies, Volume 281, Issue 18, 
Pages 4224 – 4239, Tables 1 – 4, Figures 1 – 6, and Text. Copyright 2014 is given to the 
publication in which the material was originally published. 
Copyright (C) Tyler D. Huber 2019  
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Chapter Four: Functional AdoMet isosteres resistant to classical AdoMet degradation 
pathways 
 
4.1 Introduction 
 
 Methyltransferase (MT)-catalyzed S-adenosyl-L-methionine (AdoMet)-dependent 
methylation is essential to all walks of life where it contributes to modulating the function 
of a vast array of biomolecules ranging from small metabolites1,5,74,154,155 to 
macromolecules.2–5,26,93,156–160 Consistent with this, alterations in methylation-dependent 
processes are associated with cancer,161 neurodegenerative/neuropsychiatric disorders,162–
164 inflammation,165,166 metabolic disorders,167 fundamental development/regenerative 
medicine,168,169 susceptibility to disease/adverse drug response,170,171 and drug resistance.2–
4,172,173 While there have been great advances in methylation-dependent bioinformatics and 
disease-associated biomarkers,174–176 the study of intracellular MT spatial/temporal 
resolution, specificity and/or function remains a challenge.3,4,158,170–173,177–181 Toward this 
end, the pioneering demonstration of AdoMet analogs, bearing alternative alkyl donor 
substituents, as cosubstrates for DNA6 or natural product (NP)7 MTs have inspired new 
tools and strategies to study NP,8–11 protein,12–15,19,61,62,67,182 and nucleic acid20,22,32,39,53,93,183 
methylation where the recent development of enzyme-based strategies for the synthesis of 
differentially alkylated AdoMet analogs has simplified access to these unique 
cosubstrates.11,14,19,24,27,39 However, the stability of AdoMet or its corresponding 
differentially alkylated analogs under physiological conditions limits their utility as 
reagents or therapeutics by virtue of two fundamental degradative processes: 
intramolecular cyclization to homoserine lactone and 5′-deoxy-5′-(alkylthio)adenosine 
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(Figure 4.1, pathway a) and depurination (Figure 4.1, pathway b).19,35,36,184 To address this 
deficiency, herein we report the chemoenzymatic synthesis of AdoMet isosteres designed 
to circumvent the major AdoMet degradative pathways and demonstrate, via both 
biochemical and structural studies, these analogs to serve as productive MT cosubstrates 
for the prototypical class I MT DnrK. This work highlights a unique conceptual strategy to 
modulate the fundamental properties of AdoMet and corresponding analogs as reagents in 
epigenetic, proteomic, biocatalytic and/or therapeutic applications2 and also demonstrates 
a high-throughput colorimetric assay for DnrK based upon the non-native surrogate 
substrate 2-chloro-4-nitrophenol (ClNP). 
 
4.2 Results and discussion 
 
4.2.1 Synthesis of AdoMet carboxylate isosteres 
 Adenine isosteres, such as 7-deazaadenine (7dzA), have been successfully employed 
to reduce the propensity for nucleotide depurination (Figure 4.1, pathway b).185–187 Thus, 
we focused our attention on addressing the AdoMet degradative intramolecular cyclization 
to homoserine lactone and 5′-deoxy-5′-(alkylthio)adenosine (Figure 4.1, pathway a) by 
replacing the AdoMet carboxylate with a sterically constrained and/or less nucleophilic 
isosteric functional group. As potential carboxylate isosteres,188,189 tetrazolates display a 
similar pKa,190 are less nucleophilic,191 and offer improved membrane permeability.192 In 
addition, MM2 calculations predict the formation of a sterically strained tetrazole-
containing bicyclic ring structure via intramolecular cyclization (Figure 4.1, pathway a) as 
energetically unfavorable. To test this concept, the tetrazole-L-methionine isostere (L-tMet) 
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was synthesized from commercially available N-Fmoc-L-methionine in four simple steps 
(Figure 4.2, 41% overall yield) via a slight modification of previously reported methods193–
200 and subsequently evaluated as a substrate for the permissive methionine 
adenosyltransferase hMAT2A.11 Importantly, this study revealed the kcat of hMAT2A-
catalyzed reactions using native substrate L-methionine (L-Met) or isosteric L-tMet as 
nearly identical (L-Met, 8.0  0.1 min−1; L-tMet, 6.1  0.6 min−1; Table 1, Figure 4.6) with 
an 18-fold observed reduction in Km (L-Met, 397  27 µM; L-
tMet, 7,212  1,250 µM) and 
enabled ~50% conversion to desired AdotMet in 20 h in a standard non-optimized small 
scale assay (10 mM L-tMet, 2 mM ATP, 10 µM hMAT2A, 25 mM Tris·HCl, pH 8.0, 10 
mM MgCl2, 50 mM KCl, 37 °C). Using these parameters as a guide, a subsequent large 
scale (100 mL) chemoenzymatic reaction followed by preparative HPLC provided 19.9 mg 
of AdotMet (0.047 mmol, ~25% recovered yield based on the limiting reagent ATP), the 
purity and composition of which was confirmed via HPLC, NMR and HRMS (see 
Appendix B, Figures 4.5 and 4.10). 
 
4.2.2 Evaluation of AdoMet carboxylate isosteres 
 The subsequent comparison of AdoMet and AdotMet stability in 100 mM Tris·HCl, 
pH 8.0, at 37 °C revealed AdotMet as > 5-fold improved in overall stability (AdotMet t1/2 
= 5,007  6 min; AdoMet t1/2 = 942  7 min; Table 1, Figures 4.5 and 4.9). Consistent with 
our hypothesis, similar levels of AdoMet and AdotMet depurination (Figure 4.1, pathway 
b) were observed while AdotMet enabled complete inhibition of the observed AdoMet 
degradative intramolecular cyclization reaction (Figure 4.1, pathway a). It is important to 
note that while the decay of AdoMet has been reported to follow zero order19 or first order35 
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kinetics, our results are consistent with the former as is our determined AdoMet t1/2 value 
consistent with those previously reported.19,20,35 To assess the utility of the stabilized 
AdotMet as a cosubstrate for MTs, we selected the prototypical class I MT DnrK as a 
model. DnrK is the carminomycin 4-O-MT that catalyzes a culminating step in the 
biosynthesis of the anticancer agent daunorubicin in Streptomyces peucetius and has also 
been reported to methylate various modified anthracyclines and flavonoids as surrogate 
substrates.201–206 Capitalizing on the permissive nature of DnrK and inspired by the recent 
application of ClNP as a surrogate acceptor for glycosyltransferases,89 we developed a real-
time colorimetric assay for DnrK-catalyzed alkylation using ClNP as a surrogate acceptor 
substrate where alkylation abolishes the classical nitrophenolate color (A410) observed 
under basic conditions (Figure 4.3A). While the kinetic parameters for the native DnrK 
substrate carminomycin have not been reported, the determined ClNP kinetic parameters 
(kcat = 0.019  0.001 min−
1, Km = 106  10 µM with AdoMet as the alkyl-donating 
cosubstrate) are consistent with ClNP as a sufficient non-native surrogate where clear 
concentration-dependency was observed in real-time assays (Figure 4.3B). A comparison 
of the DnrK kinetic parameters for AdoMet (kcat = 0.017  0.001 min−
1, Km = 138  7 µM) 
and AdotMet (kcat = 0.031  0.001 min−
1, Km = 335  40 µM) revealed nearly equivalent 
specificity constants (kcat/Km) (Table 1, Figure 4.8). As a simple robust high-throughput 
colorimetric assay for a prototypical class I model MT, this newly validated assay also 
presents an enabling platform for future class I MT engineering, biochemical studies and/or 
tool  development. 
 
4.2.3 Elucidation of DnrK/AdotMet/ClNP ligand-bound structures 
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 To better understand the molecular recognition of surrogate substrates AdotMet and 
ClNP by DnrK, the three-dimensional structures of the DnrK/S-adenosyl-tetrazole-L-
homocysteine (AdotHcy, the byproduct after methyltransfer) and DnrK-ClNP-AdoHcy 
were determined at 2.25 and 1.82 Å resolution in space groups C2 and P21, respectively. 
The average real-space correlation coefficient of all ligands built into these two DnrK 
structures is over 0.96, and the electron density maps can be found in Figure 4.11. In both 
crystal forms, DnrK is identified as a tightly packed dimer with a buried surface area of 
~3100 Å2, which is consistent with previously reported DnrK structures.206 As expected, 
the DnrK-AdotHcy structure reveals AdotHcy and AdoHcy to bind in a nearly identical 
manner where the AdotHcy tetrazolate forms extra hydrogen bonds to water molecules and 
the corresponding sulfur resides slightly closer to the donor nucleophile (Figure 4.4A). This 
observation is also in agreement with reports of reduced donor-acceptor distances in O-
MTs correlating with higher turnover rates,207 as the kcat of DnrK with Ado
tMet is nearly 
double the kcat of DnrK with AdoMet. Consistent with the biochemical data, the orientation 
of one molecule of CINP in the DnrK-ClNP ligand-bound structure is poised for alkylation 
reminiscent to that of the native acceptor carminomycin. Surprisingly, five additional 
ordered CINPs were also observed in the same structure (Figure 4.4B), suggesting a wide 
array of unproductive ClNP binding modes by virtue of key hydrogen bonds and -stacking 
interactions. 
 
4.2.4 Synthesis and evaluation of AdoMet surrogates containing base isosteres 
 To confirm that base isosteres prohibit AdoMet depurination and to assess the 
potential for synergism with carboxylate isosteric replacement, the turnover of 7dzATP by 
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hMAT2A in the presence of L-Met and L-tMet was subsequently assessed. In hMAT2A-
catalyzed 24 h end-point assays, 7dzATP (1 mM) and L-Met (10 mM) gave 92% conversion 
to 7dzAdoMet compared to 57% conversion with 7dzATP (1 mM) and L-tMet (10 mM) 
(Figure 4.7). Stability studies with the purified 7dzAdoMet and 7dzAdotMet confirmed the 
corresponding 7dzAdoMet as resistant to depurination and 7dzAdotMet as completely 
resistant to depurination and intramolecular cyclization (7dzAdoMet t1/2 = 1,243  1 min; 
7dzAdotMet t1/2 = no detectable degradation over 3,300 min; Table 1, Figures 4.5 and 4.9). 
Finally, simple coupled ClNP-based hMAT2A-DnrK assays (10 µM hMAT2A, 30 µM 
DnrK, 2 mM ATP or 7dzATP, 10 mM L-Met or L-tMet, 1 mM ClNP, 25 mM Tris·HCl, pH 
8.0, 10 mM MgCl2, 50 mM KCl, 37 °C, 24 h) revealed all stabilized AdoMet surrogates to 
serve as suitable MT cosubstrates (ATP/L-Met, 52%; ATP/L-tMet, 19%; 7dzATP/L-Met, 
21%; 7dzATP/L-tMet, 14%) (Figure 4.5 and Table 4.2). 
 
4.3 Conclusions 
 
 In summary, this study highlights the efficient chemoenzymatic synthesis of 
enzymatically competent AdoMet isosteres that are considerably less prone to the two 
primary AdoMet physicochemical degradation pathways (intramolecular cyclization 
and depurination, Figure 4.1), where the corresponding tetrazole isosteric replacement also 
restricts the potential for AdoMet carboxylate participation in sulfonium epimerization.4,36 
Based on the DnrK-AdotMet biochemical and structural studies presented, AdotMet is able 
to substitute for AdoMet as a functional enzyme cosubstrate and implicates the isosteric 
modification as potentially advantageous in the context of other AdoMet-dependent 
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enzymatic processes, as exemplified by AdoMet decarboxylase (AdoMetDC)-catalyzed 
AdoMet decarboxylation. Notably, AdoMetDC, a central catalyst in polyamine 
biosynthesis, is a validated anticancer and antiprotozoal drug target where substrate 
surrogates lacking the requisite AdoMet carboxylate (reminiscent of AdotMet) serve as 
potent inhibitors.185,208 Thus, the new conceptual framework for engineering AdoMet 
chemical and metabolic stability put forth presents unique opportunities to advance 
AdoMet biocatalytic and therapeutic applications including, but not limited to, those 
involving MTs. 
 
4.4 Methods 
 
4.4.1 General materials 
 Unless otherwise stated, all general chemicals and reagents were purchased from 
Sigma-Aldrich (St. Louis, MO) or Acros (New Jersey, USA) and were reagent grade or 
better. S-adenosyl-L-methionine was purchased as a 32 mM solution in 10% EtOH/5 mM 
H2SO4 from New England Biolabs (Ipswich, MA). 7-Deazaadenosine-5′-triphosphate 
(7dzATP, lithium salt form) was purchased as a 100 mM solution in H2O from TriLink 
Biotechnologies (San Diego, CA). E. coli BL21(DE3) competent cells were purchased 
from Invitrogen (Carlsbad, CA). The pET28a E. coli expression vector was purchased from 
Novagen (Madison, WI). Primers were purchased from Integrated DNA Technologies 
(Coralville, IA). Pfu DNA polymerase was purchased from Stratagene (La Jolla, CA). 
Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs 
(Ipswich, MA). PD-10 columns and Ni-NTA superflow columns were purchased from GE 
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Healthcare (Piscataway, NJ). Crystal screen kits were purchased from Hampton Research 
(Aliso Viejo, CA), Molecular Dimensions (Altamonte Springs, FL), Rigaku (Seattle, WA) 
and Microlytic (Burlington, MA). 
 
4.4.2 General methods 
 High-throughput assay absorbance readings were conducted using a FLUOstar 
Omega plate reader (BMG LABTECH GmbH, Offenburg, Germany) at λ = 410 nm with 
a bandwidth of 2 nm and the path length was corrected to a depth corresponding to 100 µL 
liquid volume per well. X-ray data were collected at beamline 21-ID-F (LS-CAT) in the 
Advanced Photon Source at Argonne National Laboratory (Chicago, IL). NMR spectra 
were obtained on Varian Unity Inova 400 or 500 MHz instruments (Palo Alto, CA) at the 
NMR facility of the College of Pharmacy at University of Kentucky using “100%” CDCl3 
(D, 99.96%) with 0.05% v/v TMS, CD3OD (D, 99.8%) with 0.05% v/v TMS, DMSO-d6 
(D, 99.9%) with or without 0.05% v/v TMS, or D2O (D, 99.9%) from Cambridge Isotopes 
(Cambridge Isotope Laboratories, MA, USA). 1H and 13C chemical shifts were referenced 
to internal solvent resonances. Multiplicities are indicated by s (singlet), d (doublet), dd 
(doublet of doublets), t (triplet), q (quartet), quin (quintet), m (multiplet), and br (broad). 
Chemical shifts are reported in parts per million (ppm) and coupling constants J are given 
in Hz. Routine 13C NMR spectra were fully decoupled by broad-broad WALTZ 
decoupling. All NMR spectra were recorded at ambient temperature.  
 Normal-phase flash chromatography was performed on 40–63 µm, 60 Å silica gel 
(Silicycle, Quebec, Canada). Analytical TLC was performed on silica gel glass TLC plates 
(EMD Chemical Inc). Visualization was accomplished with UV light (254 nm) followed 
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by staining with dilute H2SO4 (5% in EtOH) solution, KMnO4 solution (1.5 g of KMnO4, 
10g K2CO3, and 1.25 mL 10% NaOH in 200 mL water) and heating, or 10% ninhydrin in 
EtOH and heating. HPLC was accomplished using an Agilent 1260 system equipped with 
a DAD detector (Method A) or a Varian ProStar system equipped with a PDA detector 
(Method B). Method A (HPLC): To monitor the degradation of 
AdoMet/AdotMet/7dzAdoMet/7dzAdotMet and to monitor enzyme reactions, analytical 
reverse-phase (RP) HPLC was conducted with a Luna C18 (5 μm, 4.6 mm × 250 mm; 
Phenomenex, Torrance, California, USA) column  [gradient of 1% B to 20% B over 5 min, 
20% B to 55% B over 15 min, 55% B to 100% B over 1 min, 100% B for 5 min, 100% B 
to 1% B over 1 min, 1% B for 8 min (A = ddH2O with 0.1% formic acid; B = acetonitrile) 
flow rate = 0.4 mL min-1; A254, A260, A317]. Method B (HPLC): To purify hMAT2A-
generated 7dzAdoMet and 7dzAdotMet, preparative RP-HPLC was conducted with a 
Discovery® BIO Wide Pore C18 (10 µm, 21.2  250 mm; Supelco, Bellefonte, 
Pennsylvania, USA) column [gradient of 1% B to 20% B over 5 min, 20% B to 55% B 
over 15 min, 55% B to 100% B over 1 min, 100% B for 5 min, 100% B to 1% B over 1 
min, 1% B for 8 min (A = ddH2O with 0.1% formic acid; B = acetonitrile) flow rate = 8.0 
mL min-1; A254]. HPLC peak areas were integrated with Star Chromatography Workstation 
Software (Varian, Palo Alto, CA, USA).  
High resolution electrospray ionization (ESI) mass spectra (HRMS) (for L-tMet) 
were recorded on an AB Sciex Triple TOF 5600 instrument coupled with an Eksigent 
Ekspert micro LC 200 system with source temperature of 150 °C, ion spray voltage floating 
(ISVF) of 5000 V in positive mode. Samples were infused at 20 µL min-1 and spectra 
collected for 3 min at a resolution greater than 31000. In negative mode ISVF of -4000 V 
101 
 
was used. C17 lysophosphatidyl choline with a mass of 510.3554 and C17 
lysophosphatidic acid with a mass of 423.2517 were used as internal references to calibrate 
the spectra in positive and negative modes respectively. High-resolution electrospray 
ionization mass spectra (for AdotMet, 7dzAdoMet, 7dzAdotMet, and 2-chloro-1-methoxy-4-
nitrobenzene) were recorded on a Thermo Scientific (Rockford, IL, USA) Q Exactive 
(Orbitrap mass spectrometer) via direct infusion at 3 μL/min. Full-scan mass spectra were 
recorded in positive (3.8 kV) and negative (3.8 kV) ion modes (capillary temperature: 
225 °C; nominal resolution: 140,000). 
 Accession codes. The gene sequence of Homo sapiens methionine 
adenosyltransferase II-α (hMAT2A) and Streptomyces peucetius carminomycin O-
methyltransferase (dnrK) involved in this study can be found at GenBank as accession 
numbers AAH01686.1104 and L40425.1,201 respectively. The DnrK-ClNP-AdoHcy crystal 
structure can be found at the Research Collaboratory for Structural Bioinformatics (RCSB) 
Protein Data Bank (PDB) as PDB ID 5EEH, the DnrK-AdotHcy crystal structure can be 
found as PDB ID 5EEG, and the previously reported DnrK-carminomycin-AdoHcy crystal 
structure can be found as PDB ID 1TW2.206 
 
4.4.3 Synthesis of tetrazole-L-methionine (L-tMet) 
The synthesis of L-tMet was accomplished in four steps from commercially-
available starting material. The procedures for the synthesis of L-tMet described herein are 
derived from previously reported methods with slight modifications.193–197,199,209,210 
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(S)-(9H-fluoren-9-yl)methyl [1-amino-4-(methylthio)-1-oxobutan-2-yl]carbamate (2). 
Fmoc-L-methionine (1) (10 g, 26.9 mmol) was dissolved in 300 mL of 1:1 DMF:dioxane 
in a round-bottom flask. To this solution was added (Boc)2O (1.1 eq., 6.5 g, 29.6 mmol), 
NH4HCO3 (1.1 eq., 2.2 g, 29.6 mmol), and pyridine (1.1 eq., 2.6 mL, 29.6 mmol). The 
reaction was left to stir at room temperature for 48 h under an argon atmosphere. Upon 
completion of the reaction, as indicated by TLC (CHCl3:MeOH, 9:1), the entire reaction 
mixture was poured into 1.5 L of EtOAc, transferred to a separatory funnel, washed with 
ddH2O (2 x 1.5 L), and 5% H2SO4 (1 x 1.5 L). The organic fraction was concentrated in 
vacuo to give the product as a white powder (9.7 g, 26.2 mmol, 97% yield). 1H NMR 
(400 MHz, DMSO-d6) δ ppm 7.85 (d, J = 7.5 Hz, 2 H), 7.69 (dd, J = 7.5, 4.0 Hz, 2 H), 
7.45 (d, J = 8.4 Hz, 1 H), 7.38 (td, J = 7.5, 1.1 Hz, 2 H), 7.29 (tt, J = 7.4, 1.4 Hz, 2 H), 
7.00 (s, 2 H), 4.31 – 4.14 (m, 3 H), 4.03 – 3.93 (m, 1 H), 2.44 – 2.32 (m, 2 H), 2.00 (s, 3 
H), 1.92 – 1.69 (m, 2 H); 13C NMR (100 MHz, DMSO-d6) δ ppm 174.0, 156.4, 144.3, 
144.2, 144.1 (2 carbons), 128.1 (2 carbons), 127.5 (2 carbons), 125.7 (2 carbons), 120.5 
(2 carbons), 66.0, 54.1, 47.1, 32.0, 30.3, 15.0. 
 (S)-(9H-fluoren-9-yl)methyl [1-cyano-3-(methylthio)propyl]carbamate (3). A 
suspension of 2 (9.7 g, 26.2 mmol) in THF (450 mL) was stirred in a round-bottom flask 
at 0 °C for 15 min. After 15 min, a 1:1 solution of (TFA)2O:pyridine [total volume 8.5 
mL, 1.1 eq. of (TFA)2O and 2.2 eq. of pyridine] was added in drop-wise fashion via 
syringe and the reaction was left to stir for 3 h at 0 °C under argon. Upon completion of 
the reaction, as indicated by TLC (CHCl3:MeOH, 9:1), 1.5 kg of crushed ice was added 
to the reaction mixture and the corresponding precipitated nitrile product isolated as an 
off-white powder via vacuum filtration. The recovered filtrate was washed with ddH2O 
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(500 mL) and subsequently dried via lyophilization (7.4 g, 20.9 mmol, 80% yield). 1H 
NMR (400 MHz, DMSO-d6) δ ppm 8.16 (d, J = 7.9 Hz, 1 H), 7.86 (d, J = 6.9 Hz, 2 H), 
7.65 (d, J = 7.7 Hz, 2 H), 7.38 (t, J = 7.5 Hz, 2 H), 7.30 (t, J = 7.5 Hz, 2 H), 4.59 (t, J = 
7.6 Hz, 1 H), 4.40 (d, J = 6.7 Hz, 2 H), 4.22 (t, J = 6.6 Hz, 1 H), 2.46 (m, 2 H, overlaps 
with DMSO-d6), 2.01 (s, 3 H), 2.00 – 1.92 (m, 2 H); 
13C NMR (100 MHz, DMSO-d6) δ 
ppm 155.9, 144.1 (2 carbons), 141.2 (2 carbons), 128.1 (2 carbons), 127.5 (2 carbons), 
125.47 (2 carbons), 120.6 (2 carbons), 119.8, 66.3, 47.0, 41.6, 31.5, 29.2, 14.9. 
(S)-(9H-fluoren-9-yl)methyl [3-(methylthio)-1-(1H-tetrazol-5-yl)propyl]carbamate 
(4). NaN3 (2 eq., 2.7 g, 41.9 mmol) and ZnBr2 (0.5 eq., 2.4 g, 10.5 mmol) was added to 
a stirred suspension of compound 3 (7.4 g, 20.9 mmol) in 950 mL 2:1 ddH2O:2-propanol 
in a round-bottom flask. The reaction mixture was refluxed (85 °C) with stirring for 16 
h and, upon completion based upon TLC (CHCl3:MeOH, 9:1), the reaction was cooled 
to room temperature and 3 N HCl (105 mL) and EtOAc (630 mL) were added, in 
respective order, with continued stirring until no solid remained. Organics were 
recovered via separatory funnel and the aqueous fraction was subsequently extracted with 
EtOAc (2 x 650 mL). The organic fractions were combined and concentrated under 
vacuum. The recovered crude was dissolved in 650 mL of EtOAc and recovered as the 
tetrazolate salt via extraction with 10% K2CO3 (3 x 650 mL). The combined aqueous 
phase was cooled to 0 °C, with stirring, and carefully acidified to pH 2.5 with 6 N HCl. 
The mixture was extracted with EtOAc (3 x 600 mL) and the recovered organics 
combined, washed with ddH2O (1.8 L) and concentrated under vacuum to afford the 
desired product as an off-white powder (5.4 g, 13.6 mmol, 65% yield). 1H NMR (400 
MHz, DMSO-d6) δ ppm 8.11 (d, J = 7.9 Hz, 1 H), 7.90 (d, J = 7.7 Hz, 2 H), 7.71 (t, J = 
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8.4 Hz, 2 H), 7.42 (t, J = 7.4 Hz, 2 H), 7.38 – 7.27 (m, 2 H), 5.06 (td, J = 8.5, 5.7 Hz, 1 
H), 4.47 – 4.19 (m, 3 H), 2.50 (m, 2 H, overlaps with DMSO-d6), 2.24 – 2.02 (m, 2 H), 
2.05 (s, 3 H); 13C NMR (100 MHz, DMSO-d6) δ ppm 156.3, 144.2, 144.1 (2 carbons), 
141.2 (2 carbons), 128.1 (2 carbons), 127.5 (2 carbons), 125.66, 125.63, 120.57, 120.54, 
66.1, 47.1, 45.5, 32.7, 29.8, 15.0. 
(S)-3-(methylthio)-1-(1H-tetrazol-5-yl)propan-1-amine (5). Compound 4 (5.4 g, 13.6 
mmol) was dissolved in 300 mL DCM and treated with 100 mL Et2NH while stirring at 
room temperature for 30 min. The crude reaction was concentrated under vacuum and 
the recovered crude, dry material was dissolved in 500 mL of H2O and the mixture 
washed with 500 mL of Et2O. The recovered aqueous phase was dried in vacuo to give 
the desired free amine as a brown-orange amorphous solid (1.9 g, 11.2 mmol, 82% yield). 
1H NMR (400 MHz, D2O) δ ppm 4.93 (t, J = 6.4 Hz, 1 H), 2.48 – 2.19 (m, 4 H), 1.91 (s, 
3 H); 13C NMR (100 MHz, D2O) δ ppm 158.8, 46.0, 31.4, 28.5, 13.9; HRESI calculated 
for C5H12N5S ([M+H]
+) m/z 174.0808; measured m/z 174.0804. 
 
4.4.4 Synthesis of 2-chloro-1-methoxy-4-nitrobenzene (7) 
 To a solution of 2-chloro-4-nitrophenol (6) (0.05 g, 0.29 mmol) in 5 mL DCM was 
added CH3I (22 µL, 35 mmol) and Na2CO3 (0.03 g, 0.29 mmol) and the reaction was stirred 
at room temperature for 3 h. The reaction was concentrated in vacuo, diluted with 50 mL 
EtOAc, and washed with water (30 mL) and brine (30 mL). The organic phase was dried 
over Na2SO4, filtered, and the solvent was removed under reduced pressure. The residue 
was purified by normal phase silica gel column chromatography (using a gradient from 
100:0 to 50:50, hexanes:EtOAc) to give the pure product (0.04 g,  0.21 mmol, 74% yield) 
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as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 2.7 Hz, 1 H), 8.15 (dd, J = 9.1, 
2.7 Hz, 1 H), 6.98 (d, J = 9.1 Hz, 1 H), 4.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 160.1, 
141.2, 126.0, 124.0, 123.2, 111.0, 56.8. 
 
4.4.5 Protein crystallization, data collection, and structure refinement 
 Initial crystallization screens were performed using an in-house screen comprised 
of IndexHT, SaltHT, Peg/ion, PegRx (Hampton Research), MIDAS, Morpheus, JCSG+ 
(Molecule Dimensions), Wizard screens 1-4 (Rigaku), and MCSG screens 1-4 (Microlytic) 
by the sitting drop method using a Mosquito® dispenser (TTP labTech Hertfordshire, 
United Kingdom). The co-crystallization crystals of DnrK and AdotHcy were grown by 
mixing 0.2 μl of protein sample solution (20 mg/ml DnrK, 1 mM AdotHcy and 20 mM Tris 
pH 8.0) with 0.2 μl of reservoir solution (100 mM magnesium formate dihydrate and 15% 
(w/v) PEG 3,350) at 20 °C using the hanging drop method. The crystals were then 
cryoprotected with 15% glycerol and 15% (w/v) PEG 3,350 and flash frozen in liquid 
nitrogen for data collection. The co-crystallization crystals of DnrK, AdoHcy and CINP 
were grown by mixing 0.2 μl of protein sample solution (20 mg/mL DnrK, 2.5 mM 
AdoMet, 7.5 mM CINP and 20 mM Tris pH 8.0) with 0.2 μL of reservoir solution (1.26 M 
ammonium sulfate, 0.1 M Tris pH 8.0 and 0.2 M lithium sulfate) at 20 °C using the hanging 
drop method. The crystals were then soaked and cryoprotected with 80% reservoir solution, 
15% glycerol and 5 mM CINP and then flash frozen in liquid nitrogen for data collection. 
 X-ray diffraction data were collected at the Life Sciences Collaborative Access 
Team (LS-CAT) with an X-ray wavelength of 0.98 Å at the Advanced Photon Source at 
Argonne National Laboratory. Some trail crystals were also tested at Structural Biology 
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Center (SBC-CAT) and GM/CA at the Advanced Photon Source at Argonne National 
Laboratory. Data sets were indexed and scaled using HKL2000 (http://www.hkl-
xray.com/how-reference-hklhkl-2000) or XDS.148 For phasing experiments, molecular 
replacement was utilized using 1TW2206 as starting model, and then phenix.autobuild was 
used for automatic model building.150 The structural model was then completed after 
several rounds of manual model building with COOT211 and refinement with 
phenix.refine.150 Structures were visually interpreted using a stereographic collaborative 
commodity 3D TV arrangement.212 Structure quality was validated by Molprobity.152 
  
4.4.6 Gene cloning, protein expression and purification 
 N-His6-hMAT2A was produced and purified as previously described.
11 The dnrK 
gene encoding carminomycin 4-O-methyltransferase from Streptomyces peucetius was 
amplified from pWHM903201 using primers (forward, 5’- 
AGAGCAGTCATATGACCGCTGAACCGACCGTCGCGGCCCGGCCGCAGCAG -
3’; reverse, 5’- TACAGTGAATTCTCAGGCGCCGGTGGCCGCGGGGGCAAGGAC -
3’) containing NdeI (forward) and EcoRI (reverse) restriction sites. The PCR product was 
digested and ligated into pET28a to provide an expression plasmid to enable N-His6-DnrK 
production. The corresponding E. coli BL21(DE3) host was grown in the presence of 50 
μg mL-1 of kanamycin at 37 °C to an OD600 of ~0.6, at which point the temperature was 
lowered to 25 ºC and gene expression induced with 0.5 mM IPTG. Cells were allowed to 
continue to grow at 25 ºC for approximately 18 h at 220 rpm. Cells were harvested by 
centrifugation (30 min, 5000 rpm), resuspended in buffer A (20 mM NaH2PO4, 300 mM 
NaCl, 10 mM imidazole, pH 7.8) and lysed via incubation with 1 mg mL-1 lysozyme 
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(~50,000 U mg-1) for 30 min on ice followed by sonication (VirSonic 475; Virtis, Gardiner, 
NY; 100 W, 10  15 s pulses, ~1 min between pulses) on ice.  N-His6-DnrK was purified 
via affinity chromatography (5 mL HiTrap Ni-NTA chelating column, GE Healthcare, 
Piscataway, NJ) using a standard linear gradient (50 mM NaH2PO4, 300 mM NaCl, pH 8.0 
with a linear gradient of imidazole of 10-500 mM) using an AKTA Purifier 10 (GE 
Healthcare). Concentration of the pooled fractions containing the purified protein was 
accomplished using an Amicon Ultracel® centrifugal filter unit (30 kDa molecular weight 
cutoff; Merck Millipore Ltd., Tullagreen, Carrigtwohill, Co. Cork, IRL). Buffer exchange 
of combined and concentrated fractions containing the purified protein was accomplished 
using a PD-10 column (GE Healthcare) eluted with 25 mM Tris-HCl, pH 8.0. Protein 
concentrations were determined by Bradford assay (Bio-Rad, Hercules, CA, USA) using 
BSA as a standard. For this study, all proteins retained the N-terminal-His6 affinity tag. 
 
4.4.7 MAT assay 
 To determine the Km and kcat of hMAT2A with varying concentrations of L-Met or 
L-tMet, in vitro hMAT2A reactions were conducted in a volume of 50 μl with saturating 
ATP (2 mM), varied concentrations of L-Met or L-tMet (20, 50, 100, 200, 500, 1,000, 2,000, 
4,000, 6,000, 8,000, and 10,000 µM), 10 μM purified hMAT2A in 25 mM Tris, pH 8.0, 10 
mM MgCl2, 50 mM KCl. Reactions were incubated for 10 min at 37 °C and subsequently 
quenched by adding an equal volume of MeOH followed by centrifugation (10,000 x g, 20 
min) to remove the precipitated protein. Product formation for each reaction was 
subsequently analyzed by RP-HPLC using method A (see Figure 4.5). For each reaction, 
product (AdoMet or AdotMet) concentration was based upon the integration of species at 
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260 nm and calculated by multiplying the initial concentration of ATP by the quotient of 
the integrated product (AdoMet plus MTA or AdotMet) HPLC peak area (mAU*sec) over 
the sum of the integrated peak areas for product and remaining ATP. MTA derives from 
AdoMet and was thereby also considered as contributing to the total product concentration. 
Assays were repeated in triplicate where the Michaelis-Menten plots in Figure 4.6 represent 
an average of replicates. Controls lacking hMAT2A, L-Met, L-tMet, and/or ATP led to no 
product. 
 To determine if 7dzATP (TriLink Biotechnologies, San Diego, CA) was a viable 
cosubstrate for hMAT2A in combination with L-Met or L-tMet, hMAT2A assays 
containing 10,000 µM L-Met or L-tMet and variable 7dzATP (500 µM, 1,000 µM, 2,000 
µM, and 4,000 µM) were conducted in a similar fashion. Aliquots recovered at defined 
incubation times (10 min, 30 min, 60 min, 1,500 min, and 2,940 min) were analyzed via 
HPLC following an identical protocol as above and the results are summarized in Figure 
4.7. Controls lacking hMAT2A, L-Met, L-tMet, and/or 7dzATP led to no product. 
 
4.4.8 DnrK assay 
 DnrK reactions were conducted in a volume of 100 μl containing 30 μM purified 
DnrK in 100 mM Tris, pH 8.0. Acceptor (2-chloro-4-nitrophenol, ClNP) concentrations 
were saturating (1,500 µM) or variable (7.8125, 31.25, 125, 500, 1,000, 1,500, 1,750, or 
2,000 µM) and donor (AdoMet or AdotMet) concentrations were saturating (1,600 µM) or 
variable (25, 50, 100, 200, 400, 800, 1,600, and 3,200 µM). Reactions were incubated for 
120 min at 37 °C and subsequently quenched and analyzed via HPLC as previously 
described for the hMAT2A assays using HPLC method A with detection at 317 nm (Figure 
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4.5). Assays were repeated in triplicate where the Michaelis-Menten plots in Figure 4.8 
represent an average of replicates. Corresponding identical plate-based DnrK assays were 
conducted in clear-bottom 96-well plates where the plate reader limit of quantification 
required assay dilution at ClNP concentrations >500 µM. The change in absorbance 
(ΔA410, representing disappearance of ClNP) over time was used as an indirect measure of 
ClNP methylation where product concentration was inferred by multiplying the percentage 
change in A410 at t = 0 min and A410 at t = 120 min by the initial ClNP concentration (Figure 
4.8).89 Controls lacking DnrK, AdoMet, AdotMet, and/or ClNP led to no product. 
 
4.4.9 Coupled hMAT2A-DnrK assay 
 Coupled hMAT2A-DnrK reactions were conducted in a total volume of 50 µL 
containing 25 mM Tris·HCl, pH 8.0, 50 mM KCl, 10 mM MgCl2 with 10 µM hMAT2A, 
30 µM DnrK, 1,000 µM ClNP (saturating), and one of the following combinations of 
hMAT2A cosubstrates per reaction: L-Met (10,000 µM) and ATP (2,000 µM), L-tMet 
(10,000 µM) and ATP (2,000 µM), L-Met (10,000 µM) and 7dzATP (2,000 µM), or L-tMet 
(10,000 µM) and 7dzATP (2,000 µM). Reactions were incubated at 37 °C in PCR tubes on 
a thermocycler with a heated lid for 24 h and subsequently quenched and analyzed via 
HPLC as previously described for DnrK assays using HPLC method A (Figure 4.5 and 
Table 4.2). Controls lacking hMAT2A, DnrK, ClNP, L-Met, L-tMet, ATP, and/or 7dzATP 
led to no product. 
 
4.4.10 Chemoenzymatic synthesis and purification of AdotMet, 7dzAdoMet, and 7dzAdotMet 
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 Preparative MAT reactions to produce AdotMet (10 mM L-tMet, 1 mM 7dzATP), 
7dzAdoMet (10 mM L-Met, 1 mM 7dzATP), or 7dzAdotMet (10 mM L-tMet, 1 mM 7dzATP) 
were conducted in a volume of 100 mL, 0.8 mL, or 0.8 mL, respectively  with 10 µM 
hMAT2A in 25 mM Tris·HCl, pH 8.0, 50 mM KCl, and 10 mM MgCl2.  
 The preparative AdotMet reaction was conducted in 2 x 50 mL Falcon tubes 
incubated at 37 °C for 48 h in a hybridizing oven (Techne Hybridiser HB-1D, Bibby 
Scientific, Staffordshire, United Kingdom) with rotation. After 48 h, the reactions were 
combined in a 500 mL round-bottom flask, flash-frozen, and lyophilized to dryness. The 
mixture was purified via C18 column (3.5 cm x 18 cm) washed with 800 mL ddH2O (wash) 
followed by elution with 600 mL 5:95 CH3CN:ddH2O, 600 mL 10:90 CH3CN:ddH2O and 
800 mL 15:85 CH3CN:ddH2O (40 mL fractions collected throughout elution). Analytical 
HPLC (Method A) revealed fractions 18 – 50 to contain the desired pure AdotMet and 
these product-containing fractions were combined, concentrated in vacuo, flash frozen and 
lyophilized to yield 19.9 mg of a brown-orange amorphous solid. Aqueous stock solutions 
were prepared in 10% EtOH, 5 mM H2SO4 aqueous solution (identical to commercial 
AdoMet stock preparations) where corresponding concentrations were based upon the 
molar extinction coefficient for AdoMet (15,400 L mol-1 cm-1 at 254 nm)36 and verified via 
analytical HPLC (Method A) comparison to commercial AdoMet standards. 
 The preparative 7dzAdoMet/7dzAdotMet reactions were conducted in several PCR 
tubes (8 x 100 µL for each reaction) and incubated in a thermocycler (with a heated top to 
prevent evaporation) at 37 °C for 1.5 h (L-Met and 7dzATP) or 24 h (L-tMet and 7dzATP). 
Recombinant shrimp alkaline phosphatase (rSAP; New England BioLabs, Ipswich, 
Massachusetts, USA) was subsequently added to a final concentration of 0.1 U µL-1 and 
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the reactions incubated for an additional 20 min (to convert unreacted 7dzATP to 
7dzadenosine). For each target, the cumulative reactions were combined, quenched with an 
equal volume of MeOH, centrifuged (10,000  g, 20 min, 4 °C) to remove precipitated 
protein and the supernatant concentrated to ~250 µL in vacuo. The desired product in each 
case was recovered via HPLC (Method B), concentrated, flash frozen and lyophilized to 
dryness. Aqueous stock solutions were prepared in 10% EtOH, 5 mM H2SO4 aqueous 
solution (identical to commercial AdoMet stock preparations) where corresponding 
concentrations were based upon the molar extinction coefficient for 7-deaza-adenosine 
(9,100 L mol-1 cm-1 at 260 nm)213 and verified via analytical HPLC (Method A) comparison 
to commercial 7dzATP and AdoMet standards. 
 
4.4.11 Determination of t1/2 of AdoMet, Ado
tMet, 7dzAdoMet, and 7dzAdotMet 
 AdoMet, AdotMet, 7dzAdoMet, or 7dzAdotMet (1 mM 10% EtOH, 5 mM H2SO4 
stock) was diluted to 100 µM in 100 mM Tris buffer pH 8.0 and incubated at 37 °C. 
Aliquots of each solution were taken at t = 0 min (and at various time points thereafter) and 
analyzed via HPLC (method A, A254). The concentrations of AdoMet species and 
corresponding degradation products were determined, graphed on an XY-scatterplot, and 
linear regression was performed on each dataset to obtain degradation rates (Figure 4.9) as 
previously described.19,46 The t1/2 of each AdoMet species was determined from the line 
slope considering zeroth order kinetics, as in the following equation [1]: 
    
[1]  𝑡1
2
=
[𝐴𝑑𝑜𝑀𝑒𝑡]0
2𝑘
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where 𝑡1
2
 is the time (in min) that it takes for one half of a chemical species (in this example, 
AdoMet) to degrade, [𝐴𝑑𝑜𝑀𝑒𝑡]0 is the starting % concentration of a chemical species, and 
𝑘 is the zero-order rate constant of degradation of a chemical specie (in % min-1). 
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Table 4.1. Kinetic parameters and stability measurements of 
Met/AdoMet isosteres with hMAT2A and DnrK. 
 
Enzyme Substrate kcat 
min-1 
Km 
µmol L-1 
kcat/Km 
Relative 
t1/2 
mina 
hMAT2A L-Metb 
8.0  0.1 397  29 1 -c 
 L-tMetb 
6.1  0.6 7,212  1,250 0.04 -c 
DnrK ClNPd 0.019  0.001 106  10 N.A.e -c 
 AdoMetf 0.017  0.001 138  7 1 942  7 
 AdotMetf 0.031  0.001 335  40 0.8 5,007  6 
 7dzAdoMet -c -c -c 1,243  1 
 7dzAdotMet -c -c -c no degradationg 
aStability studies conducted at 37 °C, pH 8.0. bhMAT2A substrates were assayed in the presence of 
saturating ATP (2 mM). cNot determined. dDnrK substrate ClNP was assayed in the presence of saturating 
AdoMet (1.6 mM). eNot applicable. fDnrK substrates AdoMet and AdotMet were assayed in the presence 
of saturating ClNP (1.5 mM). gNo detectable degradation after 3,300 min  standard error (SEM) at 95% 
confidence interval (CI). 
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Table 4.2. Turnover of ClNP in hMAT2A-DnrK coupled reactions. Assay conditions are 
described in the Materials and Methods of the main text. 
ATP or 7dzATP L-Met or L-tMet % Turnover 
ATP L-Met 52 
ATP L-tMet 19 
7dzATP L-Met 21 
7dzATP L-tMet 14 
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Figure 4.1. Utilization and degradation of AdoMet. General scheme highlighting 
methyltransferase (MT)-catalyzed use of AdoMet in methylation reactions (upper) and 
major chemical degradation pathways of AdoMet (lower). AdoMet, S-adenosyl-L-
methionine (also referred to as SAM); AdoHcy, S-adenosyl-L-homocysteine (also referred 
to as SAH). 
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Figure 4.2. Synthesis of AdoMet analogs and corresponding relevant degradation 
pathways. (A) Synthesis of L-tMet: i) (Boc)2O, pyridine, NH4HCO3, rt, 5 h, 97%; ii) 
(TFA)2O/pyridine (1:1), THF, 0 °C, 3 h, 80%; iii) NaN3, ZnBr2, H2O/2-propanol (2:1), 80 
°C, 16 h, 65%; iv) Et2NH, CH2Cl2, rt, 0.5 h, 82%. (B) General scheme for hMAT2A-
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catalyzed synthesis of AdoMet, AdotMet, 7dzAdoMet and 7dzAdotMet. (C) Degradative 
pathways for AdotMet, 7dzAdoMet and 7dzAdotMet. Fmoc, Fluorenylmethyloxycarbonyl. 
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Figure 4.3. DnrK colorimetric assay. (A) General scheme for a high-throughput DnrK 
colorimetric assay enabled by the surrogate acceptor 2-chloro-4-nitrophenol (ClNP). (B) 
Representative assay results demonstrating DnrK-catalyzed alkylation of ClNP diminishes 
classical ClNP color (A410) over time [30 µM DnrK; 500 µM ClNP; AdoMet: (i) 100 µM, 
(ii) 500 µM, (iii) 800 µM, (iv) 1,000 µM, (v) 1,600 µM, and (vi) 2,000 µM; 25 mM 
Tris·HCl; pH 8.0]. 
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Figure 4.4. DnrK ligand-bound structures. (A) DnrK-AdotHcy (grey) and DnrK-AdoHcy-
carminomycin (green) ligand-bound structures. Polar contacts between AdotHcy and 
nearby residues (stick models) and water molecules (spheres) are highlighted by dashed 
lines. In this model, the distance between carminomycin O-4 and the AdoHcy or AdotHcy 
sulfur is 4.2 Å and 3.8 Å, respectively. (B) DnrK-AdoHcy-ClNP (purple) and DnrK-
AdoHcy-carminomycin (green) ligand-bound structures with ligands represented as stick 
models. In this model, the distance between carminomycin O-4 or ClNP O-1 and the 
AdoHcy sulfur is the same (4.2 Å). 
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Figure 4.5. Representative analytical HPLC.  All chromatograms were obtained using 
HPLC Method A. (A) AdoMet at 0 min (blue) and 1,415 min (red) (A260). (B) Ado
tMet at 
0 min (blue) and 1,450 min (red) (A260). (C) 
7dzAdoMet at 0 min (blue) and 488 min (red) 
(A260) where product peak broadening and UV-vis profile are consistent with commercially 
available starting material (7dzATP). (D) 7dzAdotMet at 0 min (blue) and 1,500 min (red) 
(A260). (E) hMAT2A-DnrK coupled reactions (10 µM hMAT2A, 30 µM DnrK, 1,000 µM 
ClNP) plus: L-Met (10,000 µM) and ATP (2,000 µM) (blue); L-tMet (10,000 µM) and ATP 
(2,000 µM) (red); L-Met (10,000 µM) and 7dzATP (2,000 µM) (green); or L-tMet (10,000 
µM) and 7dzATP (2,000 µM) (pink) after 24 h (A317). (F) 1 mM synthetic 2-chloro-1-
methoxy-4-nitrobenzene standard (blue); ClNP methylation reaction (30 µM DnrK, 3,200 
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µM AdoMet, and 1,000 µM ClNP) after 19 h (red); co-injection of synthetic standard and 
ClNP methylation reaction (green) (A317). AdoMet, Ado
tMet, 7dzAdoMet, or 7dzAdotMet 
are annotated by a star; Adenine is annotated by a square; MTA or MT7dzA are annotated 
by a triangle; ClNP is denoted by a diamond; and 1-methoxy-2-chloro-4-nitrobenzene is 
annotated by a plus. 
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Figure 4.6. Determination of kinetic parameters for hMAT2A-catalyzed reactions. 
[hMAT2A] = 10 µM in all experiments. (A) [ATP]i = 2000 µM, [Met]i = varied. (B) [ATP]i 
= 2000 µM, [tMet]i = varied. 
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Figure 4.7. Turnover of 7dzATP and L-Met/L-tMet with hMAT2A. Assay conditions are 
described in the Materials and Methods of the main text. [7dzATP]i = 500 µM (grey), 1,000 
µM (orange), 2,000 µM(green), 4,000 µM (purple). Solid lines represent reactions with L-
Met as cosubstrate, dashed with L-tMet. 
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Figure 4.8. Determination of kinetic parameters for DnrK-catalyzed reactions. [DnrK] = 
30 µM in all experiments and assays were conducted via HPLC (panels A-C) or plate-
based (panels D and E) colorimetric format. (A) [2-chloro-4-nitrophenol]i = 1500 µM, 
[AdoMet]i = varied; (B) [2-chloro-4-nitrophenol]i = 1500 µM, [Ado
tMet]i = varied; (C) [2-
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chloro-4-nitrophenol]i = varied, [AdoMet]i = 1600 µM. (D) [2-chloro-4-nitrophenol]i = 500 
µM, [AdoMet]i = varied; (E) [2-chloro-4-nitrophenol]i = varied, [AdoMet]i = 2,500 µM. 
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Figure 4.9. Time-dependent AdoMet, AdotMet, 7dzAdoMet, and 7dzAdotMet degradation. 
AdoMet (grey, solid), AdotMet (green, solid), 7dzAdoMet (purple, solid), or 7dzAdotMet 
(orange, solid) were incubated at 37 °C with 100 mM Tris·HCl, pH 8.00 and monitored via 
HPLC for over 55 h. Corresponding degradations products MTA (grey, dotted), MT7dzA 
(purple, dotted), and/or adenine (grey and dashed if from AdoMet, green and dashed if 
from AdotMet) are also indicated. 
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Figure 4.10. Key AdotMet 1H–1H-COSY, HMBC and NOESY correlations. 
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Figure 4.11. DnrK electron density maps. (A) 2mFo-DFc omit map of AdotHcy was 
contoured at 1.3σ. (B) 2mFo-DFc omit map of AdoHcy and CINPs was contoured at 1.3σ.  
 
 
 
 
 
 
 
 
**Portions of Chapter 4 were previously published.40 Reproduced with permission from 
the American Chemical Society: ACS Chemical Biology, Volume 11, Issue 9, Pages 2484 
– 2491, Table 1, Figures 1 – 4, and Text. Copyright 2016 is given to the publication in 
which the material was originally published. 
Copyright (C) Tyler D. Huber 2019  
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Chapter Five: Methionine adenosyltransferase engineering to enable bioorthogonal 
platforms for AdoMet-utilizing enzymes 
 
5.1 Introduction 
 
Methyltransferase (MT)-catalyzed transfer of the activated S-adenosyl-L-methionine 
(AdoMet) contributes to the functional modulation of biomolecules ranging from small 
metabolites1,5,74,154,155 to macromolecules.2–5,26,93,156–160 Alterations in methylation-
dependent processes are associated with cancer,161 neurodegenerative/neuropsychiatric 
disorders,162–164 inflammation,165,166 metabolic disorders,167 fundamental 
development/regenerative medicine,168,169 susceptibility to disease/adverse drug 
response,170,171 and drug resistance.2–4,172,173 Yet, the structural conservation among MTs 
and large array of discrete and redundant MTs in any given cell present major challenges 
to the direct study of individual MTs in situ.3,57,67,214–216 Based on proof of concept studies 
that revealed MTs to utilize non-native AdoMet analogues to afford differential 
alkylation,7,21,28 similar approaches have leveraged MT promiscuity and differentially-S-
alkylated AdoMet analogues for MT-catalyzed alkylation of  DNA/RNA,6,21–23,28,52,54,217–
225 proteins,12,14–17,33,57,59,61,62,65,226–229 and bioactive secondary metabolites.7–11,24,77,229 This 
conceptual advance, and the corresponding chemical biology reagents developed, enabled 
more recent efforts to develop bioorthogonal allele-specific chemical genetics strategies 
(also referred to as ‘bump-and-hole’)78,79,230–236 for intracellular metabolic profiling of 
individual MTs.14,17,67 Such bioorthogonal approaches employ an engineered target MT 
with complementary non-native AdoMet cosubstrates and seek to achieve orthogonal 
biochemically competent catalysis that uniquely distinguishes (via delivery of 
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chemoselective tags) the intracellular function of the target MT. Current efforts, which rely 
on varying the S-alkyl substituent as the bioorthogonal element, remain hampered by 
selectivity as most, if not all, of the non-native S-alkyl AdoMet analogues employed to date 
for bioorthogonal applications remain substrates for wild-type MTs.14,17,50,53,59 While MTs 
are also known to accommodate modifications to the AdoMet adenine80 or terminal 
carboxylate,40 attempts to exploit adenine and/or carboxylate alteration for bioorthogonal 
reagent development have been hampered, in part, by accessibility of the corresponding 
AdoMet analogues. 
As a first step toward alternative formats for bioorthogonal design (Figure 5.1), herein 
we describe the evaluation of a range of putative bioorthogonal human methionine 
adenosyltransferase II-α (hMAT2A) mutations and methionine analogues, the emphasis of 
which focused on modulation of hMAT2A binding interactions with the l-methionine (l-
Met) terminal carboxylate and α-amine. Specifically, we describe the evaluation of 38 
unique hMAT2A mutants (deriving from site-saturation at 4 different active-site residues) 
with 14 non-native methionine analogues modified at the terminal carboxylate and/or α-
amine. Enabled by the development and implementation of a hMAT2A high-throughput 
(HT) assay, this assessment revealed hMAT2A K289L to display a 160-fold inversion of 
the hMAT2A selectivity index for the non-native methionine analog S-(–)-methioninol 
(metol) over L-Met. Subsequent structural studies of K289L were consistent with design 
principles and notably, the product of the K289L/metol reaction (AdoMetol) was also 
found to be resistant to the classical AdoMet intramolecular cyclization degradation 
pathway.19,35,36,40,184 This study also revealed hMAT2A mutations (D258H and D258N) 
that converted hMAT2A to a putative ATPase. This work provides additional insights 
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regarding hMAT2A substrate recognition and sets the stage for similar conceptual 
engineering of downstream AdoMet-utilizing enzymes (including, but not limited to, MTs) 
to provide the basis for a general bioorthogonal platform. 
 
5.2 Results and Discussion 
 
5.2.1 Bioorthogonal design for site saturation and methionine analogue synthesis 
Our overarching goal was to develop hMAT2A mutants with demonstrated 
selectivity for non-native methionine analogues over the native hMAT2A substrate L-Met. 
To achieve this goal, disruption of 4 key hMAT2A active-site side chain interactions with 
L-Met terminal carboxylate and α-amine were targeted (E70, Q113, D258, and K289; 
Figure 5.2A). Potential anticipated alternative non-native substrate binding interactions 
included (Figure 5.2A and 5.2B): putative salt-bridge inversion [e.g., pairing mutants 
K289D/E or Q113D/E with metamine (11) or metamide (12), or E70R/H/K or D258H/N 
mutants with methionine analogue αK-Met (13)];  potential alternative van der Waal’s 
interactions [e.g., pairing mutants Q113A/V/I/L/M/W or K289A/V/I/L/M/F/Y with 
methionine analogues metOOMe (2), metolMe (4), metolEt (5), metolPr (6), or methionine 
ethers (7–10)]; or varied hydrogen-bonding interactions [e.g., pairing mutants Q113T or 
K289C/S/T with metol (3)]. This conceptual design was inspired, in part, by our recent 
discovery that l-Met carboxylate isosteres were hMAT2A substrates of hMAT2A, where 
the corresponding AdoMet analogues were also both stable to rapid degradative 
intramolecular cyclization and functional as MT substrates.40 Substrate surrogates 4–6 
were synthesized from commecially-available N-Fmoc-L-methionine in 4 steps with 
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overall yields ranging from 15–18%, while analogues 7–10 were constructed from 
commercially-available N-Boc-L-methioninol in 2 steps with overall yields ranging from 
49 – 81%. 
 
5.2.2 Assay development and validation 
A standard luciferase-based assay for [ATP] (Promega Corporation, Kinase-Glo 
Max) was used as a basis for 384-well plate-based assay development and the subsequent 
primary screen. While the reported intracellular concentration of ATP in E. coli (1.54 
mM)237 surpasses the linear range of the assay (linear up to 500 µM ATP), ATP quickly 
depletes in cellular extracts. Endogenous [ATP] added to the assay and post-lysis assay 
incubation time were optimized to maximize Δluminescence between the positive and 
negative controls to obtain a Z′ value > 0.5 (Figure 5.3).238 Optimized reaction conditions 
contained 10 mM L-Met and 1.5 mM ATP in 25 mM Tris·HCl (pH 8.0) containing 10 mM 
MgCl2 and 50 mM KCl incubated at 37 °C for 1 h prior to incubation at ambient 
temperature for 20 min. Negative controls for assay validation and Z′ value determination 
included pET28a-E. coli BL21 extract (empty vector control), pET28a/wtOleD-E. coli 
BL21 extract (non-specific protein overproduction strain; macrolide glucosyltransferase 
OleD)116,239 and assays with pET28a/hMAT2A-E. coli BL21 extract lacking L-Met. Based 
on comparison to the positive control (pET28a/hMAT2A-E. coli BL21), three separate Z′ 
values were calculated (pET-28a vector control, Z′ = 0.44; OleD, Z′ = 0.67; and hMAT2A 
lacking L-Met, Z′ = 0.63). 
 
5.2.3 Primary screen 
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Using the optimized assay platform described above, 38 saturation mutants 
(representing site-saturation at 4 different active-site residues (E70, Q113, D258, and 
K289) were screened in parallel. Assays containing 5 µL of clarified extract, 1.5 mM ATP, 
and 10 mM methionine analogue, were incubated at 37 °C for 1 h, cooled to room 
temperature over 20 min and then analyzed using the luciferase assay. Plate-to-plate 
standardization was based on inclusion of internal replicate positive (hMAT2A/L-Met) and 
negative (hMAT2A but lacking L-Met; empty vector) controls. To facilitate mutant-
substrate pairing comparisons and hit selection, HT screening results were represented as 
the mean percent change in luminescence from the negative control (corresponding 
hMAT2A mutant lacking methionine analogue) (Figure 5.4). Specifically, in this analysis 
the color of each square for each hMAT2A mutant correlates to the percent change in mean 
relative luminescence units (RLU) among assays in the presence or absence of methionine 
analogue (where red represents increased MAT activity and blue represents decreased 
MAT activity compared to the negative control). 
This cumulative analysis led to the following observations. First, mutation of K289 
and, to a lesser extent Q113, led to increased turnover of metol and metolMe compared to 
the wild-type hMAT2A conversion of these non-native surrogates. Within this context, the 
best substitutions at K289 included variable polar (Cys, Ser and Thr), hydrophobic (Ala, 
Ile, Leu, Met and Phe) or acidic (Asp and Glu) substitutions. While similar variable polar 
(Thr) or hydrophobic (Ala, Val, Ile, Leu and Met) substitutions at Q113 provided slight 
improvements, acidic side chains (Asp and Glu) offered the best outcomes with metol and 
metolMe. Second, mutation of K289 generally led to a reduction in turnover of native 
substrate l-Met with the most notable reductions observed with Leu, Ser, Val and Tyr 
135 
 
substitution. These results are consistent with the prior observation that patients with 
K289N mutation in hMAT1A, an hMAT2A isoform with 84% sequence identity, exhibit 
persistent hypermethioninemia.240 In contrast, most mutations of Q113 had little effect on 
L-Met turnover. Q113, through its interaction with L-Met, is perceived as important to 
closure of hMAT2A gating loop and stabilization of the corresponding closed 
conformation.241 Finally, mutagenesis of D258 to basic residues (most notably His and, to 
a lesser extent, Asn) surprisingly led to non-specific ATPase activity irrespective of L-Met 
or methionine surrogates employed. Consistent with this, identical assays of D258H in the 
absence of L-Met or methionine surrogate revealed similar ATPase activity (data not 
shown). Substitution of D258 with other amino acids were inhibitory, consistent with the 
strong interactions between the hMAT2A D258 side chain carboxylate and the substrate 
methionine alpha-amine.241,242 
Based on the primary screen, several hMAT2A mutant and methionine analogue 
pairs were selected for confirmatory studies based on a perceived potential selectivity 
index. Namely, mutant/methionone analog pairings were advanced if they met the 
following criteria: i) reduced turnover of methionine by mutant;  ii) reduced methionine 
analogue turnover with native hMAT2A; and iii) improved turnover of the methionine 
analogue by the mutant (less than -35% mean change in luminescence from the negative 
control). 
 
5.2.4 Hit confirmation 
To eliminate potential artifacts deriving from strain to strain variability in hMAT2A 
mutant protein levels, hit confirmation was conducted via a time-course assays using fixed 
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concentrations (10 µM) of purified enzymes. Assays were analyzed via RP-HPLC (Figure 
5.7) and corresponding AdoMetol and AdoMetolMe product peaks were collected and 
confirmed via HRMS (Appendix C). Variable protein production levels (ranging from 8.7 
mg L-1 for mutant K289L to 26.6 mg L-1 for mutant Q113D) were observed among the test 
set, contributing to observed inconsistencies between the primary and secondary screens.  
The results of the cumulative secondary screen are summarized in Figure 5.5. 
Under the defined time-course assay conditions, low to moderate wt-hMAT2A-catalyzed 
turnover of metol and racemic metolMe was observed over 240 min (39% and 17%, 
respectively) compared to the corresponding efficient turnover of L-Met  in 10 min (49%). 
K289L/metol represented the best mutant-analogue combination (62% turnover in 240 min 
compared to 14% turnover of L-Met in 240 min) and K289L also displayed moderate 
efficiency with metolMe (28% in 240 min). Mutants Q113D, K289S and K289T also 
displayed some selectivity toward metol (39%, 38% and 14%, respectively; 240 min) over 
L-Met (13%, 14% and 2.5%, respectively; 240 min). In contrast, K289F lacked selectivity 
(33% metolMe versus 30% L-Met; 240 min) while E70S lacked appreciable activity in the 
presence of non-native methionine surrogates (3.2% metol, 240 min versus 25%  L-Met, 
10 min). Interestingly, comparative hMAT2A/mutant assays with racemic metolMe or 
corresponding diastereomers (R,S-metolMe or S,S-metolMe) revealed no enzymatic 
differentiation among metolMe stereoisomers (data not shown). 
 
5.2.5 Kinetic parameters and non-native AdoMet stability 
 Native hMAT2A exhibited a 40-fold specificity (kcat/Km) preference for L-Met over 
metol. Conversely, mutant K289L exhibited a 4-fold specificity preference for metol over 
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L-Met (Table 5.1). This analysis highlights the 17-fold difference between L-Met and metol 
Km as the main contributor to substrate differentiation in hMAT2A. In contrast, a 5-fold 
kcat distinction with metol versus L-Met serves as the K289L primary differentiator. 
Importantly, the K289L kcat with metol (4.1 min
-1) is approaching that of hMAT2A with L-
Met (25.7 min-1) while the metol Km of Q113D (338 µM) is approaching the L-Met Km of 
hMAT2A (138 µM). This may suggest there to be potential for further improvement of the 
bioorthogonal selectivity index via second generation mutant combinations. 
A primary chemical degradation pathway of AdoMet (t1/2 = 942 min, pH 8) occurs 
via intramolecular cyclization of the terminal carboxylate and the activated gamma carbon 
to form 5′-deoxy-5′-(methylthio)adenosine (MTA) and L-homoserine lactone (HSL). We 
previously demonstrated that replacing the AdoMet carboxylate with a carboxylic acid 
isostere prohibits this reaction and the corresponding production of MTA.40  Likewise, the 
conversion of AdoMetol or AdoMetolMe to MTA was not observed in any of the 
enzymatic reactions throughout the course of this study, even after 24 hr incubation (Figure 
5.7). This AdoMetol/AdoMetolMe chemical stability may present unique advantages in 
the context of future intracellular bioothorgonal applications. 
 
5.3 Conclusions 
 
In summary, this study highlights the first example of exchanging L-Met terminal 
carboxylate/amine recognition elements within the hMAT2A active-site to enable non-
native bioorthgonal substrate utilization (Figure 5.1D). As many AdoMet-producing (e.g., 
hMAT2A) and AdoMet-utlizing (e.g., MTs) enzymes adopt similar active-site strategies 
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for substrate recognition,241–245 the proof of concept first generation hMAT2A engineering 
highlighted herein is expected to translate to a range of AdoMet-utilizing target enzymes. 
Importantly, the new conceptual design put forth affords two distinct advantages over 
previously reported innovative bioorthogonal strategies for AdoMet production/utilization 
(Figure 5.1B and 5.1C). First, unlike strategies that rely on MAT/MT engineering to 
accomodate additional steric bulk of specific S-alkyl substitutions (e.g., the S-butynyl 
AdoMet analogue-based approach reported by Klimašauskas and coworkers or the coupled 
S-(E)-hex-2-en-5-ynyl l-Met/AdoMet analogue-based platform reported by Luo and 
colleagues;14,17,246 Figure 5.1B), the current strategy does not rely on specific substrate S-
alkyl substitutions as a bioorthogonal differentiator and is thereby anticipated to afford 
greater flexibility in the S-alkyl ‘tags’ that can be employed. Second, in contrast to all 
previously reported L-Met/AdoMet platforms (Figure 5.1B and 5.1C),83,235,247,248 the 
current strategy’s replacement of L-Met/AdoMet terminal nucleophilic carboxylate as the 
bioothogonal recognition element provides uniquely stable AdoMet reagents for 
biochemical or intracellular studies.  
Based on comparative kinetic parameters, the first generation hMAT2A 
engineering strategy highlighted herein led to a 160-fold inversion of the hMAT2A 
selectivity index (from 40-fold L-Met/metol bias for hMAT2A to a 4-fold metol/L-Met 
preference for K289L). This compares favorably to previously reported bioorthogonal 
engineering approaches to AdoMet-producing/utlizing enzymes.  For example, Schultz and 
Gray reported a 260-fold inversion of the selectivity index as the first application of ‘bump-
and-hole’ engineering principles to a protein arginine MT (Rmt1) via a designed E117G 
mutant to accommodate a nucleoside N6-benzyl-modified AdoMet analogue.80 The 
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subsequent DNA cytosine-5 MT, M.HhaI, double mutant Y254S/N304A, designed by 
Klimašauskas and coworkers to pair with S-butynyl AdoMet, led to a 24-fold increase in 
turnover with the non-native substrate based on comparative end point assays.246 In the 
most recent published example, Luo and colleagues noted a 30–50-fold selectivity 
preference using an S-(E)-hex-2-en-5-ynyl L-Met analogue in an engineered MAT 
(hMAT2A I117A) – chromatin-modifying protein MT (G9a Y1154A) coupled reaction 
based on 30-50-fold enrichment of chromatin DNA (compared to control group transfected 
with hMAT2A I117A mutant alone).14,17 
 
5.4 Methods 
 
5.4.1 General materials 
 Unless otherwise stated, all general chemicals and reagents (including methionine 
analogues 2, 3, and 13 – 15) were purchased from Sigma-Aldrich (St. Louis, MO) and were 
reagent grade or better. Metamine, or (2S)-4-(methylsulfanyl)butane-1,2-diamine, was 
purchased from Enamine Ltd. (Kyiv, Ukraine). Metamide, or (S)-2-amino-4-
(methylthio)butanamide, was synthesized as previously described.40 S-adenosyl-L-
methionine (AdoMet) was purchased as a 32 mM solution in 10% EtOH/5 mM H2SO4 
from New England Biolabs (Ipswich, MA). E. coli BL21(DE3) competent cells were 
purchased from New England Biolabs (Ipswich, MA). The pET28a E. coli expression 
vector was purchased from Novagen (Madison, WI). Primers were purchased from 
Integrated DNA Technologies (Coralville, IA). QuikChange II site-directed mutagenesis 
kits were purchased from Agilent Technologies (Santa Clara, CA). PD-10 columns and Ni-
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NTA superflow columns were purchased from GE Healthcare (Piscataway, NJ). Crystal 
screen kits were purchased from Hampton Research (Aliso Viejo, CA), Molecular 
Dimensions (Altamonte Springs, FL), Rigaku (Seattle, WA) and Microlytic (Burlington, 
MA). 
 
5.4.2 General methods 
 X-ray data were collected at beamline 21-ID-F (LS-CAT) in the Advanced Photon 
Source at Argonne National Laboratory (Chicago, IL). NMR spectra were obtained on a 
Varian Unity Inova 400 MHz instrument (Palo Alto, CA) at the University of Kentucky 
College of Pharmacy NMR facility using CDCl3 (D, 99.96%) with or without 0.05% v/v 
TMS from Cambridge Isotopes (Cambridge Isotope Laboratories, MA). 1H and 13C 
chemical shifts were referenced to internal solvent resonances. Multiplicities are indicated 
by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), quin (quintet), m 
(multiplet), and br (broad). Chemical shifts are reported in parts per million (ppm) and 
coupling constants J are given in Hz. Routine 13C NMR spectra were fully decoupled by 
broad-broad WALTZ decoupling. All NMR spectra were recorded at ambient temperature.  
 Normal-phase flash chromatography was performed on 40–63 µm, 60 Å silica gel 
(Silicycle, Quebec). Analytical TLC was performed on silica gel glass TLC plates (EMD 
Chemicals Inc, Gibbstown, NJ). Visualization was accomplished with UV light (254 nm) 
followed by staining with dilute H2SO4 (5% in EtOH) solution, KMnO4 solution (1.5 g of 
KMnO4, 10g K2CO3, and 1.25 mL 10% NaOH in 200 mL water) and heating, or 10% 
ninhydrin in EtOH and heating. HPLC was accomplished using an Agilent 1260 system 
equipped with a DAD detector. HPLC Method: To monitor enzyme reactions, analytical 
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reverse-phase (RP) HPLC was conducted with a Luna C18 (5 μm, 4.6 mm × 250 mm; 
Phenomenex, Torrance, California, USA) column  [gradient of 1% B to 20% B over 5 min, 
20% B to 55% B over 15 min, 55% B to 100% B over 1 min, 100% B for 5 min, 100% B 
to 1% B over 1 min, 1% B for 8 min (A = ddH2O with 0.1% formic acid; B = acetonitrile) 
flow rate = 0.4 mL min-1; A254, A260]. 
 
5.4.3 General procedure for the synthesis of metOMe, metOEt, metOPr, and metOBu 
 
 
 
Rxn 1: NaH (26 mg, 0.65 mmol) was added to a solution of compound A (0.7 equivalents) 
in 4.3 mL dry THF at 0 oC. The mixture was stirred for 10 min, alkyl halide (1.3 
equivalents) was added, and the reaction continued for an additional 1.5 hr with stirring 
(monitored by TLC and LC-MS). The organics were removed under vacuum and the 
residue was purified by normal-phase column chromatography (n-hexane:EtOAc, 20:1 ~ 
8:1) to give the desired product B. 
 
Rxn 2: Compound B (0.2 mmol) was dissolved in 1.5 mL MeOH. 0.5 mL concentrated 
HCl was added and the mixture was refluxed at 60 oC for 1.5 hr (monitored by TLC, stained 
by iodine). Upon completion, solvent was removed under vacuum to give the HCl salt of 
product 7, 8, 9, or 10. 
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5.4.4 Specific procedures for the syntheses of metOMe, metOEt, metOPr, and metOBu 
 
 
 
(S)-1-Methoxy-4-(methylthio)butan-2-amine (metOMe, 7). Methyl iodide (122 mg, 
0.86 mmol) was used to obtain the product as a white solid (66 mg, 2 steps, 81% yield). 1H 
NMR (400 MHz, CDCl3) δ: 8.49 (s, 2H), 3.53-3.69 (m, 3H), 3.42 (s, 3H), 2.62-2.75 (m, 
2H) 2.14-2.26 (m, 1H), 2.12 (s, 3H), 1.92-2.05 (m, 1H). 13C NMR (100 MHz, CDCl3) δ: 
71.2, 59.2, 50.6, 29.8, 28.5, 15.2. HRMS [M+H] + calculated for C6H16NOS 150.0947, 
found 150.0946. 
 
 
 
(S)-1-Ethoxy-4-(methylthio)butan-2-amine (metOEt, 8). Ethyl iodide (135 mg, 0.86 
mmol) was used to obtain the product as a white solid (38 mg, 2 steps, 55% yield). 1H 
NMR (400 MHz, CDCl3) δ: 8.47 (s, 2H), 3.49-3.73 (m, 5H), 2.60-2.75 (m, 2H) 2.14-2.25 
(m, 1H), 2.12 (s, 3H), 1.94-2.05 (m, 1H), 1.24 (t, J = 7.0 Hz 3H). 13C NMR (100 MHz, 
CDCl3) δ: 69.0, 67.0, 50.8, 29.8, 28.5, 15.1, 15.0. HRMS [M+H]
 + calculated for C7H18NOS 
164.1104, found 164.1101. 
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(S)-4-(Methylthio)-1-propoxybutan-2-amine (metOPr, 9). 1-Bromopropane (105 mg, 
0.86 mmol) was used to obtain the product as a light yellow solid (115 mg, 2 steps, 49% 
yield). 1H NMR (400 MHz, CDCl3) δ: 8.48 (s, 2H), 3.52-3.71 (m, 3H), 3.40-3.51 (m, 2H), 
2.61-2.76 (m, 2H) 2.14-2.25 (m, 1H), 2.12 (s, 3H), 1.94-2.05 (m, 1H), 1.57-1.68 (m, 2H), 
0.92 (t, J = 7.5 Hz 3H). 13C NMR (100 MHz, CDCl3) δ: 73.3, 69.2, 50.7, 29.8, 28.5, 22.6, 
15.1, 10.5. HRMS [M+H] + calculated for C8H20NOS 178.1260, found 178.1255. 
 
 
 
(S)-1-Butoxy-4-(methylthio)butan-2-amine (metOBu, 10). n-Butyl bromide (118 mg, 
0.86 mmol) was used to obtain the product as a light yellow solid (251 mg, 2 steps, 55% 
yield). 1H NMR (400 MHz, CDCl3) δ: 8.45 (s, 2H), 3.55-3.71 (m, 3H), 3.46-3.53 (m, 2H), 
2.62-2.77 (m, 2H) 2.15-2.25 (m, 1H), 2.13 (s, 3H), 1.94-2.07 (m, 1H), 1.54-1.64 (m, 2H), 
1.31-1.42 (m, 2H), 0.92 (t, J = 7.5 Hz 3H). 13C NMR (100 MHz, CDCl3) δ: 71.5, 69.2, 
50.8, 31.4, 29.8, 28.5, 19.2, 15.1, 13.9. HRMS [M+H] + calculated for C9H22NOS 
192.1417, found 192.1416. 
 
5.4.5 General procedure for the synthesis of metolMe, metolEt, and metolPr 
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Rxn 1: N,O-dimethylhydroxylamine hydrochloride (1.25 g, 12.5 mmol), HOBt (1.7 g, 12.5 
mmol) and EDCl (2.4 g, 12.5 mmol) were added to a solution of compound C (3.7 g, 10 
mmol) in 25 mL dry DMF. The mixture was stirred for 1 hr, then Et3N (1.7 mL, 12.5 mmol) 
was added and the reaction stirred for an additional 5 hr (monitored by TLC and LC-MS). 
Upon completion, the reaction was diluted with 100 mL H2O and extracted with EtOAc 
(50 mL x 2), washed with water (100 mL x 2), brine (50 mL x 1) and then dried over 
Na2SO4. The mixture was filtered, organic solvent was removed under vacuum, and the 
crude mixture purified by normal-phase column chromatography (n-hexane:EtOAc, 4:1 ~ 
1:1) to give the desired product D as a white solid, 75% yield. 
 
Rxn 2: Alkyl magnesium halide (3 M in THF, 3.0 mmol, 1 mL total volume) was added 
dropwise to a solution of D (1.0 g, 2.4 mmol) in 20 mL dry THF at 0 oC and the mixture 
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was stirred at room temperature for 6 hr (monitored by TLC and LC-MS). Saturated NH4Cl 
solution (50 mL) was added to quench the reaction and the reaction was extracted by 
EtOAc (50 mL x 2), washed with water (50 mL x 2), brine (50 mL x 1) and dried over 
Na2SO4. The organic solvent was removed under vacuum and the residue was purified by 
normal-phase column chromatography (n-hexane:EtOAc, 8:1 ~ 2:1) to give the desired 
product E (R = Me, 69% yield; R = Et, 60% yield; R = n-Pr, 51% yield).  
 
Rxn 3: NaBH4 (74 mg, 2.0 mmol) was added to a solution of E (1.0 mmol) in 5 mL of 
MeOH at 0 oC and the mixture was stirred at room temperature for 8 hr (monitored by TLC 
and LC-MS). The reaction was quenched with the addition of 30 mL H2O and the mixture 
was extracted by EtOAc (30 mL x 2), washed with water (30 mL x 2), brine (30 mL x 1) 
and then dried over Na2SO4. The organics were removed under vacuum and the residue 
was purified by normal-phase column chromatography (n-hexane:EtOAc, 8:1 ~ 2:1) to 
give the desired product F (R = Me, 75% yield; R = Et, 66% yield; R = n-Pr, 71% yield). 
 
Rxn 4: Piperidine (1 mL, 12.5 mmol) was added to a solution of F (0.26 mmol) in 4 mL 
THF and the mixture was stirred for 30 min (monitored by TLC). Upon completion, solvent 
was removed under vacuum and the residue was purified by normal-phase column 
chromatography (CH2Cl2:MeOH, 10:1 ~ 4:1) to give the desired product 4, 5, or 6. 
 
5.4.6 Specific procedures for the syntheses of metolMe, metolEt, and metolPr 
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(9H-Fluoren-9-yl)methyl [(3S)-4-hydroxy-1-(methylthio)pentan-3-yl]carbamate (N-
Fmoc-4, N-Fmoc-R,S-4, and N-Fmoc-S,S-4). Methyl magnesium bromide (3 M in THF), 
(1 mL, 3 mmol) was used to obtain the diastereomeric mixture (N-Fmoc-4) as a white solid 
(280 mg, 3 steps, 32% yield), which was resolved by normal-phase column 
chromatography to obtain N-Fmoc-R,S-4 (31 mg, 3 steps, 3.5 % yield) and N-Fmoc-S,S-4 
(95 mg, 3 steps, 10.8% yield).  Enantioselectivity was determined by the NMR analysis of 
(R) and (S) Mosher esters, N-Fmoc-S,S-4-(R)-MTPA and N-Fmoc-S,S-4-(S)-MTPA, 
obtained from N-Fmoc-S,S-4 (see below) following standard protocols.249 
 
 
 
(9H-Fluoren-9-yl)methyl [(3S,4R)-4-hydroxy-1-(methylthio)pentan-3-yl]carbamate 
(N-Fmoc-R,S-4). 1H NMR (400 MHz, CDCl3) δ: 7.75 (d, J = 7.4 Hz 2H), 7.58 (d, J = 7.4 
Hz 2H), 7.38 (t, J = 7.4 Hz 2H), 7.30 (t, J = 7.4 Hz 2H), 4.98 (d, J = 9.4 Hz 1H), 4.44 (d, 
J = 6.7 Hz 2H), 4.20 (t, J = 6.7 Hz 1H), 3.80-3.88 (m, 1H), 3.55-3.65 (m, 1H), 2.49 (s, 2H), 
2.08 (s, 3H), 1.75-1.85 (m, 2H), 1.16 (d, J = 6.3 Hz 3H). HRMS [M+H] + calculated for 
C21H26NO3S 372.1628, found 372.1625. 
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(9H-Fluoren-9-yl)methyl [(3S,4S)-4-hydroxy-1-(methylthio)pentan-3-yl]carbamate 
(N-Fmoc-S,S-4). 1H NMR (400 MHz, CDCl3) δ: 7.75 (d, J = 7.4 Hz 2H), 7.58 (d, J = 7.4 
Hz 2H), 7.38 (t, J = 7.4 Hz 2H), 7.30 (t, J = 7.4 Hz 2H), 4.98 (d, J = 9.4 Hz 1H), 4.44 (d, 
J = 6.7 Hz 2H), 4.20 (t, J = 6.7 Hz 1H), 3.80-3.88 (m, 1H), 3.55-3.65 (m, 1H), 2.49 (s, 2H), 
2.08 (s, 3H), 1.75-1.85 (m, 2H), 1.16 (d, J = 6.3 Hz 3H). HRMS [M+H] + calculated for 
C21H26NO3S 372.1628, found 372.1629. 
 
 
 
N-Fmoc-S,S-4-(R)-MTPA. The procedures applied to the synthesis of N-Fmoc-S,S-4-(R)-
MTPA used N-Fmoc-S,S-4 (10 mg, 0.027 mmol), pyridine (10 µL, 0.1 mmol) and (S)-
Mosher chloride (20 µL, 0.1 mmol) to obtain the product as a white solid (12 mg, 89% 
yield). 1H NMR (400 MHz, CDCl3) δ: 7.77 (d, J = 7.4 Hz 2H), 7.57 (d, J = 7.4 Hz 2H), 
7.28 -7.50 (m, 9H), 5.09-5.17 (m, 1H), 4.58 (d, J = 9.4 Hz 1H), 4.48 (d, J = 6.3 Hz 2H), 
4.20 (t, J = 6.3 Hz 1H), 3.90 (t, J = 10.1 Hz 1H), 3.45 (s, 3H), 2.31-2.52 (m, 2H), 2.04 (s, 
3H), 1.78-1.90 (m, 1H), 1.45-1.55 (m, 1H), 1.28 (d, J = 6.7 Hz 3H). HRMS [M+H] + 
calculated for C31H33F3NO5S 588.2026, found 588.2023. 
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N-Fmoc-S,S-4-(S)-MTPA. The procedures applied to the synthesis of N-Fmoc-S,S-4-(S)-
MTPA used N-Fmoc-S,S-4 (10 mg, 0.027 mmol), pyridine (10 µL, 0.1 mmol) and (R)-
Mosher chloride (20 µL, 0.1 mmol) to obtain the product as a white solid (15 mg, 97% 
yield). 1H NMR (400 MHz, CDCl3) δ: 7.77 (d, J = 7.5 Hz 2H), 7.57 (d, J = 7.5 Hz 2H), 
7.28 -7.50 (m, 9H), 5.12-5.20 (m, 1H), 4.41-4.53 (m, 3H), 4.20 (t, J = 6.2 Hz 1H), 3.84 (t, 
J = 10.2 Hz 1H), 3.54 (s, 3H), 2.25-2.48 (m, 2H), 1.99 (s, 3H), 1.73-1.84 (m, 1H), 1.35-
1.45 (m, 1H), 1.34 (d, J = 6.3 Hz 3H). HRMS [M+H] + calculated for C31H33F3NO5S 
588.2026, found 588.2020. 
 
 
 
(2R,3S)-3-Amino-5-(methylthio)pentan-2-ol (R,S-metolMe, R,S-4). The procedures 
applied to the synthesis of (2R,3S)-3-amino-5-(methylthio)pentan-2-ol used N-Fmoc-R,S-
4 (10 mg, 0.027 mmol) to obtain the product as a colorless oil (6 mg, 63% yield). 1H NMR 
(400 MHz, CDCl3) δ: 3.84-3.96 (m, 1H), 3.20-3.29 (m, 1H), 2.69-2.81 (m, 2H), 2.13 (s, 
3H), 1.85-2.05 (m, 2H), 1.33 (d, J = 5.8 Hz 3H). 13C NMR (100 MHz, CDCl3) δ: 71.3, 
59.2, 50.7, 29.9, 28.5, 15.3. HRMS [M+H] + calculated for C6H16NOS 150.0947, found 
150.0943. 
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(2S,3S)-3-Amino-5-(methylthio)pentan-2-ol (S,S-metolMe, S,S-4). The procedures 
applied to the synthesis of (2S,3S)-3-amino-5-(methylthio)pentan-2-ol used N-Fmoc-S,S-
4 (25 mg, 0.067 mmol) to obtain the product as a colorless oil (10 mg, 78% yield). 1H NMR 
(400 MHz, CDCl3) δ: 4.15-4.25 (m, 1H), 3.43-3.52 (m, 1H), 2.61-2.81 (m, 2H), 2.13 (s, 
3H), 1.96-2.08 (m, 1H), 1.82-1.95 (m, 1H), 1.27 (d, J = 6.7 Hz 3H). 13C NMR (100 MHz, 
CDCl3) δ: 71.2, 59.3, 50.5, 29.8, 28.5, 15.2. HRMS [M+H] 
+ calculated for C6H16NOS 
150.0947, found 150.0945. 
 
 
 
(4S)-4-Amino-6-(methylthio)hexan-3-ol (metolEt, 5). Ethyl magnesium bromide (1 M 
in THF) (1 mL, 1 mmol) was used to obtain the diastereomeric mixture of the product as a 
colorless oil (27 mg, 4 steps, 18% yield). 1H NMR (400 MHz, CDCl3) δ: 3.37-3.44 (m, 
1H), 2.87-2.95 (m, 1H), 2.49-2.71 (m, 2H), 2.10 (s, 3H), 1.71-1.81 (m, 1H), 1.49-1.61 (m, 
1H), 1.35-1.48 (m, 2H), 0.98 (t, J = 7.5 Hz 3H). 13C NMR (100 MHz, CDCl3) δ: 69.2, 67.2, 
51.0, 30.0, 28.7, 15.4, 15.2. HRMS [M+H] + calculated for C7H18NOS 164.1104, found 
164.1105. 
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(3S)-3-Amino-1-(methylthio)heptan-4-ol (metolPr, 6). n-Propyl magnesium bromide (1 
M in THF) (1 mL, 1 mmol) was used to obtain the diastereomeric mixture of the product 
as a colorless oil (29 mg, 4 steps, 15% yield). 1H NMR (400 MHz, CDCl3) δ: 3.93-4.00 
(m, 1H), 3.33-3.42 (m, 1H), 2.63-2.85 (m, 2H), 2.13 (s, 3H), 1.83-2.05 (m, 2H), 1.45-1.64 
(m, 2H), 1.29-1.43 (m, 2H), 0.95 (t, J = 7.0 Hz 3H). 13C NMR (100 MHz, CDCl3) δ: 73.1, 
69.0, 50.5, 29.6, 28.3, 22.4, 14.9, 10.3. HRMS [M+H] + calculated for C8H20NOS 
178.1260, found 178.1258. 
 
5.4.7 Preparation of mutant library 
The pET28a-hMAT2A plasmid used for heterologous hMAT2A production and as 
the template DNA for all site-directed mutagenesis PCR reactions was previously 
reported.11,24,40 Mutants were generated using the QuikChange II kit (Agilent 
Technologies, Santa Clara, CA) according to the manufacturer’s instructions. Mutagenic 
primers were designed using the online QuikChange Primer Design software 
(www.genomics.agilent.com) and are listed in Table S1. Following mutagenesis reactions, 
an aliquot (1 µL) of each reaction was transformed into chemically competent E. coli XL-
1 Blue cells (provided in QuikChange II kit) following the manufacturer’s directions. The 
transformation mixture was plated on LB-agar plates containing 50 µg mL-1 kanamycin 
and incubated at 37 °C for 18 h. 
 
5.4.8 DNA analysis and sequencing 
Single colonies from mutagenic transformations (above) were individually cultured 
via standard protocols and corresponding mutant plasmid DNA was isolated from each 
151 
 
cultured strain using the QIAprep Spin Miniprep kit (QIAGEN GmbH, Hilden, Germany).  
Glycerol stocks of each colony were made by mixing equal volume culture with 50% (v/v) 
glycerol and stored at –80 °C. Mutants were sequence confirmed via forward and reverse 
sequencing. All DNA sequencing was performed by ACGT, Inc (Wheeling, IL) with T7 
promoter (5′-TAATACGACTCACTATAGGG) and T7 terminator (5′-
GCTAGTTATTGCTCAGCGG) primers. 
 
5.4.9 Library transformation 
Leftover plasmid DNA encoding each desired mutation was transformed into 
chemically competent E. coli BL21(DE3) cells (New England Biolabs, Ipswich, MA) 
following manufacturer’s protocol and plated on LB-agar plates supplemented with 50 µg 
mL–1 kanamycin. Individual colonies selected from corresponding plates grown overnight 
were used to inoculate wells of a 96-deep-well microtiter plate (Corning® Costar® Assay 
Block, 2 mL, 96 Well, Square V-Bottom; Corning, NY) in which each well contained 1 
mL of LB medium supplemented with 50 µg mL–1 kanamycin. Culture plates were tightly 
sealed with AeraSeal breathable film (Excel Scientific, Inc, Victorville, CA). After cell 
growth at 37 °C for 18 h with shaking at 325 rpm, a glycerol copy was made via addition 
of 1 mL of 50% (v/v) glycerol. The master glycerol stock plate was tightly sealed with 
TempPlate sealing foil (USA Scientific, Inc, Ocala, FL), and stored at –80 °C. Each 96-
well culture plate contained 2 copies of each mutant-expressing construct, 8 copies each of 
wild-type hMAT2A and empty pET28a constructs, and 2 sterile wells. 
 
5.4.10 Protein production 
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A 96-deep-well microtiter plate containing 1 mL of LB medium supplemented with 
50 µg mL–1 kanamycin was inoculated from the master glycerol stock plate. Culture plates 
were tightly sealed with AeraSeal breathable film. After cell growth at 37 °C for 18 h with 
shaking at 325 rpm, 100 µL of each culture was transferred to a fresh deep-well plate 
containing 1 mL of LB medium supplemented with 50 µg mL–1 kanamycin. The freshly 
inoculated plate was incubated at 37 °C for 1 h 45 min with shaking at 325 rpm. N-terminal 
His6-tagged hMAT2A gene transcription was induced at an optical cell density (OD600) of 
~0.7 via the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, final concentration 
0.5 mM) and the plate was incubated for 18 h at 18 °C with shaking at 325 rpm. Cells were 
harvested by centrifugation at 3,000 × g for 20 min at 4 °C. Each cell pellet was thoroughly 
resuspended in 50 µL of 25 mM Tris·HCl (pH 8.0) containing 10 mM MgCl2, 50 mM KCl, 
and 10 mg mL–1 lysozyme (Millipore Sigma) at 4 °C, transferred to a 96-well full-skirt 
PCR plate (TempPlate, USA Scientific, Inc), sealed with TempPlate sealing foil, and 
subjected to a single freeze-thaw cycle to lyse the cells. Cell debris was then collected by 
centrifugation at 3,000 × g for 20 min at 4 °C, and the cleared supernatant was used for 
enzyme assays. 
 
5.4.11 Library screening 
In a white 384-well plate (OptiPlate, PerkinElmer, Inc, Waltham, MA), 5 µL of 
cleared supernatant was mixed with an equal volume (5 µL) of 25 mM Tris·HCl (pH 8.0) 
containing 10 mM MgCl2, 50 mM KCl, 20 mM L-Met (or methionine surrogate) and 3.0 
mM ATP using a VIAFLO 96 handheld 96-channel pipette (INTEGRA Biosciences Corp., 
Hudson, NH). Upon mixing, the plates were tightly sealed with sealing foil and the 
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reactions were incubated at 37 °C for 1 h and cooled to room temperature over 20 min. 
After the reactions were equilibrated to room temperature, each reaction was mixed with 
an equal volume (10 µL) of Kinase-Glo Max reagent (Promega Corporation, Madison, WI) 
previously also equilibrated to room temperature. The assay plate was incubated for 10 min 
at room temperature and luminescence subsequently measured using a FLUOstar Omega 
plate reader (BMG LABTECH GmbH, Offenburg, Germany). 
 
5.4.12 In vitro time-course assays (hit confirmation) 
In vitro hMAT2A mutant reactions were conducted in a volume of 100 μL with 
saturating ATP (2 mM) and methionine or methionine analogue (10 mM), 10 µM purified 
mutant or wt-hMAT2A in 25 mM Tris, pH 8.0, 10 mM MgCl2, 50 mM KCl. Reactions 
were incubated at 37 °C and 20 µL aliquots were taken at various time intervals (10, 20, 
40, 80, 120, 180, and 240 min) and quenched with equal volume MeOH followed by 
centrifugation (10,000 × g, 20 min) to remove the precipitated protein. Product formation 
for each reaction was subsequently analyzed by RP-HPLC (Figure 5.7). For each reaction, 
product (AdoMet, AdoMetol, or AdoMetolMe) concentration was based on the integration 
of species at 260 nm and calculated by multiplying the initial concentration of ATP by the 
quotient of the integrated product (AdoMet plus MTA, AdoMetol, or AdoMetolMe) HPLC 
peak area (mAU*sec) over the sum of the integrated peak areas for product and remaining 
ATP as previously reported.11,24,40 MTA derives from AdoMet and was thereby also 
considered as contributing to the total product concentration. Assays were repeated in 
triplicate where Figure 5.5 represents an average of replicates. Controls lacking enzyme, 
methionine, metol, metolMe, and/or ATP led to no product. 
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5.4.13 In vitro kinetic assays 
To determine the Km and kcat of select hMAT2A mutants with L-Met and/or 
analogues thereof, in vitro hMAT2A mutant reactions were conducted in a volume of 50 
μL with saturating ATP (2 mM), varied concentrations of L-Met or analogues thereof (0.3 
- 12 mM), 10 μM purified mutant or wt-hMAT2A in 25 mM Tris, pH 8.0, 10 mM MgCl2, 
50 mM KCl. Reactions were incubated at 37 °C and subsequently quenched, while the 
reactions still exhibited linear kinetics per the reaction progress curves (Figure 5.5), by 
adding an equal volume of MeOH followed by centrifugation (10,000 × g, 20 min) to 
remove the precipitated protein. Product formation for each reaction was subsequently 
analyzed by RP-HPLC as described in the preceding section (Figure 5.7). Assays were 
repeated in triplicate where the Michaelis-Menten plots in Figure 5.6 represent an average 
of replicates. Controls lacking enzyme, methionine, metol, metolMe, and/or ATP led to no 
product. 
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Table 5.1. Kinetic parameters of wild-type hMAT2A and mutants with methionine 
analogs. 
  
hMAT2A 
variant 
Substratea kcat 
min-1 
Km 
µmol L-1 
kcat/Km 
L µmol-1 min-1 
kcat/Km 
Relative 
Selectivity 
Index 
Wild-type 
L-Met 
26  1.0 140  50 1.9 × 10-1 1.0 
40 
L-Metol 
11  1.6 2,400  1,000 4.8 × 10-3 2.6 × 10-2 
E70S 
L-Met 11  0.5 390  120 2.7 × 10-2 1.0 
—c 
L-Metol —b —b —b —b 
Q113D 
L-Met 1.2  0.1 47  47 2.4 × 10-2 1.0 
3 
L-Metol 3.3  0.1 390  70 8.6 × 10-3 3.5 × 10-1 
K289S 
L-Met —b —b —b —b 
—c 
L-Metol 4.9  0.1 1,300  120 3.7 × 10-3 —c 
K289L 
L-Met 0.8  0.1 780  170 1.1 × 10-3 1.0 
-4 
L-Metol 4.1  0.1 1,000  130 4.1 × 10-3 3.8  
aEnzyme substrates were assayed in the presence of saturating ATP (2 mM).  standard error 
(SEM) at 95% confidence interval (CI). bNot determined. cNot applicable. 
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Figure 5.1. Complementary approaches to AdoMet-producing/utilizing enzyme 
bioorthogonal platform development. (A) Native function of representative AdoMet-
producing/utilizing enzymes. In this context, AdoMet serves as the central substrate for all 
AdoMet-utilizing enzymes (including, but not limited to, methyltransferases). (B) S-alkyl-
based bioorthogonal approach where steric bulk of the substrate S-alkyl substituent 
(represented by a triangle), paired with the appropriate AdoMet-producing/utilizing 
enzyme mutants, serves as the bioorthogonal differentiator. (C) Nucleoside-based 
bioorthogonal approach where a sterically-modified nucleoside (structural modification 
represented by a triangle), paired with the appropriate AdoMet-producing/utilizing enzyme 
mutants, serves as the bioorthogonal differentiator. (D) Carboxylate/amino-termini-based 
bioorthogonal approach where alternative substrate-termini binding modalities (structural 
modification represented by a triangle), paired with the appropriate AdoMet-
producing/utilizing enzyme mutants, serves as the bioorthogonal differentiator. MAT, 
methionine adenosyltransferase; MT, methyltransferase; AdoHcy, S-adenosyl-L-
homocysteine; AdoMet, S-adenosylmethionine (SAM). 
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Figure 5.2. Active-site of hMAT2A with key residues targeted for mutagenesis highlighted 
and L-Met substrate surrogates used in the study. (A) Active-site of ligand-bound hMAT2A 
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(PDB: 2P02) with key conserved active-site residues targeted for mutagenesis highlighted. 
Distances between targeted active-site amino acid side chains and the AdoMet (white) 
carboxylate oxygen or ammonium nitrogen are highlighted in yellow.  (B) L-Met substrate 
surrogates used in the current study. Met, L-methionine; metOOMe, L-methionine methyl 
ester; metol, (S)-(–)-methioninol; metolMe, (3S)-3-amino-5-(methylthio)pentan-2-ol; 
metOMe, (S)-1-methoxy-4-(methylthio)butan-2-amine; metOEt, (S)-1-ethoxy-4-
(methylthio)butan-2-amine; metOPr, (S)-4-(methylthio)-1-propoxybutan-2-amine; 
metOBu, (S)-1-butoxy-4-(methylthio)butan-2-amine; metamine, (S)-4-
(methylthio)butane-1,2-diamine; metamide, (S)-2-amino-4-(methylthio)butanamide; αK-
Met, α-keto-γ-(methylthio)butyric acid. β-NAm-Met, H-Met-β-napthylamide; p-NAn-
Met, L-methionine p-nitroanilide. 
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Figure 5.3. Plate-based hMAT2A assay development and validation. (A) hMAT2A 
reaction scheme and bioactivity detection strategy. (B) Wild-type hMAT2A E. coli extract 
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(5 µL) with L-Met (10 mM) and ATP (1.5 mM); positive control. (C) Wild-type hMAT2A 
E. coli extract (5 µL) with ATP (1.5 mM) but lacking L-Met; negative control, Z′ value of 
0.63. (D) Glucosyltransferase OleD E. coli extract (non-reactive protein, 0.005 mL) with 
L-Met (10 mM) and ATP (1.5 mM); negative control, Z′ value of 0.67. (E) Empty pET-28a 
E. coli extract (0.005 mL) with L-Met (10 mM) and ATP (1.5 mM); negative control, Z′ 
value of 0.44. For panels B-E, each point represents determined raw luminescence units 
(RLU) from a single reaction/well. Comparison of RLU of positive and negative controls 
were used to calculate Z′ values. Solid lines indicate population mean; dotted lines indicate 
population mean  3 standard deviations. 
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Figure 5.4. Combinatorial plate-based screen of targeted hMAT2A mutants with L-Met 
analogues highlighted in Figure 2. The heat map compares the relative activity of hMAT2A 
mutant (y-axis) and L-Met analogue (x-axis) pairings. The color of each square is 
dependent on the percent change in mean relative luminescence units (RLU) under 
experimental conditions from the mean RLU of the negative control (no added methionine 
or analogue thereof in the reaction mixture) for that mutant. Red corresponds to lower 
observed luminescence (i.e., lower [ATP]) as an indirect measure of turnover; blue 
indicates higher observed luminescence (i.e., higher [ATP]) as an indirect measure of lack 
of turnover; X, not tested. Standard assay conditions: 10 mM L-Met analogue, 1.5 mM 
ATP, 37 °C, 60 min. 
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Figure 5.5. Turnover of ATP and L-Met, metol, or metolMe by wt-hMAT2A and mutants 
over time. All enzymes were at a concentration of 10 µM in 25 mM Tris·HCl, pH 8.0, 50 
mM KCl, and 10 mM MgCl2. [L-Met]i = 10 mM, [metol]i = 10 mM, [metolMe]i = 10 mM, 
[ATP]i = 2 mM. The mean of 3 independent experiments are represented by each bar 
(except for those with metolMe) and each error bar represents  standard error (SEM) at 
95% confidence interval (CI).  
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Figure 5.6. Determination of kinetic parameters for mutant and wt-hMAT2A-catalyzed 
reactions. [hMAT2A or hMAT2A mutant] = 10 µM and [ATP]i = 2000 µM in all 
experiments. (A) wt-hMAT2A, [L-Met]i = varied. (B) wt-hMAT2A, [Metol]i = varied. (C) 
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hMAT2A mutant E70S, [Met]i = varied. (D) hMAT2A mutant K289S, [Metol]i = varied. 
(E) hMAT2A mutant Q113D, [Met]i = varied. (F) hMAT2A mutant Q113D, [Metol]i = 
varied. (G) hMAT2A mutant K289L, [Met]i = varied. (H) hMAT2A mutant K289L, 
[Metol]i = varied.  
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Figure 5.7. Representative analytical HPLC at A260. (A) hMAT2A mutant K289L (10 µM) 
with 10 mM metol and 2 mM ATP after 24 hr, highlighting the lack of MTA (13.5 min) 
production. (B) hMAT2A mutant K289L (10 µM) with 10 mM l-Met and 2 mM ATP after 
24 hr, highlighting notable production of MTA (13.5 min). (C) hMAT2A mutant K289F 
(10 µM) with 10 mM R,S-metolMe and 2 mM ATP after 24 hr, highlighting the lack of 
MTA (13.5 min) production. AdoMet analogues (5.8 min), adenine (7.2 min), ATP (11.6 
min), MTA (13.5 min).  
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Chapter Six: Conclusions and Prospectus 
 
6.1 Conclusions 
 
This work’s ultimate goal is (1) to provide a technology affording researchers the 
ability to bioorthogonally identify which methylation events each specific MT is 
responsible for in vivo and (2) to aid researchers in their efforts to diversify NP scaffolds 
by enabling further exploitation of novel, MT-catalyzed transformations, creating safer 
and/or more effective pharmaceuticals, herbicides/pesticides, dyes, food additives, and 
biofuels. At the start of this dissertation work, several Specific Aims were set forth to 
augment the scope of chemical biology and semisynthetic NP diversification by enabling 
the facile incorporation of MATs/MTs and Met/AdoMet analogs. The Specific Aims set 
forth were: (1) Develop robust, combinatorial methods for the synthesis of methionine 
analogs; (2) Develop a general platform for MAT engineering and evolution; (3) Develop 
a coupled MAT-MT platform for MT target elucidation and NP alkylrandomization. While 
much of this dissertation’s aspirations were realized, several feats remain to be 
accomplished. 
 
6.1.1 Robust, combinatorial methods for the synthesis of methionine analogs enables facile 
access to AdoMet analogs 
The use of S/Se-alkylated L-S/Se-Met analogs and MATs to chemoenzymatically 
synthesize the corresponding S/Se-alkylated AdoMet analogs is the preferred method of 
S/Se-alkylated AdoMet analog synthesis because of all the aforementioned liabilities of 
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chemically synthesized AdoMet analogs. Additionally, AdoMet and its analogs exhibit 
poor cell membrane permeability,80 while Met and some Met analogs can traverse cell 
membranes readily.14 Therefore, robust, combinatorial methods for the synthesis of Met 
analogs necessitated development. The synthesis of Met analogs should evade the need for 
chromatographic purification and result in high yields of the desired products. While some 
of the synthetic routes to Met analogs employed in Chapters Two and Three of this work 
required chromatographic separation, a protecting group (e.g. N-Boc) would bring the 
intermediates into the organic phase for simple organic extraction of N-Boc-protected S-
alkylated products. Next, the Boc protecting group could be removed to afford the final S-
alkylated Met analog product without the need for chromatographic separations. 
Furthermore, synthetic modifications to L-S/Se-Met other than S/Se-alkylation were 
explored for bioorthogonal applications and circumvention of AdoMet and AdoMet analog 
degradation pathways. For example, in Chapter Four, a Met analog in which the carboxyl 
moiety was replaced with a tetrazole moiety was able to be turned over by wt-hMAT2A. 
The corresponding AdoMet analog, AdotMet, was markedly more stable than AdoMet. 
Also, in Chapter Four, an AdoMet analog bearing a 7-deaza-adenine ring was 
chemoenzymatically synthesized and, when combined with tMet, resulted in a 7dzAdotMet 
analog where no degradation was measurable over the observed time of 50 hours. In 
Chapter Five, several Met analogs with modifications to the carboxylate moiety were 
converted by MAT mutants to the corresponding AdoMet analogs—none of which were 
found to degrade into MTA in the observed time period. 
Finally, greater than 80% of the 44 S/Se-alkylated L-S/Se-Met analogs turned over 
after being screened against six different wild-type MATs in Chapters Two and Three. 
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Following these discoveries, we determined that little to no engineering would be necessary 
for MAT enzymes to accept bulkier alkyl groups. However, Minkui Luo and coworkers 
have seen marginal improvements in catalytic efficiency by mutating the isoleucine residue 
in the MAT active site, which is adjacent to the methyl group of AdoMet in wild-type 
crystal structures, to alanine. 
 
6.1.2 A general platform for MAT engineering and evolution leads to the discovery of 
several MAT-mutant/Met-analog pairs 
The second aim of this work was the development of a high-throughput assay for 
MAT engineering and/or evolution to enable the discovery of a MAT-mutant/Met-analog 
pair capable of producing an AdoMet analog incapable of being turned over by wild-type 
MTs. While several biochemical assays exist to quantify AdoMet, none are compatible 
with AdoMet analogs that are substantially modified. However, there are commercially-
available biochemical assays available to quantify ATP in solution—the most amenable to 
high-throughput screening being a luciferase assay that, in the presence of ATP, produces 
photons measurable via luminometric spectroscopy. While there were initial concerns 
about a luciferase assay producing a prohibitively high baseline signal due to endogenous 
ATP in bacterial cell lysates, an excellent Z′ score was still achieved. This was 
accomplished by optimizing both the amount of exogenous ATP added and the incubation 
time (post ATP and Met analog additon, pre luciferase addition). 
After the development of a suitable high-throughput screen for MATs in cell lysate, 
a mutant hMAT2A libarary production campaign ensued. The mutant library was produced 
via site-directed mutagenesis. The hMAT2A residues to be mutated were selected based 
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on their proximity to the AdoMet product in previously published crystal structures. More 
specifically, hMAT2A residues were selected for mutagenesis if they formed salt bridges 
with the ammounium or carboxylate moieties of the Met end of the AdoMet product. The 
objective of hMAT2A mutagenesis was either inversion of said salt bridges or their 
conversion to van der Waals bonds in combination with Met analogs baring complimentary 
substitutions. In one example, this objective was realized after screening results indicated 
that hMAT2A mutant K289L proficiently turned over Met analog Metol. In this instance, 
the lysine-carboxylate salt bridge was substituted for a leucine-methylene van der Waals 
bond, resulting in a capable hMAT2A-mutant/Met-analog pair. More examples of capable 
hMAT2A-mutant/Met-analog pairs that were successfully discovered via this strategy 
were discussed in Chapter Five. 
 
6.1.3 Examples of successful MAT-MT coupled platforms 
 Several successful MAT-MT coupled systems utilizing Met and/or ATP analogs 
were discovered throughout this work. In Chapter Two, it was revealed that the O-MT 
RebM was able to work in a coupled system by accepting S/Se-alkylated AdoMet analogs 
generated in situ by MATs. Additionally, it was revealed in Chapter Four that the O-MT 
DnrK can utilize AdoMet analogs, generated in situ by wild-type hMAT2A, baring 
isosteric substitutions at both the imidazole moiety of adenine and the carboxylate moiety 
of the amino acid Met. Furthermore, DnrK was found to accept radically different 
molecules, like 2-chloro-4-nitrophenol, in place of its natural cosubstrate, carminomycin. 
The discovery of DnrK’s ability to methylate 2-chloro-4-nitrophenol presented the 
opportunity to develop a colorimetric screen for DnrK mutants by utilizing the natural shift 
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in maximal UV-Vis light absorbance when 2-chloro-4-nitrophenol is methylated and in a 
≥ pH 8 solution. This auspicious discovery enables the facile screening of DnrK mutant 
libraries against AdoMet analogs, with the goal being the discovery of a DnrK mutant able 
to turn over an AdoMet analog that wild-type MTs typically cannot. 
 
6.2 Prospectus 
 
6.2.1 Streamline combinatorial synthesis of methionine analogs 
 Several synthetic routes to S/Se-alkylated Met analogs were developed and used to 
successfully synthesize over 50 Met analogs in this and other works. However, these 
synthetic routes require chromatographic purification for most of the S/Se-alkylated Met 
analog products synthesized. It was briefly touched on in this chapter that adding an N-Boc 
protecting group to methionine analog intermediates may enable the substitution of 
chromatographic purification for organic phase extraction; in fact, preliminary data 
gathered in tandem with this work suggests just that. Unfortunately, trifluoroacetic acid 
(TFA) is needed to remove Boc and, while this allows for the simple evaporation of residual 
TFA, TFA salts of the methionine analogs are formed. When sufficient amounts of 
methionine-analog-TFA salt is added to buffered MAT reactions, it lowers the pH to 
enzyme-denaturing levels. There are two ways to solve this problem: (1) increase the 
buffering capacity of the enzyme reaction solution or (2) neutralize the methionine-analog 
TFA salt with a base prior to transferring to the enzyme reaction solution. Either solution 
requires experimentation. For example, it is not known how high the buffer concentration 
can be without diminishing the performance of MAT or MT enzymes. Likewise, it is 
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unknown whether TFA salts, or even higher salt concentrations in general, diminish the 
performance of MAT or MT enzymes. Therefore, increasing buffer and TFA salt 
concentrations should be added to MAT and MT reactions to assess MAT and MT 
enzymes’ tolerance towards buffer and TFA salts. 
 
6.2.2 Engineer methyltransferases to accept AdoMet analogs for bioorthogonal 
elucidation of targets and alkylrandomization of natural products 
 The goal of this work was to provide the necessary upstream technology to enable 
the realization of two ultimate goals: (1) The bioorthogonal utilization of AdoMet analogs 
by MTs in vivo to map the methylome and (2) The utilization of AdoMet analogs by MTs 
in vitro or even in vivo to diversify natural products. To realize the first goal, in vitro 
experiments must provide evidence that wild-type MTs do not accept the AdoMet analog 
being tested, while engineered MTs are able to utilize the same AdoMet analog. Already, 
work performed in conjunction with this dissertation has shown that the wild-type MT 
CouO does not accept at least one of the AdoMet analogs chemoenzymatically synthesized 
in Chapter Five. This same AdoMet analog should be screened against other wild-type 
MTs to ensure they also are unable to utilize this analog. Afterward, CouO should be 
engineered to accept this or another comparable AdoMet analog. Since MT active sites are 
highly conserved, the same or similar residues in MTs other than CouO can be engineered 
in a parallel manner. 
If it is discovered that other wild-type MTs accept the AdoMet analog that wild-
type CouO does not, then more Met analogs should be screened against the hMAT2A 
mutant library created in Chapter Five to produce additional AdoMet analogs for testing. 
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Since a high-throughput screen for CouO is not currently known, it may be advantageous 
to screen AdoMet analogs against wild-type DNA methyltransferases using high-
throughput DNA break-light assays already developed. 
 Accomplishing the second goal (engineering a MT for the alkylrandomization of 
natural products) should employ a slightly different strategy. While it is necessary in a 
bioorthogonal system for AdoMet analogs to be compatible with only engineered MTs (and 
incompatible with wild-type MTs), this is not the case in an alkylrandomization platform. 
In an alkylrandomization platform, it is only necessary that the MT accepts an array of 
differentially S-alkylated AdoMet analogs and alkyl-accepting cosubstrates. Engineering 
such a MT will require the use of a high-throughput screening platform that is able to 
evaluate MT mutants’ ability to accept an array of alkyl acceptors in vitro. Such high-
throughput assays exist which can quantify SAH, hence MT activity, and are commercially 
available. However, these assays will only work provided that the AdoMet analogs tested 
with MTs will produce SAH; that is, the AdoMet analogs are only analogs because the 
methyl group on the sulfonium center was replaced by a different alkyl group. 
Nevertheless, when such an assay is used to screen an array of AdoMet analogs and 
cosubstrates against a robust MT mutant library created via random mutagenesis, it is 
highly probable that a MT capable of diversifying molecules via alkylrandomization will 
be discovered. 
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Appendix A. NMR and HRMS spectra for Chapter Two 
 
1H NMR Spectra of S/Se-alkylated Met analogs 
(2S)-2-amino-4-(ethylsulfanyl)butanoic acid (3): 1H NMR (DMSO-d6/TFA-d1 = 20/1, 500 
MHz) 
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(2S)-2-amino-4-(ethylselanyl)butanoic acid (3-Se): 1H NMR (D2O, 400 MHz) 
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(2S)-2-amino-4-(prop-2-yn-1-ylsulfanyl)butanoic acid (4): 1H NMR (D2O/TFA = 20/1, 
400 MHz) 
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(2S)-2-amino-4-(prop-2-yn-1-ylselanyl)butanoic acid (4-Se): 1H NMR (D2O, 400 MHz 
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(2S)-2-amino-4-(propa-1,2-dien-1-ylsulfanyl)butanoic acid (5): 1H NMR (D2O, 400 MHz) 
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(2S)-2-amino-4-[(cyanomethyl)sulfanyl]butanoic acid (6): 1H NMR (D2O, 500 MHz) 
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(2S)-2-amino-4-[(cyanomethyl)selanyl]butanoic acid (6-Se): 1H NMR (D2O, 400 MHz)    
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(2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic acid (7): 1H NMR (D2O/TFA = 20/1,400 
MHz) 
 
  
182 
 
(2S)-2-amino-4-(prop-2-en-1-ylselanyl)butanoic acid (7-Se): 1H NMR (D2O, 400 MHz)   
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(2S)-2-amino-4-(propylsulfanyl)butanoic acid (8): 1H NMR (DMSO-d6/TFA-d1 = 20/1, 
500 MHz) 
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(2S)-2-amino-4-(propylselanyl)butanoic acid (8-Se): 1H NMR (D2O, 400 MHz)    
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(2S)-2-amino-4-(propan-2-ylsulfanyl)butanoic acid (9): 1H NMR (D2O, 400 MHz)    
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(2S)-2-amino-4-(propan-2-ylselanyl)butanoic acid (9-Se): 1H NMR (D2O, 400 MHz)  
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(2S)-2-amino-4-(but-3-yn-1-ylsulfanyl)butanoic acid (10): 1H NMR (D2O, 400 MHz)  
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(2S)-2-amino-4-(but-3-yn-1-ylselanyl)butanoic acid (10-Se): 1H NMR (D2O, 400 MHz)  
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(2S)-2-amino-4-[(2E)-but-2-en-1-ylsulfanyl]butanoic acid (11): 1H NMR (D2O, 400 MHz)     
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(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)sulfanyl]butanoic acid (12): (DMSO-d6/TFA-d1 
= 20:1, 500 MHz)   
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(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)selanyl]butanoic acid (12-Se): 1H NMR (D2O, 
400 MHz)    
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(2S)-2-amino-4-(butylsulfanyl)butanoic acid (13): 1H NMR (D2O, 400 MHz)   
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(2S)-2-amino-4-(butylselanyl)butanoic acid (13-Se): 1H NMR (D2O, 400 MHz)  
 
  
194 
 
(2S)-2-amino-4-[(2-methylpropyl)sulfanyl]butanoic acid (14): 1H NMR (D2O/TFA = 20/1, 
400 MHz 
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(2S)-2-amino-4-[(3-aminopropyl)sulfanyl]butanoic acid (15): 1H NMR (D2O, 400 MHz)     
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(2S)-2-amino-4-[(3-aminopropyl)selanyl]butanoic acid (15-Se): 1H NMR (D2O, 400 MHz) 
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(2S)-2-amino-4-[(2E)-penta-2,4-dien-1-ylsulfanyl]butanoic acid (16): 1H NMR (D2O, 400 
MHz)   
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(2S)-2-amino-4-[(2-azidoethyl)sulfanyl]butanoic acid (17): 1H NMR (D2O, 400 MHz)     
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(2S)-2-amino-4-[(3-methylbutyl)sulfanyl]butanoic acid (18): 1H NMR (D2O/TFA = 20/1, 
400 MHz)     
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(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)sulfanyl]butanoic acid (19): 1H NMR (DMSO-
d6/TFA-d1 = 2011, 500 MHz)    
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(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)selanyl]butanoic acid (19-Se): 1H NMR 
(D2O/TFA = 20/1, 400 MHz)       
 
  
202 
 
(2S)-2-amino-4-(cyclohex-2-en-1-ylsulfanyl)butanoic acid (20): 1H NMR (D2O, 400 MHz)  
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(2S)-2-amino-4-(cyclohex-2-en-1-ylselanyl)butanoic acid (20-Se) : 1H NMR (D2O, 400 
MHz)  
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(2S)-2-amino-4-[(3-azidopropyl)sulfanyl]butanoic acid (21): 1H NMR (D2O, 400 MHz)   
 
  
205 
 
(2S)-2-amino-4-(benzylsulfanyl)butanoic acid (22): 1H NMR (D2O/TFA = 20/1, 400 MHz)      
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(2S)-2-amino-4-(benzylselanyl)butanoic acid (22-Se): 1H NMR (D2O, 400 MHz)    
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(2S)-2-amino-4-{[(2E)-4-azidobut-2-en-1-yl]sulfanyl}butanoic acid (23): 1H NMR (D2O, 
400 MHz)      
 
  
208 
 
(2S)-2-amino-4-{[(2E)-4-azidobut-2-en-1-yl]selanyl}butanoic acid (23-Se): 1H NMR 
(D2O, 400 MHz)      
 
  
209 
 
.(2S)-2-amino-4-{[(2E)-4-aminobut-2-en-1-yl]selanyl}butanoic acid (24-Se): 1H NMR 
(D2O, 400 MHz)         
 
  
210 
 
(2S)-2-amino-4-{[(4-methylphenyl)methyl]sulfanyl}butanoic acid (25): 1H NMR (D2O, 
400 MHz)   
 
  
211 
 
(2S)-2-amino-4-{[(2E)-3-phenylprop-2-en-1-yl]sulfanyl}butanoic acid (26): 1H NMR 
(D2O, 400 MHz)      
 
  
212 
 
(2S)-2-amino-4-{[(4-nitrophenyl)methyl]sulfanyl}butanoic acid (27): 1H NMR (D2O, 400 
MHz)          
 
  
213 
 
(2S)-2-amino-4-{[(4-nitrophenyl)methyl]selanyl}butanoic acid (27-Se): 1H NMR (D2O, 
400 MHz)   
 
  
214 
 
(2S)-2-amino-4-[(2-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}ethyl)sulfanyl]butanoic 
acid (28): 1H NMR (D2O, 400 MHz)           
 
  
215 
 
(2S)-2-amino-4-[(3-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}propyl)sulfanyl]butanoic 
acid (29): 1H NMR (D2O, 400 MHz)         
 
  
216 
 
(2S)-2-amino-4-{[(2E)-4-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}but-2-en-1-
yl]sulfanyl}butanoic acid (30): 1H NMR (D2O, 400 MHz)                        
 
  
217 
 
13C NMR Spectra of S/Se-alkylated Met analogs 
(2S)-2-amino-4-(ethylsulfanyl)butanoic acid (3): 13C NMR (DMSO-d6/TFA-d1 = 20/1, 125 
MHz) 
 
  
218 
 
(2S)-2-amino-4-(ethylselanyl)butanoic acid (3-Se): 13C NMR (D2O, 100 MHz)    
 
  
219 
 
(2S)-2-amino-4-(prop-2-yn-1-ylsulfanyl)butanoic acid (4): 13C NMR (D2O/ TFA = 20/1, 
100 MHz)     
 
  
220 
 
(2S)-2-amino-4-(prop-2-yn-1-ylselanyl)butanoic acid (4-Se): 13C NMR (D2O, 100 MHz)      
 
  
221 
 
(2S)-2-amino-4-[(cyanomethyl)sulfanyl]butanoic acid (6): 13C NMR (D2O, 125 MHz)   
 
  
222 
 
(2S)-2-amino-4-[(cyanomethyl)selanyl]butanoic acid (6-Se): 13C NMR (D2O, 100 MHz)     
 
  
223 
 
(2S)-2-amino-4-(prop-2-en-1-ylsulfanyl)butanoic acid (7): 13C NMR (DMSO-d6/TFA-d1 = 
20/1, 125 MHz)      
 
  
224 
 
(2S)-2-amino-4-(prop-2-en-1-ylselanyl)butanoic acid (7-Se): 13C NMR (D2O, 100 MHz)   
 
  
225 
 
(2S)-2-amino-4-(propylsulfanyl)butanoic acid (8): 13C NMR (DMSO-d6/TFA-d1 = 20/1, 
125 MHz)   
 
  
226 
 
(2S)-2-amino-4-(propylselanyl)butanoic acid (8-Se): 13C NMR (D2O, 100 MHz)    
 
  
227 
 
(2S)-2-amino-4-(propan-2-ylsulfanyl)butanoic acid (9): 13C NMR (D2O, 100 MHz)    
 
  
228 
 
(2S)-2-amino-4-(propan-2-ylselanyl)butanoic acid (9-Se): 13C NMR (D2O, 100 MHz)  
 
  
229 
 
(2S)-2-amino-4-(but-3-yn-1-ylsulfanyl)butanoic acid (10): 13C NMR (D2O, 100 MHz)  
 
  
230 
 
(2S)-2-amino-4-(but-3-yn-1-ylselanyl)butanoic acid (10-Se): 13C NMR (D2O, 100 MHz) 
 
  
231 
 
(2S)-2-amino-4-[(2E)-but-2-en-1-ylsulfanyl]butanoic acid (11): 13C NMR (D2O, 100 MHz)    
 
  
232 
 
(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)sulfanyl]butanoic acid (12): 13C NMR (DMSO-
d6/TFA-d1 = 20/1, 125 MHz)  
 
  
233 
 
(2S)-2-amino-4-[(2-methylprop-2-en-1-yl)selanyl]butanoic acid (12-Se): 13C NMR (D2O, 
100 MHz)    
 
  
234 
 
(2S)-2-amino-4-(butylsulfanyl)butanoic acid (13): 13C NMR (D2O, 100 MHz)  
 
  
235 
 
(2S)-2-amino-4-(butylselanyl)butanoic acid (13-Se):  13C NMR (D2O, 100 MHz)  
 
  
236 
 
(2S)-2-amino-4-[(2-methylpropyl)sulfanyl]butanoic acid (14) : 13C NMR (D2O/TFA = 
20/1, 100 MHz)      
 
  
237 
 
(2S)-2-amino-4-[(3-aminopropyl)sulfanyl]butanoic acid (15): 13C NMR (D2O, 100 MHz)         
 
  
238 
 
(2S)-2-amino-4-[(3-aminopropyl)selanyl]butanoic acid (15-Se): 13C NMR (D2O, 100 
MHz)            
 
  
239 
 
(2S)-2-amino-4-[(2E)-penta-2,4-dien-1-ylsulfanyl]butanoic acid (16): 13C NMR (D2O, 100 
MHz)   
 
  
240 
 
(2S)-2-amino-4-[(2-azidoethyl)sulfanyl]butanoic acid (17): 13C NMR (D2O, 100 MHz)    
 
  
241 
 
(2S)-2-amino-4-[(3-methylbutyl)sulfanyl]butanoic acid (18): 13C NMR (D2O/TFA = 20/1, 
100 MHz)   
 
  
242 
 
(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)sulfanyl]butanoic acid (19): 13C NMR (DMSO-
d6/TFA-d1 = 20/1, 125 MHz)    
 
  
243 
 
(2S)-2-amino-4-[(3-methylbut-2-en-1-yl)selanyl]butanoic acid (19-Se): 13C NMR 
(D2O/TFA = 20/1, 100 MHz)     
 
  
244 
 
(2S)-2-amino-4-(cyclohex-2-en-1-ylsulfanyl)butanoic acid (20): 13C NMR (D2O, 100 
MHz)   
 
  
245 
 
(2S)-2-amino-4-(cyclohex-2-en-1-ylselanyl)butanoic acid (20-Se): 13C NMR (D2O, 100 
MHz)      
 
  
246 
 
(2S)-2-amino-4-[(3-azidopropyl)sulfanyl]butanoic acid (21): 13C NMR (D2O, 100 MHz)      
 
  
247 
 
(2S)-2-amino-4-(benzylsulfanyl)butanoic acid (22): 13C NMR (D2O/TFA = 20/1, 100 
MHz)      
 
  
248 
 
(2S)-2-amino-4-(benzylselanyl)butanoic acid (22-Se): 13C NMR (D2O, 100 MHz)   
 
  
249 
 
(2S)-2-amino-4-{[(2E)-4-azidobut-2-en-1-yl]sulfanyl}butanoic acid (23): 13C NMR (D2O, 
100 MHz)    
 
  
250 
 
(2S)-2-amino-4-{[(2E)-4-azidobut-2-en-1-yl]selanyl}butanoic acid (23-Se): 13C NMR 
(D2O, 100 MHz)         
 
  
251 
 
(2S)-2-amino-4-{[(2E)-4-aminobut-2-en-1-yl]selanyl}butanoic acid (24-Se): 13C NMR 
(D2O, 100 MHz)        
 
  
252 
 
(2S)-2-amino-4-{[(4-methylphenyl)methyl]sulfanyl}butanoic acid (25): 13C NMR (D2O, 
100 MHz)   
 
  
253 
 
(2S)-2-amino-4-{[(2E)-3-phenylprop-2-en-1-yl]sulfanyl}butanoic acid (26): 13C NMR 
(D2O, 100 MHz)     
 
  
254 
 
(2S)-2-amino-4-{[(4-nitrophenyl)methyl]sulfanyl}butanoic acid (27): 13C NMR (D2O, 100 
MHz)             
 
  
255 
 
(2S)-2-amino-4-{[(4-nitrophenyl)methyl]selanyl}butanoic acid (27-Se): 13C NMR (D2O, 
100 MHz)                 
 
  
256 
 
(2S)-2-amino-4-[(2-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}ethyl)sulfanyl]butanoic 
acid (28): 13C NMR (D2O, 100 MHz)       
 
  
257 
 
(2S)-2-amino-4-[(3-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}propyl)sulfanyl]butanoic 
acid (29): 13C NMR (D2O, 100 MHz)         
 
  
258 
 
(2S)-2-amino-4-{[(2E)-4-{[(3S)-3-amino-3-carboxypropyl]sulfanyl}but-2-en-1-
yl]sulfanyl}butanoic acid (30): 13C NMR (D2O, 100 MHz)  
 
  
259 
 
NMR spectra of O-alkylated rebeccamycin analogs 
NMR of RebM substrate (31) – 1H full spectrum 
 
 
  
260 
 
NMR of RebM substrate (31) – 1H/gHSQC of sugar region; gCOSY full spectrum 
 
  
261 
 
NMR of 4’-O-methyl-rebeccamycin – 1H full spectrum 
  
262 
 
NMR of 4’-O-methyl-rebeccamycin – 1H/gHSQC of sugar region; gCOSY full 
spectrum 
 
  
263 
 
NMR of 4’-O-ethyl-rebeccamycin – 1H full spectrum 
  
264 
 
NMR of 4’-O-ethyl-rebeccamycin– 1H/gHSQC of sugar region; gCOSY full 
spectrum 
  
265 
 
NMR of 4’-O-allyl-rebeccamycin – 1H full spectrum 
 
 
  
266 
 
NMR of 4’-O-allyl-rebeccamycin– 1H/gHSQC of sugar region; gCOSY full spectrum 
 
  
267 
 
NMR of 4’-O-propargyl-rebeccamycin – 1H expanded (top) and full (bottom) 
spectra 
 
  
268 
 
NMR of 4’-O-propargyl-rebeccamycin– gHSQC of sugar region; gCOSY/TOCSY 
full spectrum 
  
269 
 
NMR of 4’-O-acetonitrilyl-rebeccamycin – 1H full spectrum 
 
  
270 
 
 NMR of 4’-O-acetonitrilyl-rebeccamycin – 1H/gHSQC of sugar region; gCOSY full 
spectrum  
 
  
271 
 
HRMS of S/Se-alkylated SAM analogs from crude reaction samples. 
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296 
 
HRMS data of differentially alkylated rebeccamycin analogs from crude reaction samples.   
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299 
 
Appendix B. NMR and HRMS spectra for Chapter Four. 
 
(S)-(9H-fluoren-9-yl)methyl [1-amino-4-(methylthio)-1-oxobutan-2-yl]carbamate (2): 1H 
NMR (400 MHz, DMSO-d6) 
300 
 
(S)-(9H-fluoren-9-yl)methyl [1-cyano-3-(methylthio)propyl]carbamate (3): 1H NMR (400 
MHz, DMSO-d6)  
  
301 
 
(S)-(9H-fluoren-9-yl)methyl [3-(methylthio)-1-(1H-tetrazol-5-yl)propyl]carbamate (4): 
1H NMR (400 MHz, DMSO-d6) 
 
  
302 
 
(S)-3-(methylthio)-1-(1H-tetrazol-5-yl)propan-1-amine (5): 1H NMR (400 MHz, D2O) 
 
 
 
  
303 
 
(S)-(9H-fluoren-9-yl)methyl [1-amino-4-(methylthio)-1-oxobutan-2-yl]carbamate (2): 13C 
NMR (100 MHz, DMSO-d6) 
 
 
 
 
  
304 
 
(S)-(9H-fluoren-9-yl)methyl [1-cyano-3-(methylthio)propyl]carbamate (3): 13C NMR (100 
MHz, DMSO-d6) 
 
 
 
 
 
  
305 
 
(S)-(9H-fluoren-9-yl)methyl [3-(methylthio)-1-(1H-tetrazol-5-yl)propyl]carbamate (4): 
13C NMR (100 MHz, DMSO-d6) 
 
 
 
 
  
306 
 
(S)-3-(methylthio)-1-(1H-tetrazol-5-yl)propan-1-amine (5): 13C NMR (100 MHz, D2O) 
 
 
 
 
  
307 
 
2-chloro-1-methoxy-4-nitrobenzene (7): 1H NMR (400 MHz, CDCl3) 
 
 
 
 
  
308 
 
2-chloro-1-methoxy-4-nitrobenzene (7): 13C NMR (100 MHz, CDCl3) 
 
 
 
 
  
309 
 
2-chloro-1-methoxy-4-nitrobenzene (7): gCOSY NMR (400 MHz, CDCl3) 
 
 
 
  
310 
 
(S)-[(S)-3-amino-3-(1H-tetrazol-5-yl)propyl](5-adenosyl)(methyl)sulfonium (8): 1H NMR 
(500 MHz, DMSO-d6) δ ppm 8.37 (s, 1 H), 8.17 (s, 1 H), 7.34 (s, 2 H), 5.94 (d, J = 5.3 Hz, 
1 H), 4.79 – 4.75 (m, 1 H), 4.35 – 4.29 (m, 2H), 4.10 (t, J = 5.5 Hz, 1 H), 4.00 – 3.92 (m, 
1 H), 3.71 (d, J = 12.1 Hz, 1 H), 3.41 (t, J = 6.9 Hz, 2 H), 2.85 (s, 3 H), 2.19 – 2.04 (m, 2 
H). 
 
 
 
 
  
311 
 
(S)-[(S)-3-amino-3-(1H-tetrazol-5-yl)propyl](5-adenosyl)(methyl)sulfonium (8): gCOSY 
(1H-1H) NMR (500 MHz, DMSO-d6) 
 
 
 
 
  
312 
 
(S)-[(S)-3-amino-3-(1H-tetrazol-5-yl)propyl](5-adenosyl)(methyl)sulfonium (8): TOCSY 
NMR (500 MHz, DMSO-d6) 
 
 
 
 
  
313 
 
(S)-[(S)-3-amino-3-(1H-tetrazol-5-yl)propyl](5-adenosyl)(methyl)sulfonium (8): NOESY 
NMR (500 MHz, DMSO-d6) 
 
 
 
  
314 
 
(S)-[(S)-3-amino-3-(1H-tetrazol-5-yl)propyl](5-adenosyl)(methyl)sulfonium (8): gHSQC 
NMR (500 MHz, DMSO-d6) 
 
 
 
 
 
  
315 
 
(S)-[(S)-3-amino-3-(1H-tetrazol-5-yl)propyl](5-adenosyl)(methyl)sulfonium (8): gHMBC 
NMR (500 MHz, DMSO-d6)  
 
 
 
 
 
  
316 
 
HRMS of tMet (5) 
  
317 
 
HRMS of AdotMet (8) 
 
 
 
  
318 
 
HRMS of 7dzAdoMet (9) 
 
 
 
  
319 
 
HRMS of 7dzAdotMet (10) 
 
 
 
 
 
 
  
320 
 
Appendix C. NMR and HRMS spectra for Chapter Five 
(S)-1-methoxy-4-(methylthio)butan-2-amine (7): 1H NMR (400 MHz, CDCl3) 
 
  
321 
 
(S)-1-methoxy-4-(methylthio)butan-2-amine (7): 13C NMR (100 MHz, CDCl3) 
 
  
322 
 
(S)-1-ethoxy-4-(methylthio)butan-2-amine (8): 1H NMR (400 MHz, CDCl3) 
 
  
323 
 
(S)-1-ethoxy-4-(methylthio)butan-2-amine (8): 13C NMR (100 MHz, CDCl3) 
 
  
324 
 
(S)-4-(methylthio)-1-propoxybutan-2-amine (9): 1H NMR (400 MHz, CDCl3) 
 
  
325 
 
(S)-4-(methylthio)-1-propoxybutan-2-amine (9): 13C NMR (100 MHz, CDCl3) 
 
  
326 
 
(S)-1-butoxy-4-(methylthio)butan-2-amine (10): 1H NMR (400 MHz, CDCl3) 
 
  
327 
 
(S)-1-butoxy-4-(methylthio)butan-2-amine (10): 13C NMR (100 MHz, CDCl3) 
 
  
328 
 
(9H-fluoren-9-yl)methyl [(3S,4R)-4-hydroxy-1-(methylthio)pentan-3-yl]carbamate  (N-
Fmoc-R,S-4): 1H NMR (400 MHz, CDCl3) 
 
  
329 
 
(9H-fluoren-9-yl)methyl [(3S,4S)-4-hydroxy-1-(methylthio)pentan-3-yl]carbamate (N-
Fmoc-S,S-4): 1H NMR (400 MHz, CDCl3) 
 
  
330 
 
N-Fmoc-S,S-4-(R)-MTPA: 1H NMR (400 MHz, CDCl3) 
 
  
331 
 
N-Fmoc-S,S-4-(S)-MTPA: 1H NMR (400 MHz, CDCl3) 
 
  
332 
 
(2R,3S)-3-amino-5-(methylthio)pentan-2-ol (R,S-4): 1H NMR (400 MHz, CDCl3) 
 
  
333 
 
(2R,3S)-3-amino-5-(methylthio)pentan-2-ol (R,S-4): 13C NMR (100 MHz, CDCl3) 
 
  
334 
 
(2S,3S)-3-amino-5-(methylthio)pentan-2-ol (S,S-4): 1H NMR (400 MHz, CDCl3) 
 
  
335 
 
(2S,3S)-3-amino-5-(methylthio)pentan-2-ol (S,S-4): 13C NMR (100 MHz, CDCl3) 
 
  
336 
 
(4S)-4-amino-6-(methylthio)hexan-3-ol (5): 1H NMR (400 MHz, CDCl3) 
 
  
337 
 
(4S)-4-amino-6-(methylthio)hexan-3-ol (5): 13C NMR (100 MHz, CDCl3) 
 
  
338 
 
(3S)-3-amino-1-(methylthio)heptan-4-ol (6): 1H NMR (400 MHz, CDCl3) 
 
  
339 
 
(3S)-3-amino-1-(methylthio)heptan-4-ol (6): 13C NMR (100 MHz, CDCl3) 
 
  
340 
 
HRMS of AdoMetol 
  
341 
 
HRMS of AdoMetolMe 
 
 
 
  
342 
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